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1 Introduction 
 
Mankind has always sought to help those who suffer from disease and, of the curative 
methods used, one of the oldest and most successful has been treatment with drugs. This is 
especially true of drugs acting on the nervous system. In fact, the earliest historical records 
indicate that man has long had some useful folk knowledge of drugs to heal, to soothe the 
spirits and to relieve pain. Thus, the ancient Greeks were aware of the properties of naturally 
occurring salicylates: for example, Hippocrates recommended juice of the poplar tree for the 
treatment of eye deseases and extracts of the leaves of the willow for the relief of pain in 
childbirth; both of these plants contain natural salicylates, the forerunners of aspirin. Also, 
natural opioids have been in use as medicines since ancient times, when Hippocrates and 
Galen obtained them from the juice of the poppy. Throughout the Middle Ages from Avicenna 
to Paracelsus, the number of extraction forms increased, culminating in Sydenham’s entry of 
opium tincture in the pharmacopoeias. So, most of the drugs used by the early civilizations 
were herbal extracts, very often mixtures of a number of different plants and usually 
containing large amount of inactive material as well as the active constituents. Some were of 
animal origin, or were inorganic. Knowledge of the uses to which these ‘folk remedies’ could 
be put was the process of ‘trial and error’, i.e. empirically rather than by any rational process 
and, of course, it did not include any understanding of the biological actions of drugs, nor of 
their chemistry.[1] 
 
This kind of folk medicine continued into the nineteenth century, when the scientific 
revolution and developments in chemistry in particular, brought about remarkable changes. 
Though the use of chemical analysis it became possible to separate the various constituents of 
the crude herbal extracts; then each constituent could be tested separately for biological 
activity, and finally, the chemical nature of the active component or components could be 
determined. 
 
One of the most famous examples is the isolation of morphine (1-1) by Adam Sertürner in 
1805. Following the isolation of morphine, further alkaloids were isolated from opium, for 
example narcotine (1-2) in 1817, codeine (1-3) in 1832, and thebaine (1-4) in 1835.[5] 
  Introduction 2 
N
O
O
MeO
O
OMeO
MeO
H
H
O
N
H
MeO
HO
O
N
H
HO
HO
O
N
MeO
MeO
1-1 1-2
1-3 1-4  
 
Figure 1. Structures of morphine (1-1), narcotine (1-2), codeine (1-3), thebaine (1-4). 
 
Since then, morphine was recognized as a main component of opium, responsible for its 
analgesic activity. It is a very potent analgesic and is used till present days for the treatment of 
moderate to severe acute and chronic pain of various origins and is regarded as the gold 
standard for pain treatment.  
 
However, the use of morphine bears some risks of side-effects. With repeated use of 
morphine, the analgesic effects wane and the dose has to be increased. Furthermore, morphine 
can cause addiction, an accommodation of the cells of the body to its presence so that its use 
must be continued or a withdrawal symptome appears. Thus, the problems of opiate addiction 
has served in part, to intensify efforts directed toward understanding the basic mechanisms of 
action of these type of drugs and to intensify the search for a better morphine, a substance with 
morphine’s beneficial properties and with attenuated or no harmful side-effects including 
tolerance and dependence.[2] 
 
From a chemical point of view, determination of the total structure of morphine by Robinson 
in 1925 was a landmark.[3] Of primary importance in the development of new synthetic 
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analgesics was the observation that simpler morphine-like compounds could be prepared, 
which contain only a portion of the parent structure, but which are as or more effective than 
morphine as analgesics.  
 
The synthesis of hundreds of analogues of varying structure, detailed studies of their 
pharmacological activity, and the introduction of some of these into clinical medicine are clear 
indications of the progress being made. Thus, opening rings C and D in morphine (1-1) yields 
compounds containing the benzomorphan ring structure (Figure 2) which have proven to be 
particularly interesting in this regard and are an important class of analgesics and other types 
of drugs.  
 
morphine (1-1)
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H H
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B
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D
E
 
 
Figure 2. Structure of morphine (1-1) and benzomorphans (1-5, 1-6, 1-7). 
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Unfortunately, many compounds which are used today also have dependence-producing and 
other undesirable side effects of morphine. That is why, the eventual development of effective, 
strong analgesics, which have no side effects of morphine, represents a reasonable goal for 
modern synthetic chemistry. Some useful analgesics which approach this ideal may well be 
benzomorphan derivatives. 
 
In the present investigation, we focused on the design and synthesis of benzomorphan 
scaffolds, which could be subjected as a starting point in development of novel analgesic 
drugs. With the advent of new powerful organometallic transformations, such as cross-
coupling or C–H insertions, the chemical way to known drugs seem to be substantially 
broadened. A case in point is the Buchwald–Hartwig arylation of enolates in the presence of a 
palladium catalyst (Eq. 1). 
 
Z1
Z2
Z1
Z2
Br
+
Pd(0), ligand
base
Z1, Z2 = electronwithdrawing groups
(1)
 
 
Equation 1.  
 
Our goal was to apply this reaction in an intramolecular setting towards the synthesis of 
benzomorphan scaffolds (Scheme 1). Furthermore, it was planned to study the proposed 
transformation using a variety of substrates and to show the generality of this methodology as 
a powerful tool in the preparation of various benzomorphan derivatives with potential 
biological activity. 
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Scheme 1. Approach to benzomorphan synthesis based on intramolecular palladium-catalyzed 
α-ketone arylation. 
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2 Literature Review 
 
2.1 Benzomorphans – a Structural Feature of Analgesic Drugs 
 
Most drugs acting on the nervous system produce their effect by modifying or 
interfering with synaptic transmission.[4] In the mammalian nervous system, transmission at 
synapses is mediated by the release of a neurotransmitter. Thus, while the transfer of 
information from one part of a nerve cell to another is electrical (e.g. by propagated action 
potentials), the transfer of information from one neurone to another is a chemical event, i.e. via 
a neurotransmitter which is released from one neurone and acts on the other. Nerve cells all 
possess the same basic components, i.e. cell body, axon and dendrites (Figure 3). 
 
 
 
Figure 3. Schematic drawing of a nerve cell. 
 
The neurotransmitter is present in the presynaptic nerve terminals where it may be stored in 
synaptic vesicles ready for release and where, in many cases, it is also synthesized, the 
enzymes involved in the synthesis being associated with the mitochondria (Figure 4). 
 
Literature Review 7
 
 
Figure 4. Representation of a typical synapse 
 
The transmitter is released from the nerve terminals as the result of the arrival of action 
potentials, the release being dependent upon the influx of Ca2+ ions. The released transmitter 
diffuses across the synaptic gap to stimulate a receptor on the postsynaptic neurone and this 
action results in a response in the postsynaptic cell. Many substances have been proposed as 
synaptic transmitters or neurotransmitters, the best-known being acetylcholine (ACh), 
noradrenaline, dopamine, 5-hydroxytryptamine (5-HT or serotonine), certain amino acids such 
as glutamic and aspartic acids, γ-aminobutyric acid and glycine, and also many peptides. 
 
Effects on synaptic transmission by an active drug can be produced at different sites and in 
different ways: a) presynaptic (uptake of precursor, synthesis, storage or release of transmitter) 
and b) postsynaptic (agonists mimicking the action of the transmitter, antagonists blocking the 
action of the transmitter and agonist drugs, or removal of transmitter). Noteworthy, that all 
paths include the interaction with the transmitter storage or release. 
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Free nerve endings are identified as pain receptors in pain-sensitive tissues, which spreaded all 
over a body, e.g. skin, muscles and viscera. The damaged tissue sends out nerve impulses 
through nerve tracts in the spinal cord to the brain where the stimulus translates to a conscious 
pain sensation. In addition to nervous pain impulses, injured tissues produce inflammatory 
pain-producing substances, including bradykinin and other kinins, serotonin, histamine, 
acetylcholine, excesses of potassium ions, proteolytic enzymes and prostaglandins.  
 
Finally, those substances, which can modify or inhibit the process of pain formation through 
nerve cells, could in some way cleave or decrease pain and cause analgesic effects.[5] In 
general, all substances that influence the process of synaptic transmission could be of interest 
for finding a new pharmaceutical. 
 
It was found that morphine (1-1),[6] the natural lead structure confers its activity through an 
agonistic modulation at the μ-opioid receptors. In the course of structure/activity studies,[7] 
other opiod receptors, such as the κ-, the δ-, and the ORL-1 receptor were discovered.[8] The 
desired analgetic properties of opioids result mainly by binding of a ligand to the μ- and the κ-
receptor. Of clinical relevance are μ-agonists,[9] partial agonists (compounds that show 
agonistic as well as antagonistic effects at the μ-receptor) and mixed agonist/antagonists.[10] 
The latter type of drugs includes compounds that are κ-agonists/μ-agonists or κ-agonists/μ-
antagonists, respectively. For example, pentazocine (2-1) is classified as κ-agonist/partial μ-
agonist (Figure 5). 
 
Many active drugs contain a cyclic core structure, frequently incorporating heteroatoms. In 
addition, other positions are decorated with groups that directly interact with matching 
partners on the receptor. Besides the type, the relative orientation of these groups is a key 
factor in determining biological activity. 
 
As the essential structural features of such compounds the phenol and the piperidine ring were 
identified. In order to find analgesics with improved properties and reduced side effects a 
range of morphine analogs were prepared. These variations include the synthesis of truncated 
systems. Thus, opening of the cyclohexene ring yields the benzomorphans, such as 1-7.[11] 
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Also the nitrogen atoms can be repositioned, as illustrated with structures 1-5 and 1-6.[12] In 
addition, variations in the ring size have been performed in the benzomorphan series.[13] The 
5-arylmorphan skeleton (2-2) represents another important core structure.[14] 
 
morphine (1-1)
NMe
O
HO
HO
H
1-7
5-arylmorphan skeleton (2-2)1-5 1-6
N N
H
N N
H H
pentazocine (2-1)
N
H
 
 
Figure 5. Structures of morphine (1-1), and prominent analogs derived from it. 
 
Finally, a range of μ-selective opioids without morphinan structure were discovered over the 
years.[9] Among the simpler morphine analogs, the benzomorphan and benzazocine tricyclic 
ring system are one of the most extensively investigated morphine analogues, first prepared 
and studied in detail by May and Eddy at the National Institutes of Health.[11]  
 
A number of synthetic routes to benzomorphans have been developed, and chemical 
modifications have provided valuable new benzomorphan derivatives of practical and 
theoretical importance, very often with biological profiles far different from that of morphine 
(antitussive, respiratory, gastrointestinal, sedative, and other types of activity). 
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2.2 Clinically Used Benzomorphan Derivatives 
 
Morphine has always been an accepted standard analgesic, the medicament without 
which, until recently, no one could practice medicine effectively. Its use, however, bears some 
risks of side-effects (breathing depression to a life-threatening degree, nausea, vomiting, 
sweating, dizziness, and sluggishness occur frequently). With repeated use of morphine, the 
analgesic effects wane and the dose has to be increased. Furthermore, morphine can cause 
addiction. 
 
The earliest attempts to develop a non-dependence-inducing morphine derivative resulted in 
the preparation of heroin (2-3, 3,6-diacetylmorphine) by acetylation of morphine.[15] The 
potency of heroin was soon recognized. It underwent more investigation than any other 
product of time, and was introduced into clinical medicine in 1898.[16] 
 
O
N
O
O
O
O
Me
Me
Me
H
2-3  
 
Figure 6. Structure of O,O-diacetylmorphine (2-3, heroine). 
 
Reports of its reduced respiratory depression and dependence liability were soon shown to be 
unfounded, but its analgesic effects on animals and man (twice more than morphine) were 
confirmed. Pharmacological examination of acyl derivatives of morphine showed that heroin 
and its higher and lower acyl homologues have similar analgesic potencies in rodents and have 
high physical dependence liability.[17] 
 
The introduction of heroin, although based on inaccurate observations and interpretation, 
undoubtedly influenced the trend and objectives of morphine research and marked the 
beginning of the search for an improved analgesic. During the 25 years after the introduction 
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of heroin, other morphine derivatives were incorporated into medical practice some of which 
are still being used today (Figure 7). These include dihydrocodeine (2-4), thebacon (2-5, 
acetyldihydrocodeinone), hydrocodone (2-6, dihydrocodeinone). All of these are analgesics, 
but mainly used as antitussives. 
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Figure 7. Structures of dihydrocodeine (2-4), thebacon (2-5), hydrocodone (2-6). 
 
In the 1920s a most significant change in analgesic research came out: the beginning of the 
first systematic study of structure-activity relationships which endeavored to separate 
analgesic effectiveness from side-effects and addiction liability. In the USA, this plan was 
directed from 1929-1939 by the Committee on Drug Addiction of the National Research 
Council (NRC) with financial support from the Rockefeller Foundation. This program 
consisted of modification of the morphine molecule at all accessible points and also targeted 
(modified) partial structures of the morphine molecule, such as phenanthrene, hydrogenated 
phenanthrene, isoquinoline, dibenzofuran, and carbazole. More than 150 derivatives of 
morphine and more than 300 synthetic products were tested for analgesic, respiratory, 
gastrointestinal, sedative, and other central nervous system effects. The significance of the 
phenolic and alcoholic hydroxyls for intensity of analgesic action was established. Removal of 
the latter, as in desomorphine (2-7, Figure 8), resulted in the most rapidly acting and potent 
analgesic known at that time.[18] 
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Figure 8. Structure of desomorphine (2-7). 
 
After 10 years of intensive research, no significant dissociation of potent analgesia and 
dependence liability was accomplished. As an indirect result of the systematic program the 
identification of the 17-hydroxy-7,8-dihydro compounds oxycodone (2-8, patented in 1925 by 
E. Merck AG, Germany) and oxymorphone (2-9), derived from thebaine, are of particular note 
(Figure 9). 
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Figure 9. Structures of oxycodone (2-8), oxymorphone (2-9). 
 
The attempts to synthesize morphine led to the synthesis of its basic skeleton by Grewe in 
1946.[19] This work, continued by Schnider et al.,[20] yielded the significant discovery that the 
complete morphine structure is not essential for potent analgesic activity. N-Methylmorphinan 
(2-10) is analgesic, and levorphanol (2-11) is an effective therapeutic agent, more potent than 
morphine (Figure 10).  
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Figure 10. Structures of N-methylmorphinane (2-10), levorphanol (2-11), dextrometorphan 
(2-12). 
 
Anther example is dextrometorphan (2-12), which is a low to medium affinity NMDA channel 
blocker. The former has been in clinical use as an antitussive* for about 40 years and could 
therefore be considered as a very safe drug.[21] 
 
The synthesis of N-methylmorphinan (2-10) prompted the synthesis of even simpler 
modifications, benzomorphans (Figure 11). 
 
N
H
Me
NH
N-Methylmorphinan (2-10) 1-7  
 
Figure 11. From N-methylmorphinan (2-10) to benzomorphan (1-7). 
 
The first of the benzomorphans family was phenazocine (2-13) (analgesic, low dependence 
capacity). Another analog, ketocyclazocine (2-14b), was found to act as κ-agonist.[22] The 
derivative, bremazocine (2-15), is a potent, long lasting κ-agonist with activity at μ-sites as 
well, however possessing strong psychotomimetic† side effects (Figure 12). 
 
                                                 
* Antitussive: capable of relieving or suppressing coughing. 
† Psychotomimetic: tending to induce hallucinations, delusions, or other symptoms of a psychosis. 
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Cyclazocine 2-14a (X = H2)
Ketocyclazocine 2-14b (X = O)
2-13
2-15
N
HO
N
X
HO
N
HO
OH
 
 
Figure 12. Structures of phenazocine (2-13), cyclazocine (2-14a), ketocyclazocine (2-14b), 
bremazocine (2-15). 
 
Crobenetine (2-16, BIII 890 CL, Figure 13), is in clinical trials and characterized as a voltage- 
and frequency-dependent sodium channel blocker.[23] It was demonstrated that BIII 890 CL is 
a potent, selective, and highly use-dependent Na+ channel blocker that protects brain tissue 
from the deleterious effects of permanent focal cerebral ischemia in rodents at doses that do 
not disturb motor coordination. It therefore could be used as a neuroprotective therapy for the 
treatment of acute thromboembolic stroke. 
 
Crobenetine (2-16)
(Boehringer Ingelheim Pharma KG)
N
OH
O
 
 
Figure 13. Structure of crobenetine (2-16). 
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2.3 Overview of Known Methods for the Preparation of Various 
Benzomorphans 
 
As mentioned before, during the past century the desire of finding simplier morphine 
analogs resulted in the discovery that the complete morphine structure is not essential for 
analgesic activity. Besides the biological properties, benzomorphans have been recognized as 
an interesting scaffold for organic chemists to elaborate innovative approaches and to develop 
new methodologies. Some of these attempts are presented below. 
 
2.3.1 The Tetralone Route 
 
The tetralone route to benzomorphans is referred to the synthetic pathway in which the 
key intermediate is an appropriately substituted tetralone derivative. The very first result in the 
construction of the benzomorphan ring skeleton was achieved in 1947 by J. A.Baltrop.[24] The 
methyl substituted tetralone 2-17 was engaged in the alkylation reaction with 2-chloroethyl-
N,N-diethylamine to form the amino ketone 2-18 which was then brominated at the free α-
position of the keto group (Scheme 2). Treatment of the latter under basic conditions 
(NaHCO3) resulted in the intramolecular alkylation of the tertiary amine and formation of the 
quaternary salt 2-19. Although this latter synthesis suffers from low yields, it represents the 
preparation of the first member of the benzomorphan family. 
 
O
NEt2Me
O
O
Et2N
Br-Cl(CH2)2NEt2
NaNH2, toluene
1. Br2, CHCl3
2. NaHCO3
reflux, 38% 8%
2-17 2-18 2-19  
 
Scheme 2. Synthesis of benzomorphan 2-19 by J. A. Baltrop. 
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Later this route was applied for the preparation of the “naked” N-methylbenzomorphan          
2-24.[25] The main tetralone precursor for cyclization was synthesized using a very interesting 
sequence. Thus, 4-phenylcyclohexanone (2-20) was converted to the oxime followed by 
Beckmann-type rearrangement to 5-phenylcaprolactam (2-21). Hydrolysis with Ba(OH)2 
afforded the amino acid wich was methylated at the free amino function by the Clark-
Eschweiler method followed by cyclization with polyphosphoric acid to yield the aminoketone 
2-22. Bromination of the resulting tetralone and treatment with conc. aqueous NH4OH 
afforded cyclic quaternized salt 2-23 in unexpectingly high yield of 68%. After dry distillation 
and reduction under Wolff-Kishner conditions, N-methylbenzomorphan 2-24 was obtained 
(Scheme 3).  
 
O HN O
1. NH2OH
2. PPA
NMe2
O
NMe2
O
NMe
Br-
1. Ba(OH)2
2. HCHO, HCO2H
(Clark-Eschweiler)
3. PPA,70%
1. Br2, AcOH
2. NH4OH
1. dry distil.
2. NH2NH2, KOH
90%
68% 180-190°C
42%
2-20 2-21 2-22
2-23 2-24  
 
Scheme 3. Synthesis of benzomorphan 2-24 by Mitsuhashi and co-workers. 
 
A similar approach was used by G. N. Walker and D. Alkalay,[26] but avoiding quaternary salt 
formation. Instead, they employed an intramolecular reaction between α-Br-ketone and a 
mono-substituted amide moiety. The required tetralone derivative was prepared by starting 
with a Friedel-Crafts condensation of 4-(carbethoxymethyl)-4-phenyl-butyrolactone (2-25) 
with benzene providing a 48% yield of β,β-diphenyladipinic acid (2-26) which on cyclization 
with concentrated sulfuric acid afforded 4-carbethoxymethyl-4-phenyl-1-tetralone (2-27),[27] 
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(Scheme 4). Reaction of keto ester 2-27 with 40%-aqueos methylamine in ethanol for one 
week resulted in the formation of 4-carboxamidomethyl-4-phenyl-1-tetralone (2-28).  
 
O
Ph O
NHMe
O
Ph O
OEt
O
O
Ph
O
OEt
+
AlCl3
Ph
O
OEt
OH
O
H2SO4 MeNH2
48%
69% 73%
2-25 2-26
2-27 2-28  
 
Scheme 4. Preparation of 4-carboxamidomethyl-4-phenyl-1-tetralone (2-28) by Walker and 
co-workers. 
 
From this N-methylamide 2-28, after bromination and treatment with NaOMe the desired 
benzomorphan derivative 2-30 was obtained in 34% yield (Scheme 5). Interestingly, the 
authors note that only one isomer (2-29a) from the bromination reaction undergoes the desired 
cyclization. Another diastereomer 2-29b, with bromine atom and phenyl substituent are trans-, 
forms only hydroxy ketone 2-31 (Scheme 5). 
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NMePh
O
O
O
Ph O
Ph
NHMe
O
NHMe
O
Br
O
Ph
NHMe
O
Br
O
Ph
NHMe
O
OH
NaOMe
Br2
NaOMe
34%
2-28
2-29a 2-30
2-29b 2-31  
 
Scheme 5. Bromination of tetralone 2-28 and treatment of diastereomeric mixture 2-29a,b 
with sodium methoxide. 
 
Such selectivity can be satisfyingly explained by the SN2-character of this reaction, which 
involves backside attack of the α-Br-ketone with the amide as a nucleophile (Scheme 6). 
 
O
Br
NH
O
O
Br
N
O
NPh
O
O
O
Ph
HN
O
OH
OH
2-29a
2-29b
2-30
2-31  
 
Scheme 6. SN2 reactions of tetralones 2-29a and 2-29b.  
 
Extension of the tetralone route through intramolecular reaction between the α-Br-function 
and a mono-substituted amide moiety was later described by W. L. Nelson and K. F. 
Nelson.[28] In their investigation the key tetralone 2-32 was prepared by almost the same route 
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as above, but with methyl instead phenyl substituent in 4-position of the tetralone (Scheme 7). 
In contrast to the previously described method, bromination and subsequent cyclization under 
basic conditions delivered the desired benzomorphan 2-33 with significantly higher yield. 
Noteworthy, the authors did not observe the formation of hydroxy ketone in this case. 
 
Me
NHMe
O
O
Br
NaOMe
MeOH
reflux, 67%
NMe
O
Me
O
2-32 2-33  
 
Scheme 7. Synthesis of benzomorphan 2-33 by W. L. Nelson and K. F. Nelson.  
 
A rather interesting approach was described by Japanese researchers.[29] Analogously to 
previously highlighted synthetic ways, these authors first prepared the tetralone derivative     
2-34, which after hydrolysis of the urethane residue formed cyclic enamine 2-35. When this 
enamine was brominated in CH2Cl2 and the reaction mixture treated with aqueous ammonium 
hydroxide at room temperature, the 10-oxobenzomorphan 2-38 was obtained in 81% yield. A 
possible mechanism for this conversion has been proposed. Thus, attack of hydroxyl anion to 
the initially formed bromo iminium bromide 2-36 would give intermediate 2-37 which may 
undergo, presumably in a concerted manner, rearrangement to the desired benzomorphan 2-38 
(Scheme 8).  
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NMe
MeO
MeO
NMe
MeO
Br
Br2, CH2Cl2
-35°C
NMe
MeO
Br
OH
KOH
BuOH
reflux, 56%
O
NMe
3% NH4OH
5-10°C, 60%
MeO
Me
N OEt
O
2-34 2-35 2-36
2-37 2-38  
 
Scheme 8. Synthesis of benzomorphan 2-38 by Takeda and co-workers. 
 
This method had also been successfully used by the same authors to prepare the 
homobenzomorphan analogue 2-39 as a key intermediate for the synthesis of 
homobenzomorphan analgetics (Figure 14). 
 
NMeMe
HO
2-39
O
 
 
Figure 14. Structure of homobenzomorphan derivative 2-39. 
 
The formation of cyclic lactams has also found its use for the synthesis of benzomorphans 
(Scheme 9).[25] Thus, the ethyl ester of 4-tetralone-2-acetic acid (2-40) was treated with 
hydroxylamine in refluxing EtOH to give the oxime, followed by catalytic reduction over 
Adams catalyst to afford amino ester 2-41. The crude product was immediately heated to 160–
170 °C for 2 hours to form the cyclic lactam 2-42. Of course, cyclization affects only the cis 
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isomer of amino ester 2-41. The lactam was reduced with lithium aluminium hydride to 
deliver benzomorphan 2-43. 
 
CO2Et
O
CO2Et
NH2
HN
O
heat
HN
1. NH2OH
2. H2/PtO2
50% 60%
2-40 2-41
2-42 2-43
LiAlH4
 
 
Scheme 9. Synthesis of benzomorphan 2-43 by intramolecular lactam formation. 
 
The synthesis of butorphanol 2-54 is a representative example for a succesful application of a 
multi-step synthesis of a potent pharmaceutical.[30] As an alternative to previously described 
routes, the authors utilized the synthetic approach to morphinane-related structures, which lend 
itself to the introduction of the hydroxyl group at the C-14 atom (Scheme 11). 
 
Alkylation of 7-methoxy-1-tetralone 2-44 with 1,4-dibromobutane using sodium hydride in 
refluxing benzene gave the spiroketone 2-45 (Scheme 10). Cyanomethylation of 2-46 led to 
the hydroxynitrile which was reduced with LiAlH4, without prior isolation, to the amino 
alcohol 2-47. Rearrangement of the latter presumably via intermediate carbenium ion 2-48, by 
refluxing in a mixture of concentrated hydrochloric acid and ether during 24 hours afforded 
the unsaturated amine 2-49 in 74% yield.  
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MeO
O
MeO
MeO
HO
NH2
MeO
H2N
NaH
1,4-dibromobutane
1. LiCH2CN
2. LiAlH4
HCl, Et2O
80%
75%
74%
2-44 2-45
2-46
2-49
MeO
2-48
H2N
 
 
Scheme 10. Formation of spiro-aminoketon 2-46 and rearrangement to alkene 2-49. 
 
Compound 2-49 was treated with Br2 to give 72% yield the bromohasubanan hydrobromide 
salt 2-50 (Scheme 11). Cyclization of 2-50 with sodium bicarbonate in DMF at 130–135 °C 
led to the isolation of methoxymorphinan 2-52 (70% yield). When the same reaction was 
carried out at lower temperature, the aziridine hydrobromide 2-51 was isolated and allowed 
the authors to postulate the fact that this transformation passes through 2-51 as an intermediate 
in the formation of the alkene 2-52. Acylation of compound 2-52 by standard procedure 
readily afforded the corresponding amide. Epoxidation of this unsaturated amide with m-
chloroperbenzoic acid yielded the expected 8,14-β-epoxide 2-53. Reduction with LiAlH4 in 
refluxing THF gave the intermediate amino alkohol which was demethylated with boron 
tribromide in CH2Cl2, whereupon 3,14-dihydroxy-N-cyclobutylmethylmorphinan (2-54, 
butorphanol) was obtained in 86% yield. Resolution of the optical isomers was accomplished 
with l-tartaric acid to give the tartrate salt of l-butorphanol (l-2-54). 
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Scheme 11. Synthesis of butorphanol (2-54). 
 
Using this synthetic route, several other N-substituted analogues of 2-54 as well as several 
isomorphinans and hasubanan analogs were readily prepared and proved to be very potent 
analgetics.[31] 
 
Use of the Mannich reaction extended the tetralone route for the synthesis of benzomorphans. 
Thus, in 1977 it was reported as a route to benzomorphans such as 2-56.[32] Utilizing a double 
Mannich reaction of tetralone 2-55 with MeNH2 and CH2O under acidic conditions provided 
the benzomorphan scaffold 2-56 in one step although in rather low yield (Scheme 12).  
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MeO
AcOH, reflux
Me
O
MeO
Me
N
O
Me
formalin
3.5 h, 20%
2-55 2-56
MeNH2·HCl
 
 
Scheme 12. Preparation of benzomorphan derivative 2-56 using double Mannich reaction. 
 
From this ketone were then prepared three benzomorphan derivatives as subjects for biological 
activity tests (Scheme 13). Compound 2-57 was available after Wolff-Kishner reaction on 
scaffold 2-56 in 71% yield. Refluxing of methoxybenzomorphan 2-57 with conc. HBr resulted 
in O-demethylation and afforded the hydrobromide salt of 2-58.  
 
NH2NH2*H2O
4 h, 71%
MeO
Me
N
Me
HO
N
Me
HBr conc.
Me
2-56
refl., 55%
KOH
200 °C
2-57 2-58  
 
Scheme 13. Preparation of benzomorphan 2-58. 
 
Wittig reaction of ketone 2-56 with PPh3=CH2 gave alkene 2-59, which under different 
hydrogenation conditions formed two different products (Scheme 14). At first, under acidic 
conditions, hydrogenation of 2-59 with PtO2 as catalyst delivered the α-isomer in 48% yield, 
although under neutral conditions with the same catalyst and EtOH as a solvent only β-isomer 
was formed. O-Demethylation under the same conditions (refluxing with conc. aqueous HBr) 
gave 3,6,11-trimethyl-8-hydroxybenzomorphans 2-60 and 2-61.  
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Me Me
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80%
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2-59
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Scheme 14. Preparation of benzomorphans 2-60 and 2-61. 
 
Finally, it was found that compound 2-58 has analgesic potency comparable to that of codeine 
by the method of stimuli on mouse tail. The other two substances (2-60 and 2-61) were also 
found to be significantly active in the same tests.  
 
The intramolecular Mannich reaction, which leads to benzomorphans from appropriately 
substituted tetralones, has found its application later for the synthesis of various 
conformationally constrained l-tyrosine analogues as targets for their potential application to 
SH2 domain ligands.[33] 
 
Tetralone 2-62 was subjected to an initial aminomethylation of silyl enol ethers 2-63a,b which 
had been obtained as an inseparable mixture (Scheme 15). Subjecting this mixture to 
aminomethylation provided the desired primary amine 2-64 as a single regioisomer. The 
reaction occurred in high yield in spite of the fact that formation of 2-64 proceeded from        
2-63b, which was a minor component in the starting reaction mixture. As the authors note, this 
implies to the fact that during aminomethylation a reversible equilibrium between 2-63a and 
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2-63b was maintained with depletion of 2-63b occurring through transformation to product   
2-64.  
 
O
MeO
OTIPS
MeO
OTIPS
MeO
OTIPS
MeO
NH2
TIPSOTf, Et3N
benzene, r.t.
90%
TMSCH2N3, AlCl3
CH2Cl2
2-62
2-63a
2-63b
2-64
 
 
Scheme 15. Preparation of precursor 2-64. 
 
The aminomethylation product 2-64 was reacted with methyl glyoxalate in presence of 
magnesium sulfate to form imine 2-65 (Scheme 16). This was acetylated without purification 
to form an activated acyliminium intermediate (2-66) that underwent intramolecular 
electrophilic cyclization to yield the key tricyclic ketone 2-67 in 68% yield over 3 steps from 
enol ether 2-63. The authors note that the 2-carbomethoxy group in ketone 2-67 was obtained 
as an endo-/exo-diastereomeric mixture. Reductive deoxygenation of the keto group of ketone 
2-67 could be achieved in a two-step manner by initial thioketalization to spiro bisdithiane     
2-68, followed by desulfurization to benzomorphan 2-69 using Raney Nickel in refluxing 
EtOH. Although undesired endo 2-carbomethoxy-containing material could be removed 
chromatographically at this point, it was found that treatment of ester 2-69 with mild base (2M 
methanolic ammonia) resulted in epimerization at the 2-position to yield the desired exo 
isomer 2-70 as a single product. Remarkably, formation of the carboxamide side product was 
not detected under these conditions. 
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Scheme 16. Intramolecular Mannich reaction of imine 2-65 and completion of the synthesis of 
benzomorphan 2-70. 
 
In the course of the work on the radical chemistry of xanthates, it was found that radicals with 
a variety of substituents could be generated and captured in an intermolecular fashion with an 
unactivated, preferably unhindered olefin.[34] As an example of such a transformation the 
synthesis of polycyclic structures was peformed as well as one of benzomorphans.[35] Thus, the 
starting xanthane 2-71 derived from a ketone was treated with olefin 2-72 containing a 
protected amine in the allylic position in the presence of a radical initiator giving the addition 
product 2-73 in 66% yield. Finally, the xanthate group in adduct 2-73 was used to obtain 
tetralone 2-74 via a radical cyclization onto the aromatic ring, albeit in moderate yield (42%). 
Removal of the Boc-protecting group, followed by treatment with hydrochloric acid and 
formaldehyde allowed the efficient synthesis of the tricyclic derivative 2-75 in 71% yield 
(Scheme 17).  
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Scheme 17. Synthesis of benzomorphan 2-75 by Zard and co-workers. 
 
A synthetic sequence, which involves carbon-carbon bond formation rather than carbon-
nitrogen bond formation in the cyclization step, has been used for the synthesis of substituted 
benzomorphan 2-78 in 1967.[36] This route exhibits cyclization induced by formation of 
tertiary anion from tetraline 2-77 and NaH, followed by its intramolecular nucleophilic attack 
of chloroacetyl group, leading to benzomorphan 2-78 (yield of product is not given) (Scheme 
18). 
 
NMePh
O
O
N
Cl
NaH, benzene
reflux
Ph
O
4 steps
Ph
2-76 2-77 2-78  
 
Scheme 18. Synthesis of benzomorphan 2-78 using carbon-carbon bond forming reaction. 
 
Recently, Barry Trost presented an asymmetric approach to the benzomorphan analgesics 
metazocine (2-86) and pentazocine (2-1) as well.[37] Performing the asymmetric allylic 
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alkylation (AAA)[38] of prochiral tetralone 2-55 and allyl acetate with a catalyst derived from 
π-allylpalladium chloride dimer (0.5%) and (R,R)-ligand 2-79 (1.0%) in the presence of 
cesium carbonate in DME gave tetralone 2-80 in good yield and enantiomeric excess as shown 
in Scheme 19. 
 
MeO O MeO OAllylOAc, (Allyl-PdCl)2
DME, Cs2CO3
HN NH
OO
PPh2 Ph2P
90%, 91% ee
2-55
2-79
2-80
 
 
Scheme 19. Asymmetric allylic alkylation of tetralone 2-55. 
 
Wittig olefination gave an almost quantitive yield of exocyclic olefin 2-81 (Scheme 20). 
Although one-pot cleavage (OsO4, NaIO4) of 2-81 was not succesful, the authors applied 
stepwise operations wich led to selective cleavage of the less hindered terminal olefin in the 
presence of the 1,1-disubstituted olefin. Reductive amination provided amine 2-83 in good 
yield. Completion of the sequence was set through migratory amination, the key speculative 
step in this synthesis. Treatment of amine 2-83 with catalytic amounts of LDA (20%) in THF 
led to cycloisomerization to form 2-85 as a single diastereomer in nearly quantitive yield. The 
authors hypothesize that the high diastereoselective control at C-11 came from intramolecular 
protonation of the allylic anion 2-84 from the alpha face (i.e. cis to the aminoethyl substituent) 
of an almost flat six-membered ring. Finally, demethylation after treatment of 2-85 with BCl3 
in CH2Cl2 gave (-)-metazocine 2-86 in high yield. 
 
  Literature Review 30 
MeO2-80 MeO
O
MeO
MeHN HNMe
Me
NMe
MeO
Me
MeO
1. OsO4, NMO
2. NaIO4
CH2=PPh3
THF
98% 75% (2 steps)
LDA, THF
98%
MeNH2
NaBH4, MgSO4
(-)-Metazocine (2-86)
2-81 2-82
2-83 2-84
BCl3, CH2Cl2
Me
NMe
HO
Me
2-85
 
 
Scheme 20. Synthesis of (-)-metazocine (2-86) by B. M. Trost and W. Tang. 
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2.3.2 Grewe-type Cyclization 
 
This type of reaction first published by R. Grewe in 1946 was found to be the most widely 
used approach for the construction of the benzomorphan skeleton.[19],[39] Generally, Grewe 
cyclization is based on the acid-catalyzed intramolecular reaction of appropriately substituted 
tetrahydropyridines 2-88. Thus, electrophilic attack of intermediate carbocation 2-89 onto the 
aromatic ring results in the formation of the bridged cyclic system 2-90 (Scheme 21).  
 
NR1
R3
NR1
R2
R3
H
R4 R4
R2 NR1
R3
R2
2-88 2-89 2-90
H+
 
 
Scheme 21. Grewe cyclization. 
 
Interestingly, this mode of reaction is quite general since a variety of tetrahydropyridines are 
cyclized under acidic conditions, the major product is always that in which the alkyl groups 
are cis with respect to the newly forming ring, and therefore is α-isomer.[40] The trans or β-
isomer can also be isolated in certain instances, for example when R3 (Scheme 22) is an 
aromatic substituent.[41] 
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Scheme 22. Formation of alpha-isomer is predominant in Grewe cyclizations. 
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The first benzomorphan prepared using this transformation was the 3,6,11-trimethyl derivative 
2-93.[42] Addition of a benzylic Grignard reagent to 3,4-lutidine methiodide 2-91, followed 
immediately by reduction of the unstable intermediate dihydropyridine, afforded 2-92 which 
was cyclized with 85% H3PO4 to yield 2-93 in 20% overall yield. 
 
N
MgCl1.
2. H2, Pd/BaSO4
I
MeN
NMe
HH3PO4
20% (2 steps)
2-91 2-92 2-93  
 
Scheme 23. First synthesis of trimethylbenzomorphan 2-93 by E. May. 
 
Shortly after this work, it was reported that the tetrahydropyridine precursors could be 
obtained via Stevens rearrangement of the corresponding benzyl alkyl tetrahydropyridinium 
salts.[43] Thus, sodium borohydride reduction of a 1,3,4-trialkylpyridinium salt 2-91 afforded 
the tetrahydropyridine, which was quaternized with the appropriate benzyl halide to yield the 
benzyl alkyl tetrahydropyridinium salt 2-94. Rearrangement was effected by treating 2-94 with 
etheral phenyllithium to afford the tetrahydropyridine 2-92 (Scheme 24). The formation of the 
shown regioisomer in the Stevens rearrangement over the other possible regioisomer (C-6) is 
because the ylide intermediate leading to 2-92 is stabilized by conjugation with the double 
bond. Subsequent cyclization of tetrahydropyridine 2-92 was affected by treatment with 48% 
aq. HBr. 
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Scheme 24. Synthesis of tetrahydropyridine 2-92 by Stevens rearrangement and cyclization to 
2-93. 
 
The report of a Grewe-type cyclization of tetrahydropyridines opened a new approach to the 
synthesis of benzomorphans. As a result, hundreds of compounds have been prepared using 
this route by variation of R1-R4 in 2-90.[44] 
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2.3.3 Other Routes to the Benzomophan Ring Skeleton 
 
In this part other synthetic routes are presented which were not applied for a broad scope of 
benzomorphans but only for the synthesis of separate examples. 
 
An interesting approach, developed by Michne and co-workers[45] was applied to the 
preparation of benzomorphan 2-101 (Scheme 25). The precursor, 1,2-dihydropyridine 2-96, 
obtained from the reaction of 4-ethyl-1-methylpyridinium iodide 2-95 and benzylmagnesium 
chloride was treated with ethyl acrylate in refluxing benzene to give ethyl 3-benzyl-8-ethyl-2-
methyl-2-azabicyclo[2.2.2]oct-7-ene-6-carboxylate (2-97), isolated as its hydrochloride salt in 
30% overall yield. Treatment of carboxylate 2-97 with anhydrous HF at room temperature for 
24 hours gave the polycycle 2-98, isolated in 90% yield. Saponification of ester 2-98 to the 
acid followed by reaction with CH3Li/Et2O gave the ketone 2-99.  
 
Transformation of polycyclic amine 2-99 to benzomorphan 2-100 was accomplished by an 
acid-catalyzed retro-Mannich reaction of the β-amino ketone system followed by reduction of 
the intermediate iminium cation. Thus, heating of the ketone 2-99 in mesitylene with excess 
formic acid for 24 hours at 115–120 °C gave the benzomorphan 2-100 in 65% yield. Finally, 
treatment with CH3Li in Et2O produced the alcohol 2-101, which was isolated in 38% yield. 
Compound 2-101 was screened for analgesic activity and found to be 40% as potent as 
morphine. 
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Scheme 25. Synthesis of benzomorphan 2-101 using a tandem retro-Mannich/reduction 
reaction. 
 
Boger and Mullican[46] developed a direct method for the controlled and selective introduction 
of oxygenated aromatics for preparation of a representative series of benzomorphans. This 
route is based on the utilization of inverse electron demand Diels-Alder reaction of 3-
carbomethoxy-2-pyrones. The 3-carbomethoxy-2-pyrone 2-104 was readily available from 
bicyclic amino ketone 2-102 (Scheme 26) after enolization with LDA in THF followed by 
addition of dimethyl (methoxymethylene)malonate (2-103).  
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Scheme 26. Preparation of the 3-carbomethoxy-2-pyrone 2-104. 
 
The resulting product, 2-104, underwent smooth cycloaddition with 1,1-dimethoxyethylene   
2-105 to give the amide 2-107 at 140 °C during 20 hours (Scheme 27). Ester hydrolysis with 
aqueous NaOH and copper-promoted decarboxylation in quinoline at 220 °C provided the 
hydroxy-substituted benzomorphan 2-109. Demethylation of the aryl methyl ether ortho to the 
carboxylate occurred under the conditions of the reaction.  
 
Similarly, treatment of 3-carbomethoxy-2-pyrone 2-104 with 1,1,2-trimethoxyethylene 2-106 
followed by acid treatment of the crude Diels-Alder adduct afforded 2-108. Ester hydrolysis 
and copper-promoted decarboxylation provided the selectively protected, unsymmetrical o-
catechol benzomorphan 2-110. Selective demethylation of the aryl methyl ether ortho to the 
carboxylate occurred prior or concurrent with decarboxylation. 
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Scheme 27. Approach to benzomorphans 2-109 and 2-110 using Diels-Alder reaction of 3-
carbomethoxy-2-pyrone 2-104 with dienophiles 2-105 and 2-106. 
 
Rapoport et al. in 1979 presented a sequence for benzomorphans synthesis starting from 3-
methyl-4-(3-methoxyphenyl)-2-piperidone (2-111).[47] In their work, substituted racemic 
piperidine 2-111 was first converted to enamine 2-112 by reduction with LiAl(OEt2)H2 
(Scheme 28). The crude product was immediately added to solution containing 10 eqiuv. of 
KCN, affording aminonitrile 2-113 as a 5:4 mixture of diastereomers. Treatment of this isomer 
mixture with aqueous methanolic NaOH gave total conversion to the more stable aminonitrile 
isomer 2-114. Nitrile 2-114 was then elaborated into ketone 2-115 via inverse addition to 
CH3Li/Et2O in excellent yield. 
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Scheme 28. Synthesis of β-isomer of benzomorphan 2-116 by Rapoport. 
 
Cyclization of ketone 2-115 was attempted with BF3·Et2O and provided a 58% yield of 
methylenebenzomorphan 2-116 and significant amounts of epimerized starting material. 
Extended reaction times, higher temperatures, and varying amounts of BF3·Et2O catalyst had 
no considerable effect on the product/starting material distribution. A possible transition state 
for the Lewis acid promoted cyclization is depicted in Figure 15. 
 
Me
NMe
O
MeO
X3B
H H
H
δ+
2-115  
 
Figure 15. Possible transition state for Lewis-acid promoted cyclization of ketone 2-115. 
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Later, the intramolecular Friedel-Crafts reaction was applied by several groups for the 
synthesis of benzomorphans. For example, recently it was demonstrated, that an acid-
catalyzed cyclization of 4-benzyl-substituted 5,6-didehydropiperidin-2-ones leads to the 
formation of the corresponding benzomorphans.[48] β-Selective N-glycosylation of 2-
(trimethylsilyloxy)pyridine (2-116) with O-pivaloylated galactosyl fluoride (2-117) gave the 
N-galactosyl 2-pyridone 2-118 in good yield (Scheme 29). This unsaturated heterocyclic 
structure was transformed regio- and stereoselectively by reaction with benzyl Grignard 
reagent. After activation by O-silylation using triisopropylsilyltrifluoromethanesulfonate 
(TIPSOTf), the Grignard addition gave 4-benzylated 5,6-didehydropiperidin-2-one 2-119. The 
regioselectivity and the high diastereomeric ratio (99:1) of this process was governed by the 
facial differentiation of the carbohydrate auxiliary. The authors note, that previously published 
syntheses using the same benzylpiperidine moiety to form benzomorphans required highly 
activated aromatic systems and proceeded in a nonregioselective manner. In the case of the 4-
benzyldidehydropiperidinone 2-119, the intramolecular aminoalkylation took place at low 
temperature in the presence of a mixture of HCl/SnCl4. The intermediate N-acyl iminium ion 
underwent cyclization to yield the tricyclic benzazocinone 2-120 through electrophilic attack 
at the phenyl ring exclusively from the cis side. 
 
To release the benzomorphan moiety from the carbohydrate auxiliary the benzazocine 2-120 
was treated with Lawesson’s reagent to give the corresponding thioamide, which was 
subsequently desulfurated on Raney nickel. Acidic cleavage of the N-glycosidic bond using 
aqueous HCl in methanol provided the benzomorphan hydrochloride 2-121 with a yield of 
59% over the last 3 steps. 
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Scheme 29. Synthesis of benzomorphan 2-121 by Kunz and co-workers. 
 
Obviously, up to date there is a huge number of syntheses of benzomorphan structures 
reported in the literature. These cannot be listed within the borders of one dissertation, but 
what can be noted, is the fact, that all of them either contain minor changes from the above 
listed routes, or are direct copies of the synthetic sequences. 
 
In conclusion, this literature review of different approaches to benzomorphans and their 
derivatives, illustrates that benzomorphans represent not only a core structure of many 
biologically active substances, but are also an interesting target for the development of new 
and convergent methodologies in organic chemistry. 
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3 Goal of Research 
 
As described in the previous part, classical routes to such compounds like 
benzomorphans include SN2 reactions with a nucleophilic amine, formation of amides, 
intramolecular Friedel–Crafts alkylation, or iminium ion cyclizations. However, due to the 
reactions employed, the type of substituents is restricted at certain positions. With the advent 
of new powerful organometallic transformations, such as cross-coupling or C–H insertions, the 
chemistry of classical drugs might be substantially broadened. Thus, structures that previously 
seemed difficult to prepare might be now more easily accessible. The direct introduction of an 
aryl unit at a nucleophilic carbon is a transformation of central importance to complex 
molecule synthesis.[49] A synthetic useful subset of this class of reactions is the arylation of 
ketones at the α-position. A case in point is the Buchwald–Hartwig arylation of enolates in the 
presence of a palladium catalyst (Equation 2).[50]  
 
R2Br
+
Pd(0), ligand
base
O
R1
R2
R1
O
 
 
Equation 2. 
 
Mechanistically, the approach of Buchwald et al., and Hartwig et al. for the synthesis of α-aryl 
ketones, esters, or other carboxylic acid derivatives, involves the oxidative addition of the 
Pd(0)Ln to the aryl bromide affording the Pd(II) organometallic intermediate A (Figure 16). 
Ligand substitution of the bromide by the enolate generated by deprotonation of the 
corresponding ketone provides the Pd(II) organometallic intermediate B. Finally, reductive 
elimination from intermediate B provides the α-aryl ketone and regenerates the Pd(0)Ln 
catalyst. 
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Figure 16. Possible catalytic cycle of Pd(0)-catalyzed α-arylation of ketones. 
 
Having successful experience in this type of reactions,[51] we were interested to employ the 
Buchwald-Hartwig arylation in an intramolecular setting towards the synthesis of new 
benzomorphan scaffolds.  
 
As we have found in the literature, this idea has already proved its potency for the synthesis of 
various classes of other polycyclic systems.[52] For example, it was demonstrated, that 
substituted o-halo-N-acylanilines 3-1 under palladium catalysis with a sterically hindered 
phosphine ligand and in presence of a base undergo the desired cyclization to form 2-
oxindoles 3-2 in high yield.[53] 
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Scheme 30. Synthesis of various 2-oxindoles by intramolecular Pd-catalyzed arylation 
according to Hartwig and co-workers. 
 
Nakai and co-workers utilized the intramolecular arylation of properly designed substrates   
(3-3 – 3-4) by use of a PdCl2(Ph3P)2–Cs2CO3 reaction system to form a variety of carbocyclic 
compounds (Scheme 31).[54] 
 
O
Br
n
PdCl2(Ph3P)2, Cs2CO3,
THF or toluene, reflux
n = 1,2,3
O
n26-85%
3-3 3-4  
 
Scheme 31. Synthesis of bridged carbocyclic compounds using Pd-catalyzed intramolecular 
arylation by Nakai and co-workers. 
 
To assemble the tetracyclic ring system towards the synthesis of N-methylwelwitindolinone, 
Rawal and co-workers successfully engaged the discussed transformation.[55] Thus, indolyl 
derivative 3-5, after treatment with Pd(OAc)2, PtBu3 in toluene and KOtBu as base, underwent 
the desired cyclization in high yield to give the keto ester 3-6 (Scheme 32). 
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Scheme 32. Intramolecular Pd-catalyzed arylation to create the core bicyclo[4.3.1]decane ring 
system of welwitindolinones by Rawal and co-workers. 
 
The aforementioned examples show, that the selected strategy is a powerful transformation 
towards the synthesis of complex organic molecules. In the issue of new benzomorphan 
scaffolds synthesis, compound 3-8 after adding suitable functional groups, appeared as an 
initial target (Figure 17). Further disconnection leads to the o-bromobenzyl bromides 3-9 and 
the piperidones 3-10. Alkylation between the carbonyl and the carboxyl groups (cf. 3-8) or at 
the terminus (cf. 3-12) by Weiler alkylation[56] should provide suitable substrates for the 
intramolecular ketone arylation.  
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Figure 17. Synthetic strategy towards benzomorphans based on an intramolecular Buchwald–
Hartwig arylation. 
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4 Results and Discussion 
 
4.1 Synthesis of Benzomorphans by Intramolecular Buchwald-Hartwig 
Arylation of Substituted N-Benzyl-Piperidone Derivatives 
 
The commercially available 1-benzyl-4-oxopiperidine (4-1) was first converted into the 
keto ester 4-2 using diethyl carbonate in the presence of NaH (Scheme 33). The alkylation of 
the keto ester 4-2 with o-bromobenzyl bromide (4-3a) was performed in refluxing THF using 
potassium carbonate as the base.[57] Under these conditions a reasonable yield for the 
alkylation product 4-4a could be obtained.  
 
N
O
Br
Bn
CO2EtN
Bn
O
NaH, THF
(EtO)2C=O
62%
N
Bn
O
CO2Et
Br
Br
K2CO3, THF
reflux, 6 h, 73%
4-1 4-2
4-3a
4-4a
 
 
Scheme 33. Preparation of substituted piperidine 4-4a. 
 
Other bases like tBuOK in THF or NaH in toluene were tried, but the K2CO3/THF system 
gave the best results (Table 1). Also, after complete reaction, the inorganic materials can be 
simply filtered out without a special work-up procedure, unlike with other stronger bases. This 
is an additional advantage in contrast to other conditions tried. 
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Table 1. Alkylation of 3-carbethoxy-1-benzyl-4-oxopiperidine (4-2) with o-bromobenzyl 
bromide (4-3a) under different conditions. 
 
Entry base solvent T, °C yield, % 
1 K2CO3 THF 56 73 
2 tBuOK THF r.t. 55 
3 NaH toluene 90 55 
 
 
The intramolecular ketone α-arylation was performed using K3PO4 (3 equiv.), tBu3P (4 mol-
%) and Pd(dba)2 (2 mol-%) in refluxing toluene (Scheme 34). This way, the tricyclic 
compound 4-5a was obtained in 65% yield and other condition were not tried. These 
conditions (K3PO4, tBu3P, toluene) proved to be applicable for many substrates and are also 
very cost efficient if to compare tBu3P with other ligands used for this type of reaction.[50],[51] 
 
N
O
Br
Bn
CO2Et
4-4a
N
O
Bn
CO2Et
Pd(dba)2, tBu3P
K3PO4, toluene
110 °C, 12 h (65%)
4-5a  
 
Scheme 34. Palladium-catalyzed intramolecular ketone arylation of 4-4a to yield the 
benzomorphan derivative 4-5a. 
 
The reaction was also run on a multigram scale up to several grams of the product. In this case 
the product was isolated by precipitation from the reaction mixture after filtration of inorganic 
material. The structure of the tricyclic ring system 4-5a was additionally proven by an X-ray 
analysis (Figure 18). 
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Figure 18. X-ray structure of benzomorphan 4-5a. The crystal sample was obtained by 
crystallization from hot heptane. 
 
The diversity of the explored synthetic route to benzomorphans was demonstrated by applying 
a variety of differently substituted benzyl bromides. The compound 4-3b has the methyl 
substituent in ortho-position to the bromine atom; therefore, it plays the role of a sterically 
hindered (SH) substrate. The substrate 4-3c with a methoxy group presents an electron 
donating (ED) class of substituents. On the other hand, benzyl bromides with fluorine (4-3d) 
and cyano (4-3e) groups – are from the electron withdrawing (EW) set (Figure 19). 
 
SH ED EW
Br
Br
Br
Br
Br
Br
Br
Br
Me MeO F
N
4-3b 4-3c 4-3d
4-3e  
 
Figure 19. Benzyl bromides 4-3b-e with different types of substituent in the aromatic ring. 
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All benzyl bromides were prepared from the corresponding toluenes (available from 
commercial sources) by treatment with N-bromosuccinimide in refluxing CCl4. An exlusion 
was in the case of 1,3-dimethyl-2-bromobenzene – the attempts to reproduce literature 
procedure (with NBS in CCl4 and benzoyl peroxide as a radical initiator)[58] did not result in 
the formation of the desired product. As a result, the bromide 4-3b was obtained by reaction 
with elemental bromine and light irradiation (200W) instead of NBS. The yields for the 
bromination of the toluenes are presented in Table 2.[59] 
 
Table 2. Preparation of benzyl bromides 4-3b-e. 
 
Br
R
Br
Br
R
NBS, CCl4, reflux, 8 h
AIBN or benzoyl peroxide  
 
Entry toluene product № yield, % 
1 Br
 
4-3b 33a 
2 
Br
MeO  
4-3c 60 
3 
Br
F  
4-3d 45 
4 
Br
N
 
4-3e 63 
a Using elemental bromine and light irradiation 
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Using benzyl bromides 4-3b and 4-3c, substrate 4-4b which features a sterically demanding 
methyl group next to the bromo substituent, and substrate 4-4c with an electron-donating 
methoxy substituent (Scheme 35) were prepared.  
 
4-2, K2CO3, THF
reflux, 6 h
N
O
Br
Bn
CO2Et
N
O
Br
Bn
CO2Et
OMe
Me
Br
Me
4-3b
4-4b
4-4c
Br
4-2, K2CO3, THF
reflux, 6 h
4-3c
Br
OMe
Br
54%
52%
 
 
Scheme 35. Alkylation of ethyl 1-benzyl-4-oxopiperidine-3-carboxylate (4-2) with benzyl 
bromides 4-3b and 4-3c. 
 
On the other hand, to extend the scope of the studied transformation, two other benzyl 
bromides were applied for the preparation of compounds 4-4d and 4-4e with fluorine and 
cyano groups, respectively (Scheme 36). The products were obtained using the same 
conditions as above in yields of 72% for the product 4-4d and 29% in the case of the nitrile-
substitued compound 4-4e. 
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Scheme 36. Alkylation of ethyl 1-benzyl-4-oxopiperidine-3-carboxylate (4-2) with benzyl 
bromides 4-3d and 4-3e. 
 
After preparation of the collection of derivatives containing various types of substituents in the 
aromatic ring we then subjected them to the palladium-catalyzed cyclization under the same 
conditions as for 4-4a resulting successfully in benzomorphans 4-5b-e (Table 3).  
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Table 3. Palladium-catalyzed intramolecular ketone arylation to yield the 
benzomorphan derivatives 4-5b-e. 
N
O
Br
Bn
CO2Et
N
O
Bn
CO2Et
Pd(dba)2, tBu3P
K3PO4, toluene
110 °C, 12 h
R
R
 
Entry R product yield, % 
1 3-Me 
N
O
Bn
CO2Et
Me 4-5b
 
30 
2 5-MeO 
N
O
Bn CO2Et
OMe
4-5c
 
40 
3 5-F 
N
O
Bn CO2Et
F
4-5d
 
30 
4 4-CN 
N
O
Bn
CO2Et
N
4-5e
40 
 
 
  Results and Discussion 52 
In another venture, by changing the position of the nitrogen atom in the piperidone ring, the 
isomeric benzomorphan derivative 4-12 was synthesized. The precursor piperidone 4-10 was 
prepared in 3 steps as shown in Scheme 37 starting from ethyl 2-bromoacetate (4-6) and 
benzylamine, followed by alkylation of the resulting N-benzylglycine (4-7) with ethyl γ-
bromobutyrate (4-8) to give the diester 4-9. Treatment of the latter with NaH in dioxane 
furnished the piperidone 4-10 by Dieckmann condensation.[60] 
 
N
CO2Et
Bn
1. NaH, Et3N
dioxane
2. HCl, EtOH N
O
CO2Et
H
Bn Cl-CO2Et 75% (3 steps)
4-9 4-10
NH
CO2Et
Bn
4-7
Br
CO2Et
4-6
BnNH2
DMSO Br
CO2Et
Et3N
4-8
 
 
Scheme 37. Synthesis of N-benzyl-4-carbethoxypiperidone-3 hydrochloric salt (4-10) from 
ethyl-2-bromoacetate (4-6). 
 
Alkylation of the keto ester 4-10 with the benzyl bromide 4-3a provided the substrate 4-11. 
This piperidone (4-11) is somehow unstable at room temperature and therefore should be 
stored at lower temperatures and under inert atmosphere. Palladium-catalyzed cyclization of  
4-11 was performed under similar conditions as for 4-4a to deliver one more example of 
benzomorphans synthesized (Scheme 38).  
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Scheme 38. Alkylation of ethyl 1-benzyl-3-oxopiperidine-4-carboxylate (4-10) with benzyl 
bromide 4-3a and Pd-catalyzed cyclization to 4-12. 
 
 
4.2 Synthesis of Benzomorphans by Intramolecular Buchwald-Hartwig 
Arylation of Substituted N-Methyl-Piperidone Derivatives 
 
Because the N-methyl group is rather common in natural products as well as synthetic 
drugs (Figure 19), it was of interest to see whether compounds of type 3-7 could be accessed 
employing the discovered tranformation with N-methyl instead of a N-benzyl group.  
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Figure 19. Several examples of natural products and synthetic drugs bearing a N-methyl 
substituent. 
 
In our case, compounds containing a N-Me-substituent might be prepared from the N–H 
derivative (cf. 4-22) or directly from N-methyl-4-oxopiperidine-3-carboxylate. The precursor 
4-oxopiperidine 4-18 was prepared in an analogous fashion as for the N-benzyl derivative, by 
carboxylation of N-methyl-4-piperidone (4-1) with diethyl carbonate after treatment with NaH 
(section 4.1, Scheme 33). The C-alkylation of the enolate anion of N-methyl-3-carbethoxy-4-
piperidone (4-18) with o-bromobenzyl bromide 4-3a as it was utilized with N-benzyl-3-
carbethoxy-4-piperidone (4-2) seemed to be suitable. However, attempts to perform this 
alkylation with K2CO3 in refluxing THF did not let us to obtain the desired product, possibly 
because N- rather than C-alkylation took place (Scheme 39).  
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Scheme 39. Attempt to alkylate the N-methyl-3-carbethoxy-4-piperidone 4-18 with o-
bromobenzyl bromide 4-3a. 
 
To solve this problem it was required to use the ammonium salt 4-19 for the alkylation of 4-
18.[61] The benzylanilinium salts 4-19a,b were available directly from the previously 
synthesized o-bromobenzyl bromides 4-3a,b by stirring them with N,N-dimethylaniline in dry 
benzene for 24 hours in quantitative yield (Scheme 40).[62] Thus, treatment of the enolate 
anion of N-methyl-3-carbethoxy-4-piperidone (4-18) with o-bromobenzylanilinium salts 4-19a 
and 4-19b, proceeded through the desired C-alkylation providing compounds 4-20a,b. 
 
4-3a,b
Me2N
benzene, 23 °C
24 h (100%) Br
N
Me
Ph
Me
Br-
4-19a,b
R
N
O
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Me
CO2EtN
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O
CO2Et 1. NaH, toluene
2. salt 4-19a or 4-19b
reflux, 6 h
4-18 4-20a (R = H) 38%
4-20b (R = Me) 35%
R
 
 
Scheme 40. Synthesis of ammonium salts 4-19a,b and alkylation of N-methyl-3-carbethoxy-
4-piperidone (4-18). 
 
The crucial cyclization was run under the same conditions that had proven useful with the N-
benzyl derivatives (from 4-4a to 4-5a), but required longer reaction times (Scheme 41).  
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Scheme 41. Cyclization to the N-methylsubstituted benzomorphan derivatives 4-21a and       
4-21b. 
 
While the yield for the tricyclic compound 4-21a was not very high, this reaction provides the 
desired compound in a very efficient way. Compound 4-21b was prepared in an analogous 
fashion. To improve the yield of N-methylbenzomorphan derivative 4-21a using other bases 
than K3PO4, such as tBuOK or tBuONa in the cyclization step, did not lead to an improvement 
– the product was not even observed in the reaction mixture. 
 
4.3 Preparation of Benzomorphan Scaffold and Its Derivatization 
 
A further task was recognized in the synthesis of the strategic benzomorphan scaffold 
4-22 bearing a secondary amino group, which could be used for further derivatization. It 
seemed appropriate to remove the N-benzyl protecting group by palladium-catalyzed 
hydrogenation. However, under various conditions (Table 4) formation of the desired product 
was not observed. Most likely, steric hindrance interferes with the hydrogenation step. 
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Table 4. Attempts to cleave the N-benzyl protecting group by 
hydrogenation on Pd catalyst. 
N
H
O
CO2Et
N
O
Bn
CO2Et
Pd/C
4-5a 4-22  
Time Solvent T, °C Yield, % 
12 EtOH r.t. 0 
24 EtOH/AcOH 45 0 
72 EtOH/AcOH 60 0 
 
 
Therefore, we tried to convert the benzyl group into a more reactive urethane protecting 
group.[63] In the event, stirring of the tricyclic compound 4-5a with ethoxycarbonyl chloride at 
elevated temperature for 3 days provided the ethoxycarbonyl compound 4-23a in good yield 
(Scheme 42). Again, attempts to cleave the ethyl carbamate under acidic conditions (concd. 
HCl, reflux) or with trimethylsilyl iodide (TMSI) were not successful in our hands – the 
starting material remained unchanged.  
 
N
O
CO2Et
CO2Et
4-5a
ClCO2Et, 60 °C
3 d (64%)
4-23a
N
H
O
CO2Et
4-22
conditions*
* HCl at reflux or TMSI in acetonitrile  
 
Scheme 42. Conversion of the N-benzyl compound 4-5a to the urethane 4-23a. Attempts to 
cleave the ethoxycarbonyl group. 
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A solution was found by using Cbz chloride instead of ethoxycarbonyl chloride. Thus, heating 
of the tricyclic compound 4-5a with Cbz chloride for several days led to the Cbz-protected 
tricyclic piperidone 4-23b in 70% yield (Scheme 43). Deprotection was achieved by stirring 
the Cbz compound 4-23b with trimethylsilyl iodide (TMS-I) in acetonitrile. This reaction 
proceeded extremely fast – after 1 hour starting urethane was completely transferred to the 
secondary amine 4-22.[64] After the acetonitrile was evaporated in vacuo, the residue was 
treated with a dichloromethane-water mixture and the product could be then isolated easily by 
evaporation of the water layer. 
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Scheme 43. Conversion of the N-benzyl compound 4-5a to the urethane 4-23b. Cleavage of 
the Cbz group to yield the ammonium iodide 4-22. 
 
The deprotected compound 4-22 was isolated as the hydrate and the corresponding ammonium 
salt. The presence of the hydrate is evident from a characteristic peak in the 13C NMR 
spectrum at δ = 91.5 ppm (Figure 20). 
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Figure 20. 13C NMR spectrum of deprotected compound 4-22. 
 
With the amine 4-22 in hand, two representative N-derivatization reactions were performed in 
order to show the potential of 4-22 as a useful scaffold (Scheme 44). Thus, reaction of the 
amine 4-22 with phenyl isocyanate in the presence of triethylamine gave a high yield of the 
urea 4-24. Reaction of 4-22 was also possible with tosyl chloride under comparable conditions 
yielding the sulfonamide 4-25. 
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Scheme 44. Derivatization reactions on the tricyclic amino ketone 4-22. 
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5 Conclusion I 
 
We could show that the tactical sequence of alkylation of a cyclic keto ester with an 
ortho-bromobenzyl bromide, followed by an intramolecular ketone arylation reaction 
(Buchwald–Hartwig palladium-catalyzed cyclization) provides an efficient and innovative 
route to bicyclic benzomorphan scaffolds previously unknown. A number of substrates, which 
contain electron withdrawing, electron donating, and sterically hindered groups, respectively 
were subjected to the studied transformation. 
 
Preliminary biological activity results show that compound 4-5a is active at noradrenaline and 
serotonine sites. In 5-HT-reuptake inhibition tests, a value of 77% was achieved for a 10μM 
solution of 4-5a. Noradrenalin-reuptake inhibition tests showed 80% at the same 
concentration.[65] 
 
From the N-benzyl compound 4-5a the amine 4-22 (hydroiodide) could be obtained, which 
has served as a useful scaffold for further derivatization reactions. The synthesis of an 
isomeric benzomorphan with different nitrogen atom position (cf. 4-12) was also shown to be 
possible by the developed methodology. Other targets that contain an aryl or hetaryl ring in a 
complex structure should be accessible as well. 
 
Before this method was described there was no methodology known to provide 
benzomorphans with a broad scope of aromatic ring substituents and nitrogen position 
variations at once. Therefore, the obtained results represent a valuable contribution to the field 
of modern organic chemistry. 
 
  
Chapter II: 
 
 
Approach towards the Total Synthesis of the 
Macrolide Queenslandon. 
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6 Introduction 
 
The birth of natural product synthesis as a discipline corresponds with the synthesis of 
urea by Friedrich Wöhler from ammonium cyanate in 1828, for the reason that this compound 
is a naturally occurring substance. Besides giving birth to organic synthesis, that sign event 
served to “discredit” finally the myth that the synthesis of natural products is possible only by 
nature. These days, the discipline of natural product synthesis is an important field of 
investigation whose profits broaden from new scientific knowledge to practical 
applications.[66] Also, natural product synthesis symbolizes the power of chemical synthesis 
and defines its scope and limitations. It also serves to sharpen the tool of chemical synthesis by 
expansion into higher molecular complexity, diversity, and efficiency.[67] 
 
Natural product synthesis gives the opportunity for the discovery and invention of new 
synthetic strategies and methods to be used in a wider range of applications. Another point is 
that natural products could be produced in larger quantities for further extensive biological 
investigations and/or medicinal applications. Moreover, to the extent that a natural substance 
can be synthesized in the laboratory, in a more cost-effective process than the one which 
requires its extraction from natural source; its use could become economically more sufficient 
and desirable. Yet another point is that natural products can provide a structural platform 
which can be elaborated upon, or simplified, to achieve the enhanced potency or improved 
selectivity or physical and chemical properties.[68] Such events could lead to advanced 
pharmacological properties than those possessed by the natural products themselves. On the 
other hand, the chemical synthesis of a natural product still provides the absolute proof of the 
assigned structure.[69] 
 
Benzolactone represent an important subclass of natural products among the polyketides.[70] 
The ones that feature acetate as a starter unit normally contain a 14-membered resorcylic acid 
lactone (RAL) feature. 
 
Resorcylic acid lactones (RALs) are mycotoxins produced by a variety of different fungal 
strains via polyketide biosynthesis (Figure 21). The fungal polyketide synthases (PKSs) 
  Introduction 64 
involved in RAL biosynthesis are large multidomain enzymes that iteratively catalyze the 
condensation of nine units of acetates or malonates. Different modules can further process the 
product of each condensation by reduction of the β-ketone or dehydration of the hydroxy ester. 
Different combinatorial arrangements of the modules involved in processing of the β-ketones 
in the first five condensations can account for the diversity of functionality present around the 
RAL macrocycles.[71] Even though their structures are quite similar, each of them displays a 
characteristic and unique type of biological activity.  
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Figure 21. Biosynthesis of resorcylic acid lactones. 
 
Queenslandon (6-1) was isolated in 2002 from the strain Chrysosporium queenslandicum 
IFM51121 and its relative stereochemistry was illustrated.[72] This macrolactone showed 
distinct activity against fungi but was devoid of antibacterial activity.  
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Figure 22. Structure of Queenslandon (6-1) and simplified analog 6-2 containing no 
substituents on the aromatic part. 
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Queenslandon is an attractive target first of all because of its structural relation to other 
members of the resorcylic acid lactones, which are known to be effective therapeutic agents 
and, on the other hand, there is no synthesis of this molecule reported in the literature up to 
date. Therefore, the total synthesis of queenslandon would prove the absolute configuration of 
stereogenic centers and possibly will give access to a new promising pharmaceutical.  
 
The objective of our research was therefore aimed at the design of an efficient synthetic 
strategy, which would allow the total synthesis of queenslandon itself, as well as other 
analogues of this novel natural product. 
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7 Literature review 
 
7.1 The Family of 14-Membered Resorcylic Acid Lactones 
 
While 14-membered resorcylic lactones (RALs) have been known for a long time, 
the more recent discoveries that some members of this class of natural products are potent 
kinase inhibitors have stimulated a renewed interest in this family of natural products.[73] 
 
The classical benzolactone, the fungal metabolite zearalenone (7-1), first isolated in 1962 
from the fungus Gibberella zeae and reported as exhibiting anabolic, estrogenic and 
antibacterial properties.[74] This compound was shown to adopt a conformation that mimics 
the one of 17-estradiol which explained its agonistic estrogenic properties.[75] The 
resorcylic acid lactone   L-783,277 (7-2), a fungal metabolite as well, was reported to be a 
selective inhibitor of MEK,* a threonine/tyrosine specific kinase resulting in antitumor 
activity (Figure 23).[76]  
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Figure 23. Structures of zearalenone (7-1) and L-783,277 (7-2). 
 
Another prominent member of the benzolactone family, radicicol (7-3, Figure 24), confers 
its antitumor activity through inhibition of the chaperone HSP90.[77] The related pochonins 
seem to target HSP90 as well, inducing antiviral and antiparasitic activity.[78] Another cis-
                                                 
* MEK (MAP kinase kinase) is a dual-specificity kinase that phosphorylates the tyrosine and 
threonine residues and involved in the MAP (Mitogen-activated protein) kinase cascade. The MAP 
kinases relay, amplify and integrate signals from a variety of extracellular stimuli thereby 
regulating a cell’s response to its environment. 
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enone RAL, LL-Z1640-2 (7-4), was shown[79] to be competitive with ATP and to 
irreversibly inhibit TAK1.* 
 
O
O MeOH
HO
Cl
O
O
OH
MeO
O
O Me
O
OH
OH
Radicicol (7-3) LL-Z1640-2 (7-4)
HSP90 inhibitor TAK1 inhibitor
20 nM 8.1 nM  
 
Figure 24. Examples of potent kinase or ATPase inhibitors: radicicol (7-3) and LL-Z1640-
2 (7-4). 
 
It follows that the benzolactones are important lead structures for the search of novel 
antitumor compounds.[80] In particular, structure–activity studies might illuminate key 
factors that make out the difference in the binding of a certain kinase.[81] All such 
properties of this subclass of benzolactones make them an attractive target for further 
biological investigations and structure activity studies. 
 
Protein kinases are recognized as essential components of cellular signal pathways and are 
directly involved in numerous diseases including cancer, diabetes, and inflammation. In the 
50’s, it was discovered that phosphorylation can reversibly alter the function of enzymes 
by protein kinases which catalyze phosphorylation, or by protein phosphatases which are 
involved in the dephosphorylation step (Figure 25).[82] 
 
                                                 
* TAK1 is a MAPKKK involved in the p38 signalling cascade for proinflammation signals  
  Literature Review 68 
H
N
N
HO
OH
O
H
N
N
HO
OH
O
H
N
O
O
OH
N
H
Serine
Threonine
Tyrosine
ATP ADP
Kinase
Phosphatase
H2OO
P OHO
OH
H
N
N
HO
O
O
H
N
N
HO
O
O
H
N
O
O
O
N
H
P
P
OO
OH
O
O
OH
P OO
OH
 
 
Figure 25. Phosphorylation and dephosphorylation mediated by kinases and phosphatases. 
 
These reactions play a crucial role in living organisms for the regulation of a large number 
of cellular processes (signaling transduction pathways). At the end of 70’s, the discovery 
that the transformation factor of the Rous sarcoma virus (v-Src) is a protein kinase[83] and 
that tumor-promoting phorbol esters are potent activators of protein kinase C[84] were of 
relevant significance. These two major observations emphasized the importance of protein 
phosphorylation at the cellular level, shedding the light on the first connections between 
abnormal protein phosphorylation and disease. Intensive research over the last thirty years 
has shown that defects in transduction mechanisms are at the basis of cancer and other 
human diseases (diabetes, inflammatory disorders, cardiovascular diseases, etc.).[85] In 
addition, the macrolactam geldanamycin is an important lead in the area of HSP90 
inhibitors.[86] 
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Figure 26. Structure of geldanamycin (7-5), the lead HSP90 inhibitor. 
 
Intensive research programs have led to the identification of several specific kinase 
inhibitors that show encouraging results as a new class of therapeutics. The vast majority 
of these compounds target the ATP-binding site of the kinase. Similarly, HSP90 (Heat 
Shock Protein 90) inhibitors target the ATP-binding pocket of the protein and several of 
them have been identified as potential anticancer agents. Among them, the 14-membered 
resorcylic acid lactones (RALs) stand out as the most potent ones.  
 
Monorden (7-3) was the first resocylic acid lactone isolated in 1953 from Monosporium 
nordinii.[87] After ten years the same molecule was independently isolated from Nectria 
radicicola[88] and called radicicol. With the assignment of its three chiral centers by X-ray 
crystal structure in 1987 it was shown that the initial structure proposed for monorden was 
incorrect leading to the common acceptance of radicicol as the name of this molecule.[89] In 
1964, mild sedative and moderate antibiotic properties were reported for radicicol.[90] 
While radicicol was reported to inhibit Src in cellular assays, it was later shown that this 
observation comes from the fact that radicicol is a potent and selective HSP90 inhibitor. 
On the other hand, several RALs bearing a cis-enone on the 14-membered macrocycle 
such as LL-Z1640-2 (7-4), L-783, 277 (7-6), hypothemycin (7-7) and radicicol A (7-8) 
have all been reported to be protein kinase inhibitors (Figure 27). 
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Figure 27. Structures of L-783,277 (7-6), hypothemycin (7-7), and radicicol A (7-8). 
 
Radicicol A (7-8, Figure 24) was isolated in 1987 from the fungus strain F/87-2509.04 
while looking for interleukin 1 beta (IL1β) inhibitory activity, an important mediator of 
inflammation.[91] Several years later, Traber and co-workers corroborated this finding 
along with inhibition of the tumor necrosis factor alpha (TNF-α) secretion, another major 
factor of inflammation.[92] Its mode of action is related to the degradation of specific 
mRNA sequences containing AU-rich elements (AREs).[93] Radicicol A was found to 
inhibit tyrosine phosphorylation of several proteins differentially expressed or modified by 
a tyrosine kinase. Several other analogs were also found to inhibit IL1β secretion but, 
without destabilizing mRNA, leading to the speculation that small structural differences 
are able to change the mode of action and presumably the target of inhibition. This 
hypothesis was even later corroborated by other members of this family such as LL-Z1640-
2 (7-4) isolated in 1978,[94] hypothemycin (7-7) in 1980[95] from Hypomiyces tricothecoides 
and L-783,277 (7-6). In 1999, researchers at Merck isolated L-783,277 (7-6) from organic 
extracts of a Phoma sp. (ATCC 74403) and showed it to be a potent, ATP-competitive and 
irreversible inhibitor of MEK1 with an IC50 of 4 nM.[96] At the same time, hypothemycin 
(7-7) was shown to be a slightly less active MEK1 inhibitor with an IC50 of 15 nM, 
providing an explanation to previously reported effects such as inhibition of the ras-
signaling pathways.[97] In 2003, Matsumoto and co-workers showed that LL-Z1640-2 (7-4) 
inhibited irreversibly the kinase activity of TAK1 (IC50 = 8.1 nM) by competing with 
ATP.[79] The importance of MEK1 and TAK1 in regulating cellular response to stimuli and 
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translating them into gene expression, cell growth and apoptosis has made these kinases 
and more generally the kinases involved in the MAP cascade primary targets in drug 
discovery.  
 
In addition to the aforementioned macrolides, several other RALs have been reported so 
far in the literature. Representatives of the zearalenone family are zearalenone itself (7-1), 
zearalane (7-9), and zeranol (7-10) (Figure 28). 
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Figure 28. Structures of zearalane (7-9) and zeranol (7-10). 
 
Extensive research on zearalenone (7-1) derivatives allowed the discovery of reduced 
derivatives such as 7-9 and 7-10 and their biological evaluation showed that they both 
share the properties of zearalenone. Additionally, zearalane (7-9) has shown anthelmintic 
and immunomodulating properties whereas zearanol (7-10, Ralgro® or Ralabol®) has been 
used to promote growth in cattle and to relieve post-menopausal stress in women.[98] 
 
More recently, new RALs were discovered in a screening for anti-malarial activity.[99] In 
2002, along with hypothemycin (7-7) as the major secondary metabolite, five new analogs 
were isolated from the marine mangrove fungus Aigialus parvus (Figure 29). 
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Figure 29. Structures of Aigialomycines A-E (7-12, 7-13, 7-14, 7-15, 7-16). 
 
Aigialomycin D (7-15) exhibited moderate anti-malarial activity against Plasmodium 
falciparum K1 and showed cytotoxicity in two cancer cell lines (KB and BC-1) in the same 
range as hypothemycin (7-7), whereas their analogs were much less active. Further studies 
have shown that aigialomycin D is able to inhibit some kinases namely CDK1/cyclinB, 
CDK5/p25 and GSK3 in the micromolar range (IC50 from 5 to 14 μM).[100] 
 
In 2003, other new members of the RAL family, pochonins A-F (7-17 to 7-22) and 
radicicol (7-3) isolated from Pochonia chlamydosporia var. catenulata were reported 
(Figure 30).[101] 
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Figure 30. Structures of pochonins A-F (7-17 to 7-22). 
 
These molecules were identified in a Herpes Simplex Virus 1 (HSV1) replication assay. 
While radicicol showed activity in the nanomolar range, all the pochonins except pochonin 
D exhibited bioactivities at the low micromolar range and pochonin D (7-19) only showed 
cytostatic effects. In this assay, HSV inhibition was always accompanied by weak 
cytostatic effects, therefore providing the low tolerability of these molecules in vitro. 
 
7.2 Chemical Syntheses of 14-Membered RALs 
 
Besides the biological properties described above, the RALs have been an 
interesting scaffold for organic chemists to elaborate innovative and convergent total 
synthesis and to develop new methodologies. The first molecule targeted by synthetic 
chemists was zearalenone (7-1) with its first total synthesis reported in 1968.[102] The 
retrosynthetic analysis is based on lactone ring closure of the seco acid 7-23. This key 
intermediate 7-23 was depicted as a two component system joined by a double bond in 
which the one component is the aromatic system, 2-formyl-4,6-dimethoxybenzoic acid 
sodium salt (7-24), whereas the second component is the aliphatic moiety 7-25 in which 
the functionality at C-6 is masked via internal ketal formation (Figure 31).  
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Figure 31. Retrosynthetic analysis for zearalenone (7-1) by Taub and co-workers. 
 
The cyclic ketal 7-25 was prepared in nine steps starting from 5-ketohexanoic acid 7-26 
(Scheme 45). This acid was converted to 5-hydroxyhexanoic acid lactone 7-27 by 
reduction followed by acidification and distillation. Treatment of this lactone at –15 °C 
with 4-pentenylmagnesium bromide permitted the isolation of the 1:1 mixture of isomers 
7-28. Acidification of the latter followed by distillation produced the cyclic enol ether 7-
29. Component 7-29 was then converted in high yield to cyclic ketal 7-30 under acidic 
conditions. Ozonolysis of 7-30 followed by reduction of the intermediate ozonide provided 
the carbinol 7-31, which was transformed to its tosylate derivative with p-toluenesulfonyl 
chloride in pyridine and then to the corresponding bromide with NaBr. The latter was 
converted in turn with triphenylphosphine to the phosphonium bromide 7-25. 
 
Literature Review 75
Me OH
O O
O
Me
O
Me
O
HO
MgBr
O
Me
O
Me
OMe
1. NaBH4
83%
2. HCl aq.
-15 °C, Et2O
51%
MeOH, HCl (cat.)
88%
1. O3, MeOH, -60 °C
2. NaBH4, 92%
O
Me
OMe
OH
1. TosCl, py
2. NaBr, MeOH, reflux
3. PPh3, 55%
O
Me
OMe
PPh3 Br
7-26 7-27
7-28
7-29 7-30
7-31 7-25  
 
Scheme 45. Synthesis of phosphonium salt 7-25.  
 
The aromatic component, 2-formyl-4,6-dimethoxybenzoic acid (7-34), had been obtained 
by reduction of the 3,5-dimethoxyphtalic anhydride (7-32) with lithium tri-tert-
butoxyaluminum hydride in THF at 20 °C (Scheme 46). This phthalaldehydic acid like 
system exists in solution entirely in the hydroxyphthalide form (7-33). 
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Scheme 46. Synthesis of 2-formyl-4,6-dimethoxyphtalide (7-32). 
 
The phosphonium salt 7-25 corresponding to the aliphatic component was converted to its 
ylide with methyl sulfinyl carbanion in DMSO. Treatment of this ylide with the sodium 
salt    7-24 in DMSO caused formation of a mixture of cis and trans seco acids 7-23. Ring 
closure of the mixture of seco acids 7-23 by treatment with trifluoracetic acid anhydride 
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provided (±)-zearalenone dimethyl ether (7-35) in extremely low yield of 10%. The latter 
after selective ether cleavage with boron trichloride yielded the racemic 4-
monomethylether which was resolved to give enentiomerically enriched (S)-4-
methylzearalenone (7-36) (Scheme 47). 
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Scheme 47. Completion of 4-methylzearalenone (7-36) synthesis by Taub and co-workers. 
 
Shortly after that, another group has reported the total synthesis of racemic 
zearalenone.[103] This approach is very similar to the one presented above, but the aromatic 
and aliphatic moieties were prepared using different synthetic paths. Thus, 
carbethoxylation of l-hexen-5-one (7-37) gave the β-keto ester 7-38 (Scheme 48). Michael 
addition to methyl vinyl ketone then extended the carbon chain to the required length 
forming the diketo ester 7-39. Basic hydrolysis of the keto ester 7-39 was achieved by way 
of the intermediate mixed cyclic ketal 7-40 in which the reactive functions are protected. 
Decarboxylation and ketal cleavage under acidic conditions then generated 1-decene-5,9-
dione, which was then protected with ethylene glycol and double ethylene ketal 7-41 
formed. The latter was transferred to phosphonium salt 7-42 in 5 steps with 45% overall 
yield. Thus, hydroboration of the olefinic bond in 7-41 followed by oxidation with 
hydrogen peroxide gave the alcohol, which was further converted via the p-
toluenesulfonate ester and the bromide intermediate to the phosphonium salt 7-42 
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containing the carbon skeleton and correctly positioned oxygen atoms of the aliphatic 
portion. 
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Scheme 48. Synthesis of phosphonium salt 7-42. 
 
The aromatic portion was readily constructed from ethyl orsellinate diacetate (7-43) by 
oxidation with chromium trioxide in sulfuric acid-acetic anhydride mixture to the aldehyde 
tetraacetate 7-44, followed by hydrolysis to the phenolic aldehyde and methylation to the 
required ethyl 4,6-dimethoxy-2-formylbenzoate (7-45) (Scheme 49). 
 
  Literature Review 78 
OAc
AcO
O
OEt
OAc
AcO CH(OAc)2
O
OEt
Ac2O, H2SO4
CrO3
1. H2SO4, EtOH
2. MeI, K2CO3
OMe
MeO
O
OEt
O
20%
64%
7-43 7-44
7-45  
 
Scheme 49. Synthesis of aromatic aldehyde 7-45 from ethyl orsellinate diacetate (7-43). 
 
Coupling of the aldehyde 7-45 and phosphonium salt 7-42 proceeded by a Wittig reaction 
in dimethyl sulfoxide leading to the ester 7-46, containing the carbon skeleton of 
zearalenone. Specific cleavage of the ketal at C-10 of the side chain was achieved in 
aqueous acetone containing p-toluenesulfonic acid. (Scheme 50). The intermediate keto 
acid was esterified with diazomethane, and then the ketone at C-10 was reduced by sodium 
borohydride forming the monoketal 7-47. The lactone ring was formed in 9% yield by 
base-catalyzed intramolecular ester exchange of the hydroxy ester 7-47 in the presence of 
tert-amyl alcohol as a proton source; the methanol formed being fractionally distilled out 
of the mixture to displace the ester-lactone equilibrium in favor of the lactone formation. 
Cleavage of the remaining ketal group gave (rac)-zearalenone dimethyl ether (7-48). 
Although the yield at the lactonization stage was low (9%), the authers note, that it was 
sufficient to allow completion of the synthesis. Reaction of the dimethyl ether 7-48 with 
boron tribromide gave complete cleavage of methoxy groups in 34% yield to form racemic 
zearalenone (7-49). 
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Scheme 50. Wittig reaction of aromatic aldehyde 7-45 with phosphonium salt 7-42 and 
completion of (rac)-zearalenone (7-49) synthesis by Vlattas and co-workers. 
 
Since then, several other research groups have shown interests in developing total 
syntheses of this natural product[104] and it has also been served as a testing ground for 
development of new cyclization methodologies such as the Corey-Nicolaou 
macrolactonization,[105] Masamune’s thioester-lactonization,[106] and more recently the 
ring-closing metathesis (RCM) by Fürstner.[107]  
 
In 1992, Lett and Lampilas reported the first total synthesis of radicicol and confirmation 
of the absolute configuration of its three stereocenters.[108] Having in mind the sensitivity 
of the epoxide along with the readily enolisable ketone at the benzylic position, a 
retrosynthetic analysis with a Stille coupling and a Mitsunobu macrolactonization as key 
steps was proposed (Figure 32). 
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Figure 32. Retrosynthetic analysis for radicicol by Lett and co-workers. 
 
The isocoumarin group in 7-51 (obtained in 32% yield from orcinol hydrate) served as a 
masking moiety for the enolisable ketone in order to expose the conjugated system only at 
a late stage of the synthesis. Starting with propargyl alcohol (7-53), the stannane derivative 
7-52 was obtained in 24% yield over 10 steps through a condensation with a lithium salt, 
reduction of the alkyne and Sharpless asymmetric epoxidation (“SAE”) (Scheme 51). The 
fragment 7-52 was then used in a Stille coupling with the chlorinated isocoumarin 7-51 to 
yield the acyclic precursor 7-56 in good yield (75%). Subsequently, isocoumarin opening, 
oxidation of the resulting aldehyde, Mitsunobu macrolactonization, release of the 
conjugated dienone by heating with anhydrous K2CO3 in DME and chlorination as the 
major steps allowed the isolation of radicicol (7-3) in 10% yield over 7 steps. 
 
Literature Review 81
OTBSO
TBSO OMOM
OH
Me
O
Bu3Sn OMOM
OH
Me
O
OH
1. 2-methoxypropene,
POCl3
2. nBuLi,
BF3
O
Me
3. TBSCl
4. IRN77 (sulfonic 
    acid resin), MeOH
68%
TBSO
Me
1. LiAlH4, NaOMe
2. SAE
3. (COCl)2, DMSO
Et3N
68%
TBSO
Me
O
O
1. Bu3Sn
Li
2. MOMCl, iPr2EtN
3. TBAF
PdCl2(MeCN)2
Et3N, 7-51
75% O
O
O MeOH
TBSO
Cl
O
O
OMOM
1. DIBALH
2. NaClO2
3. DEAD, PPh3
1. TBSCl
2. K2CO3
3. Ca(OCl)2
4. Borax39%
25%
Radicicol
(7-3)
7-53 OH7-54 7-55
7-52 7-56
7-57  
 
Scheme 51. Synthesis of radicicol (7-3) by Lett and co-workers. 
 
Another important feature of this synthesis is the Mitsunobu macrolactonization in which 
the unprotected ortho-phenol was found necessary for high efficiency (71% yield). This 
way, Lett and co-workers achieved the first total synthesis of radicicol albeit in less than 
2% overall yield (18 steps, longest linear sequence) and confirmed the absolute R 
configuration of the three chiral centers of radicicol. A decade later, the same group 
reported improvements and simplifications of their first synthesis as presented on Scheme 
52.[109] 
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Scheme 52. Improved synthesis of radicicol (7-3) by Lett and co-workers. 
 
The main significant improvement involved unmasking the dienone. An orthogonal 
protecting group on the alcohol in α position to the epoxide turned out to be necessary for 
the success of the Mitsunobu macrolactonization and a PMB protecting group was found to 
be better then a MOM group. It was easily removed after the ring formation and replaced 
by a mesylate that, under basic condition, allowed release of the dienone in 76% yield over 
two steps. 
 
Shortly before the Lett work, Danishefsky and co-workers published another total 
synthesis of radicicol.[110] Inspired by their asymmetric synthesis of the radicicol core 
structure presented a year earlier,[111] the retrosynthetic analysis is based on three main 
disconnections: a ring-closing metathesis, a dithiane addition and a Mitsunobu 
esterification (Figure 33). 
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Figure 33. Rerosynthetic analysis for radicicol (7-3) by Danishefsky and co-workers. 
 
The dithiane moiety 7-62 served as a masked acyl anion equivalent, in order to prevent 
cyclization to the isocumarin. In the synthesis of the methylated analog, esterification with 
the benzoic acid bearing methyl protecting groups occurred without any problem via the 
acid chloride. However, when changing to more labile protecting groups, this step proved 
challenging because of phtalide formation under diverse conditions (Mitsunobu reaction, 
cabodiimide or acid chloride). Yet again, the presence of the free ortho-phenol was 
essential for the success of this reaction. Starting from the commercially available (R)-3-
hydroxybutyric acid methyl ester (7-63) the alcohol 7-61 bearing the three chiral centers of 
radicicol was obtained in 47% yield after 8 steps (Scheme 53). Thereafter, Mitsunobu 
lactonization with compound 7-60 using a less nucleophilic phosphane (PFur3) and 
alkylation with the dithiane adduct 7-62 allowed for the formation of the acyclic 
intermediate 7-66. Notably, alkylation conditions had to be improved to avoid γ-addition 
on the diene. Ring-closing metathesis was achieved using Grubbs’ second generation 
catalyst in good yield and excellent selectivity. However, the presence of the TBS-
protected ortho-phenol was crucial for the success of this reaction otherwise leading to low 
rate of closure and low yield. Release of the masked conjugated ketone followed by 
deprotection of silicon ether and chlorination afforded the desired natural product. This 
synthetic sequence provided radicicol in a 3% overall yield (longest linear sequence). 
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Scheme 53. Synthesis of radicicol (7-3) by Danishefsky and co-workers. 
 
Following this methodology, using Sharpless asymmetric epoxydation or the 
cyclopropanation chemistry developed by Charette and co-workers,[112] four alcohols (7-68 
and 7-69, Scheme 54) were synthesized leading to eight different analogs (7-70, 7-71) 
bearing all possible stereochemistries on the epoxide/cyclopropane moiety and on the 
methyl group.[113] All these compounds were then evaluated for HSP90 inhibition. A 
related structure-activity relationship study established that the epoxide was non-essential 
for HSP90 inhibition whereas the configurations of the methyl substituent at the ester and 
of the epoxide/cyclpropyl part were important for high activity.[113] 
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Scheme 54. Divergent synthesis of radicicol and cycloproparadicicol analogs. 
 
However, this methodology developed for radicicol itself was less efficient for the 
synthesis of the cyclopropane analog 7-72. In order to keep away from low-yielding steps 
and to prepare a large amount of cycloproparadicicol (7-72), a second-generation synthesis 
was developed.[114] The key step of the synthetic sequence was the formation of the 
aromatic ring through a Diels-Alder cycloaddition of the ynolide 7-74 as the dienophile to 
the diene 7-73 derived from dimedone (Figure 34).  
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Figure 34. Retrosynthetic analysis for cycloproparadicicol (7-72) by Danishefsky and co-
workers. 
 
The central element of this plan is the construction of the aromatic part at a late stage of the 
synthesis whereas other protocols start with a modified benzoic acid derivative (Scheme 
55). Thus, Reformatsky-like condensation of propargyl bromide with sorbaldehyde (7-76), 
followed by TBS protection and subsequent reaction of the lithium alkynide with CO2, 
provided the conjugated carboxylic acid 7-78. Following reaction of racemic 7-78 and 
optically pure and defined alcohol 7-77 under Mitsunobu conditions, gave an intermediate 
ester, which after complexation of alkyne group with cobalt carbonyl complex and RCM 
using Grubbs’ second generation catalyst under mild conditions afforded the macrocyclic 
precursor 7-79. Noteworthly, attempts to cyclize the unprotected alkyne under a variety of 
RCM conditions failed. Authors refer this negative finding to nonproductive coordination 
of the acetylene to the RCM catalytic machinery. Oxidative removal of the cobalt complex 
using cerium(IV) ammonium nitrate (CAN), generated the desired cyclic alkynoic ester 7-
74 in high yield.  
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Scheme 55. Improved synthesis of cycloproparadicicol by Danishefsky and co-workers. 
 
Construction of the resorcylic skeleton called for a Diels-Alder reaction of 7-74 with 
dimedone-derived diene, 5,5-dimethyl-1,3-bistrimethylsilyloxycyclohexa-1,3-diene (7-73, 
Scheme 55) and proceeded smoothly at 140 °C, providing the desired aromatic product 7-
80 in 75% yield, after concomitant retro-Diels-Alder loss of isobutene from the initial 
adduct and hydrolysis of the trimethylsilyl ether groups during chromatography. 
Transformation of 7-80 to the desired ketone was accomplished following protection of the 
two phenolic functions and regioselective chlorination using SO2Cl2 in CH2Cl2 to afford 
cycloproparadicicol (7-72) in 13 steps and 5% overall yield. Finally, this methodology was 
suitable to provide the final compound in gram quantities.  
 
Using the same protocol Danishefsky and co-workers published the first total synthesis of 
aigialomycin D.[115] Starting from D-desoxyribose (7-81), the chiral alcohol 7-82 was 
obtained in a 4 step synthetic sequence (Scheme 56). Subsequent oxidation followed by 
propargylation and protecting group manipulation gave alcohol 7-83 as a diastereomeric 
mixture. Transfer of the alcohol to an alkene, carboxylation and Mitsunobu esterification 
led to the precursor 7-84. 
 
Applying the procedure described for cycloproparadicicol (complexation with cobalt 
carbonyl, ring-closing metathesis, and Diels-Alder cycloaddition reactions as key steps) the 
intermediate 7-85 was prepared in 60% yield over four steps. Final protection/deprotection 
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and elimination of water allowed to complete the synthesis of aigialomycin D (7-15) in 5% 
overall yield. With the preparation of this natural product, the Danishefsky group proved 
the generality of their pathway towards the synthesis of various resorcylic acid lactones. 
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Scheme 56. First total synthesis of aigialomycin D (7-15) by Danishefsky and co-workers. 
 
In 2006, the group of Winssinger has reported another synthesis of aigialomycin D.[100] 
Their approach gave access to the molecule in solution phase, as well as using solid phase, 
allowing them the synthesis of the natural product as well as several other analogs (Figure 
35). This strategy was successfully applied earlier by the same group for the synthesis of 
radicicol (7-3) and pochonin A (7-17).[116] 
 
Literature Review 89
O
O MeHO
HO
OH
OHAlkylation/
Elimination
R*
O
O MeHO
HO
Metathesis
Mitsunobu
R* =
S
PhSe
Br
O
O
Br
or O
or
7-15
7-86
7-87
7-88
 
 
Figure 35. Retrosynthetic analysis for Aigialomycin D by Winssinger and co-workers. 
 
The aliphatic portion 7-87 was prepared in four steps from commercially available 
substrates (Scheme 57). Thus, cross-metathesis of 5-bromopentene (7-90) with unprotected 
1,4-butenediol in the presence of the second-generation Hoveyda–Grubbs catalyst afforded 
the intermediate allylic alcohol in excellent yield and E/Z ratio (>25:1). Sharpless 
epoxidation of the allylic alcohol followed by oxidation with SO3·py and Wittig olefination 
furnished the epoxide 7-88 in 60% overall yield. The epoxide was converted into the 
protected diol 7-87 by Sc(OTf)3-catalyzed opening of the epoxide followed by protection 
with an acetonide group. 
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Scheme 57. Synthesis of epoxyde 7-88 and transformation to acetonide 7-87. 
 
The aromatic portion 7-86 was obtained through a three-step sequence starting with 
Mitsunobu esterification of the unprotected orsellinic acid (7-91) followed by protection of 
both phenolic groups with the ethoxymethoxy-protecting group. The selenide was 
introduced at the benzylic position by deprotonation with LDA followed by addition of 
diphenyldiselenide (59% yield over three steps).  
 
Treatment of 7-92 with second-generation Grubbs catalyst (80 °C for 12 h) provided the 
macrocycle 7-93 with E/Z ratio in more than 10:1. This macrocycle was then treated with 
hydrogen peroxyde to oxidize and eliminate the selenide, thus affording an intermediate 
which after global deprotection of the acetonide and EOM groups gave access to 
aigialomycin D (7-15) in a total of 10 steps and 16% overall yield (Scheme 58).  
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Scheme 58. Synthesis of aigialomycin D (7-15) by Winssinger and co-workers. 
 
Using the polymer-bounded thioether, the chemistry was carried out on solid phase 
extending the scope of aigialomycin D analogs (7-97a,b). Unprotected ester 7-94 was 
loaded onto a thiophenol resin, and the phenolic hydroxyls were protected as EOM acetals 
(Scheme 59). Alkylation of the polymer-bound thioether with a variety of alkyl bromides 
yielded the desired metathesis precursors 7-96a–c. Interestingly, the RCM conditions used 
in solution phase synthesis were not suitable on the solid support leading to the necessity of 
activation by microwave irradiation in this step. Thus, good yields were attained in CH2Cl2 
solvent at 120 °C under microwave irradiation for 1.5 hours. However, as the catalyst is 
short-lived at that temperature, additional amounts therefore were required those were 
added in three portions of 6 mol% each. The compounds were released from the resin by 
using an oxidation/elimination (H2O2) procedure followed by global deprotection with 
sulfonic acid resin to obtain Aigialomycin D (7-14) and its analogues 7-97a,b as well. 
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Scheme 59. Solid phase synthesis of aigialomycin D and analogs by Winssinger and co-
workers. 
 
Simultaneously, Pan and co-workers described an enantioselective synthesis of 
aigialomyin D[117] with another set of key reactions: a Yamaguchi macrolactonization and 
two Julia-Kociensky couplings to establish the E geometry of both double bonds (Figure 
36).  
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Figure 36. Retrosynthetic analysis for aigialomycin D (7-15) by Pan and co-workers. 
 
The main intermediate, sulfone 7-101, bearing the chiral diol masked as an acetonide was 
obtained in 9 steps from propargylic alcohol (Scheme 60). Thus, alkylation of 7-102 with 
1-((3-iodopropoxy)methyl)benzene, convertion of the alkylation product into an (E)-allylic 
alcohol by LiAlH4 reduction, and Sharpless asymmetric epoxidation led to the epoxy 
alcohol 7-103 in good yield and selectivity (91% ee). The titanium-assisted regioselective 
(C-3) opening of 2,3-epoxy alcohol 7-103 with benzoic acid gave an alcohol which was 
further converted into protected tetraol 7-104 by treatment with EtMgBr followed by 
protection of the free hydroxy groups (the primary hydroxy group was protected as its 
pivaloyl derivative and the two secondary hydroxyl groups were engaged in an 
isopropylidene linkage). Compound 7-104 was easily debenzylated to the corresponding 
primary alcohol by a standard hydrogenation procedure and Mitsunobu reaction with 1-
phenyl-1H-tetrazole-5-thiol followed by oxidation of the resultant sulfide furnishing 
sulfone 7-101 in good yield. A Julia–Kocienski condensation between fragment 7-101 and 
the functionalized benzaldehyde 7-99 delivered the compound 7-105. Cleavage of the 
pivaloate ester followed by oxidation of the resulting alcohol and a second olefination 
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reaction afforded acyclic precursor 7-106. Completion of the synthesis was achieved 
through TBS deprotection, carboxylation to give the benzoic acid derivative, Yamaguchi 
macrolactonization, acetonide/MOM deprotection steps and allowed the isolation of 
aigialomycin D (7-14) in more than 3% overall yield (18 steps longest linear sequence). 
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Scheme 60. Synthesis of Aigialomycin D (7-15) by Pan and co-workers. 
 
The group of Tatsuta in 2001 described the first total synthesis of LL-Z1640-2 (7-4) 
starting from D-ribose.[118] The key elements of their synthesis are a Mukaiyama 
macrocyclization, a Corey-Fuchs procedure and Sonogashira coupling reaction (Figure 37). 
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Figure 37. Retrosynthetic analysis for LL-Z1640-2 (7-4) by Tatsuta and co-workers. 
 
D-ribose (7-109) was first transferred to the acetylene 7-110 in a six step sequence. After 
attachment of the corresponding protecting groups onto the sugar, addition of TMS alkynyl 
lithium, followed by additional protecting group manipulation, the alkyne intermediate 7-
110 was obtained (Scheme 61). Sonogashira coupling of 7-110 with bromobenzene 7-111 
in the presence of Pd(OAc)2, CuI and PPh3 and protection of alcohol with ethoxycarbonyl 
chloride furnished the acyclic precursor 7-108. Reduction with Lindlar catalyst (Pd/BaCO3, 
quinoline/EtOH), hydrogenolysis under Tsuji conditions (Pd2(dba)3, nBu3P, ammonium 
formate), deprotection of the pivaloyl group, oxidation of the resulting alcohol and 
modified Wittig olefination (CBr4, PPh3) gave the dibromo-olefin 7-112. Exposure of 7-
112 to nBuLi produced the intermediary lithiated acetylide, which reacted with optically 
pure (S)-propylene oxide followed by a second Lindlar reduction to the Z-olefin 7-113. 
Finally, saponification, Mukaiyama macrocyclization, MOM deprotection and selective 
oxidation of the allylic alcohol allowed the completion of the total synthesis of the natural 
product LL-Z1640-2 (7-4). 
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Scheme 61. First total synthesis of LL-Z1640-2 (7-4) by Tatsuta and co-workers. 
 
After that, in 2002, based on previous experience from the radicicol and monocillin 
syntheses, Lett and co-workers reported their own total synthesis of LL-Z1640-2 (7-4) 
along with hypothemycin (7-7).[119] This approach to hypotemycin is similar to that of 
radicicol,[109] and includes Mitsunobu macrolactonization and Suzuki coupling as key steps 
(Figure 38). 
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Figure 38. Retrosynthetic analysis for hypothemycin (7-7) by Lett and co-workers. 
 
The synthesis starts from 1,4-butynediol (7-116) which in eight steps was transferred to the 
epoxide 7-118. This substance was further converted through a seven step sequence into 
the aldehyde 7-119 (Scheme 62). After transmetallation of vinyl iodide 7-120 with tBuLi 
and reaction with the aldehyde 7-119 the obtained alcohol was protected with PMB-
trichloroimidate to afford the intermediate, which after hydroboration of the triple bond 
and subsequent Suzuki coupling with the aromatic bromide 7-114 furnished the desired 
acyclic precursor 7-121. The next transformations include TBS deprotection, 
saponification with NaOH, Mitsunobu macrolactonization, PMB group removal, allylic 
alcohol oxidation and acetonide deprotection, so, the desired compound LL-Z1640-2 (7-4) 
was obtained. Attempts to invert the sequence (first Mitsunobu reaction and then Suzuki 
coupling) failed to give the desired products. Final epoxidation of 7-4 using buffered 
conditions (mCPBA/NaHCO3, 3 equiv. CH2Cl2, −20 to 0 °C, 4 h) formed only one isomer 
of epoxide, identified as hypothemycin (7-7) albeit in poor yield (17%). The authors 
explain this phenomenon with the unusual low reactivity of the double bond next to the 
aromatic part and liability of the final product. 
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Scheme 62. Synthesis of L-Z1640-2 (7-4) and hypothemycin (7-7) by Lett and co-workers. 
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8 Results and Discussion 
 
8.1 Retrosynthetic Analysis 
 
The target molecule, queenslandon (6-1), consists of four major fragments (Figure 22).  
a) a salicylate-like aromatic part with two additional methoxy groups; 
b) ester function as the connection between aromatic and aliphatic moieties; 
c) one double bond with E-configuration as the second connection between aromatic 
and aliphatic moieties; 
d) α,α’-dihydroxy keton in the aliphatic region. 
 
At first, we have aimed our studies towards the asymmetric synthesis of model compound 6-2 
with no substituents in the aromatic part but with the fully functionalized aliphatic segment. 
The commercial availability and the ease of preparation of basic fragments was an important 
criterion for the design of the retrosynthesis. Thus, the construction is based on the key bond-
forming reactions indicated in Figure 39. Major challenges that we recognized from a 
synthetic point of view were the connection of the aliphatic chain to the aryl ring and the 
creation of the carbohydrate-like sector. For the formation of the macrocycle, we opted for a 
Mitsunobu macrolactonization strategy. As a further most important key disconnection, a 
Suzuki coupling at the vinylic position (C9-C10) was envisioned.[120]  
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Figure 39. Retrosynthetic analysis for the core structure of queenslandon 6-2. 
 
The necessary alkyl-borane 8-4, in turn, should result from a diastereoselective hydroboration 
of an exocyclic enol ether 8-5. The stereocenter at C13 would be the result of a glycolate aldol 
reaction of protected δ-hydroxyaldehyde 8-6 and cyclic dioxanone 8-7 (Figure 40). 
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Figure 40. Retrosynthetic analysis for alkyl-borane 8-4. 
 
While the proposed substrate 8-4 is rather complex and the key transformation (selective 
hydroboration of exocyclic enol ether 8-5) for this type of substrates was not described in the 
literature at the time when we started our synthesis, it was decided to address initital attempts 
for stereoselective construction of the polyol unit in 8-4 to model studies. Using simplier 
analogs, we sought to distinguish the selectivity in the hydroboration step and to elaborate the 
efficiency of the chosen transformation. 
 
As an alternative to the presented above retrosynthetic analysis, the aliphatic and the aromatic 
parts could be connected employing a cross-metathesis reaction between the styrene 8-12 and 
the olefin 8-13 (Figure 41).  
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Figure 41. An alternative retrosynthetic analysis for the maclolactone 8-10. 
 
The required olefin 8-13 could be available after selective addition of a chiral allylborane to 
the aldehyde 8-14, which, in turn, is the result of an Evans stereoselective aldol reaction 
between the auxiliary 8-15 and the aldehyde 8-6, followed by reductive cleavage of the 
auxiliary.  
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Figure 42. Retrosynthetic analysis for the aliphatic part 8-13. 
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8.2 Syntheses of the Key Precursors  
 
8.2.1 Substitued β-iodostyrenes 
 
The vinyl iodide 8-3 was prepared starting from the commercially available 2-formylbenzoic 
acid 8-16. Thus, esterification with MeI and potassium carbonate in CH3CN at reflux provided 
the carbmethoxyester 8-17. Takai olefination[121] of methyl 2-formylbenzoate (8-23) with CHI3 
and CrCl2 generated in situ (by heating the mixture of anhydrous CrCl3 and Zn powder)[157] 
provided the desired iodoalkene 8-3 in 74% yield. The E/Z ratio was found to be around 5:1 
(Scheme 62). 
 
I
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OMe
O
8-17
O
H
MeI, K2CO3
CH3CN, reflux
70%
OH
O
O
H
8-16  
 
Scheme 62. Synthesis of the iodoalkene 8-3 from 2-formylbenzoic acid (8-16). 
 
However, substituted 2-formylbenzoic acid derivatives are not commercially available, and 
therefore we have examined a common strategy for the synthesis of iodoalkenes of type 8-3 
with various substituents in the aromatic ring. For example, 2-methoxybenzoic acid (8-18) was 
first converted to the amide 8-19, which after ortho-metalation with sec-BuLi[122] and 
subsequent treatment using excess of DMF, delivered the known aldehyde 8-20 in excellent 
yield (Scheme 63).[123] This aldehyde after acidic hydrolysis and esterification under the same 
conditions as for the discussed above case (8-16 to 8-17) gave 2-methoxy-6-formylbenzoic 
acid methyl ester (8-21), which was used for Takai olefination to afford the desired β-
iodostyrene 8-22 in high yield. 
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Scheme 63. Synthesis of the iodoalkene 8-22 starting from 2-methoxybenzoic acid (8-18). 
 
Meanwhile, the same synthetic sequence was applied to 2,4,5-trimethoxybenzoic acid (8-23). 
In this case, after amide formation, ortho-metalation and treatment with DMF the known 
polysubstituted aromatic aldehyde 8-25 was obtained in 75% yield over three steps.[124] After 
amide hydrolysis, esterification, and Takai reaction one more example of a β-iodostyrene (8-
27) was prepared (Scheme 64).  
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Scheme 64. Synthesis of the β-iodostyrene 8-27 from 2,4,5-trimethoxybenzoic acid (8-23). 
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The formylation step should be noted here separately for the reason that, DMF must be added 
to the lithiated amide derivative 8-19 or 8-24 in one portion at –90 °C. Only so the high yield 
of the benzaldehyde can be achieved. If to proceed with the addition of dimethylformamide in 
a dropwise fashion, the product is formed in a very low yield (approx. 15%), but most of the 
starting material is then recovered. 
 
As a result, we have presented a general and high-yielding approach to the β-iodostyrenes of 
type 8-3 utilizing the formylation reaction of ortho-lithiated N,N-diethylbenzamides, followed 
by hydrolysis, esterification, and Takai reaction. This pathway opens the possibility to prepare 
a number of queenslandon analogues with various substituents in the aromatic part of this 
natural product. 
 
 
8.2.2 Protected (R)-δ-hydroxyhexanal (8-6) 
 
In contrast to the known synthesis from chiral lactate ester,[125] the TBDPS-protected aldehyde 
8-6 was synthesized starting from racemic propylene oxide [(±)-8-28] in four steps. Thus, 
Jacobsen resolution[126] furnished the pure (R)-epoxide (+)-8-28 (>99% ee, Scheme 65). The 
optical purity was determined by chiral GC and after the product was analyzed, we did not 
observe the second enantiomer on the chromatogramm (Scheme 65, see right 
chromatogramm). 
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Scheme 65. Preparation of (R)-epoxide (+)-8-28 by Jacobsen resolution of racemic propylene 
oxide and analysis using GC. 
 
Opening of this epoxide with either the Grignard reagent 8-29a or 8-29b in the presence of 
catalytic amounts of CuI led to the corresponding secondary alcohols 8-30a or 8-30b, 
respectively in good yields (Scheme 66). The hydroxy acetal 8-30a turned out to be rather 
sensitive toward internal transacetalization. It was therefore, immediately after isolation, 
protected with tert-butyldiphenylsilyl chloride (TBDPSCl). Hydrolysis of the acetal in 
compound 8-31a provided aldehyde 8-6. The six-membered acetal 8-30b after Grignard 
addition could be isolated in higher yield (75% vs 58%) and found to be more stable. 
However, cleavage of the acetal function on the silyl-protected 8-31b was less efficient.  
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Scheme 66. Synthesis of TBDPS-protected δ-hydroxyaldehyde 8-6. 
 
After all, both paths were found to be equally efficient with the overall 46% yield of the 
aldehyde 8-6 starting from epoxide (+)-8-28. 
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8.2.3 Chiral glycolate auxiliary (8-7) 
 
The glycolate 8-7, developed by Andrus and co-workers,[127] was prepared essentially 
according to the literature procedure from p-methoxybenzylalcohol (8-32), but one step was 
slightly modified. Thus, bromination of alcohol 8-32 with PBr3 afforded the bromide 8-33, 
which after distillation was converted to the diethyl p-methoxybenzylphosphonate (8-34, 
Scheme 67). Then it was found that the Wittig-Horner condensation of phosphonate 8-34 with 
anisaldehyde using NaOMe (Table 7) as it was proposed by Andrus and co-workers gave only 
low yields of the stilbene 8-35 irrespective of the solvent (DMF or THF).  
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8-35
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BrOH
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Scheme 67. Synthesis of the alkene 8-35. 
 
After trying different conditions, we have found, that a much better yield of alkene 8-35 could 
be obtained with potassium tert-butoxide as base (entry 5, Table 7). Probably the basicity of 
NaOMe was not enough for full deprotonation of the phosphonate 8-34, which then undergoes 
the condensation with anisaldehyde. 
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Table 7. Conditions optimization for Wittig-
Horner reaction of phosphonate 8-34 with p-
anisaldehyde. 
MeO
OMe
MeO
base, solvent
MeO
CHO
P(OEt)2
O
8-34 8-35  
base solvent yield, % 
NaOMe DMF 48 
NaOMe THF 38 
NaOMe 
18-crown-6 
DMF 36 
LiHMDS THF 41 
tBuOK DMF 85 (!) 
 
 
Dihydroxylation[128] of alkene 8-35 using AD-mix-α led to diol 8-36 in high yield and 
excellent optical purity (>99% ee). Reaction of diol 8-36 with di-n-butyltin oxide (nBu2Sn=O) 
by refluxing in benzene, followed by treatment with tert-butyl bromoacetate and subsequent 
cyclization gave the glycolate 8-7 (Scheme 68). In the case if cyclization does not proceed to 
the end, the addition of catalytic amounts of trifluoracetic acid to the reaction mixture 
accelerates the completion of this reaction and final auxiliary 8-7 could be isolated in 55% 
yield. 
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(84%)
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O
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2.
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Scheme 68. Conversion of alkene 8-35 to cyclic glycolate 8-7. 
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Figure 43. 1H NMR spectrum of the auxiliary 8-7. 
 
The 1H NMR spectrum of glycolate 8-7 shows AB system of the methylene protons in the 
ring. The doublet at δ = 4.52 can be assigned to 5-H. 
 
Using AD-mix-β in dihydroxylation step, the (R,R)-diol 8-36 was prepared, thus, leading to 
the other enantiomer of this auxiliary (Scheme 69), which was also employed in the model 
studies. 
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Scheme 69. Synthesis of ent-8-7 by using AD-mix-β. 
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8.3 Model Studies on the Tandem Hydroboration/Suzuki Coupling 
Sequence 
 
In general, clusters of two or more vicinal hydroxyl groups are frequently found in 
natural products. Because of the importance of 1,2-diols and 1,2,3-triols, a range of methods 
has been developed for their synthesis. For example, C-C bond-forming reactions on suitable 
substrates can be used. Thus, aldol reactions,[129] addition reactions to chiral hydroxy 
aldehydes,[130] Pinacol couplings,[131] or epoxide opening reactions[132] have been employed in 
this context. In addition, carbon-oxygen bond forming reactions such as epoxidation[133] or 
dihydroxylation[134] are valuable options. However, the famous Sharpless asymmetric 
dihydroxylation is less suitable for the synthesis of anti- and 1,2-diols. Finally, carbon-
hydrogen bond forming reactions (reductions) on carbonyl-containing substrates can be 
considered. The choice of a certain strategy is largely governed by other functional groups in 
the near or somewhat remote vicinity of the diol. 
 
Thus, in the framework of the synthesis of a complex benzolactone 6-2, an anti-diol 8-37 
flanked by a homoallylic double bond which itself is attached to a functionalized aryl ring is 
needed (Figure 44).  
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I
OP
OP
X
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X = OH or H
R = alkyl chain
P = protecting group
8-37 8-38 8-39
 
 
Figure 44. Hydroboration/Suzuki cross-coupling strategy for the synthesisof complex diols. 
 
Although homoallylic alcohols can be obtained by the addition of allylmetal compounds to 
aldehydes, this method is less attractive if a substituent is needed at the alkene terminus of the 
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product (cf. structure 8-39). To assemble a system of type 8-37, we envisioned a tandem 
diastereoselective hydroboration/Suzuki cross-coupling of (R)-alkoxy enol ethers 8-39 with 
vinyl halides such as 8-38.  
 
Olefin hydroboration is particularly useful when it can be directed by preexisting chiral 
centers. Diastereoselective hydroboration of alkenes is an illustrative example for a reaction, 
which often proceeds with high selectivity to give synthetically useful functionality and for 
that reason has been employed in the synthesis of many natural products.[135] For acyclic 
substrates of type 8-40, the anti-product (8-41) is favored (Scheme 70).[136]  
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Scheme 70. Hydroboration of allylic alcohols and ethers studied by Still and co-workers. 
 
The overall selectivity of the hydroboration may be rationalized by a simple model, which 
involves electronic and steric factors.[137] Considering the possible conformations of the 
starting allylic alcohol, one of the conformers (a) would be expected to be the most reactive 
since the primary interaction between the empty borane p-orbital (LUMO) and the filled π-
orbital of the alkene (HOMO) is enhanced by a secondary interaction between a σ-orbital from 
the asymmetric center and the alkene π-orbital (Figure 45). This secondary interaction 
destabilizes the HOMO to promote overlap with the LUMO (i.e. the borane p orbital). This 
secondary interaction will be maximal when the σ-level is energetically close to the alkene π-
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orbital, i.e. when a best electron-donating group occupies the anti position (R is alkyl group). 
Finally, the attack of the borane to the less hindered side of olefinic π-system would then lead 
to the less sterically encumbered transition state and thus to the anti-product. 
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Figure 45. A model for diastereoselective hydroboration of substituted olefin 8-13. 
 
Dialkylborane addition to cyclic allylic alcohol derivatives (8-43) takes place from the least 
hindered face (opposite to alkoxy group) avoiding also the R2B/H 1,3-diaxial interaction and 
the 1,2-anti product is predominating in the resulting product mixture (Scheme 71).[138] 
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Scheme 71. Hydroboration of cyclic allylic alcohol derivatives (8-43) studied by Evans and 
co-workers. 
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Figure 46. Possible transition state for the addition of dialkylborane to the cyclic allylic 
alcohol derivatives (8-43). 
 
In the hydroboration of exocyclic allylic alcohols and ethers (8-44) with 9-BBN only marginal 
levels of stereocontrol is detected (Scheme 72). The lack of selectivity in this case could result 
from the absence of distinguishing steric interactions between substrate and hydroborating 
reagent.[138] 
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Scheme 72. Hydroboration of exocyclic allylic alcohols  and ethers (8-44) with 9-BBN 
studied by Evans and co-workers. 
 
Applying more complex substrates containing exocyclic double bonds, Sinaÿ and co-workers 
reached reasonable selectivities.[139] The hydroboration of five-membered enol ether derivative 
8-45, obtained by Tebbe reaction from acetonide-protected mandelic acid, proceeded 
regioselectively by virtue of the highly polar nature of the substrate. The high 
diastereoselection level is expected on the basis of steric grounds (Scheme 73). 
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Scheme 73. Hydroboration of exocyclic enol ether 8-45 by Sinaÿ and co-workers. 
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It should be mentioned, that transition metal-catalyzed additions of boranes to a double bond 
also provide highly distereoselective hydroborations.[140] 
 
We wanted to show that exocyclic enol ethers prepared from 1,3-dioxolan-4-ones and 1,4-
dioxan-2-ones are useful substrates for our selected strategy leading to complex diols in high 
diastereoselectivity. Looking into the literature, there are only a few reports for the tandem 
hydroboration and Suzuki coupling of glycals derived from carbohydrates.[141] In most of these 
cases, C-glycosides were the target.[142] Also, an intramolecular diastereoselective 
hydroboration/Suzuki coupling tactic was successfully employed earlier in our laboratory in a 
synthesis of the macrolide salicylihalamide A.[143]  
 
8.3.1 Preparation of the Required Substrates  
 
First, we have defined the necessery enol ethers for the proposed transformation. Thus, 
as the acyclic substrate the mandelic acid derivative 8-49 was choosen. It can be prepared by 
esterification of commercially available of (S)-O-methyl mandelic acid (8-48) according to a 
known procedure (Scheme 74).[144]  
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Scheme 74. Methylation of the (S)-O-methyl mandelic acid (8-48). 
 
In the other venture, by treating the (S)-mandelic acid (8-50) with the 2,2-dimethoxypropane 
in refluxing benzene, the known[145] five-membered glycolate ester 8-51 was obtained and 
served as an example of a cyclic structure (Scheme 75). 
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Scheme 75. Preparation of cyclic mandelic acid derivative 8-51. 
 
As an advanced version of cyclic substrates, we have opted toward six-membered systems. In 
this regard, the glycolate derived oxapyrone (8-52 Figure 45), developed by Andrus et al.[127] 
seemed to be the substrate of choice. Not only are both the enantiomers of this auxiliary 
readily synthesized but also it affords 1,2-anti selective aldol addition products, and the para-
methoxyphenyl (PMP) part can be removed very easily at a later stage to unmask the diol 
functionality in the product. All these properties make the cyclic substrate 8-52 a very 
attractive target. 
 
O O
O
PMPPMP
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Figure 45. Glycolate derived oxapyrone 8-52 developed by Andrus and co-workers. 
 
The synthesis of the six-membered chiral glycolate 8-7 and ent-8-7 (R = H in 8-52) is 
discussed in section 8.2.3. The more complex substrates 8-54 and 8-56 were obtained via 1,2-
anti selective aldol reaction between the auxiliary 8-7 and corresponding aldehydes (Scheme 
75).  
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Scheme 75. Anti-selective aldol reactions of the glycolate auxiliaries 8-7 and ent-8-7 with 3-
phenylpropanal and aldehyde 8-6, respectively, followed by MOM-protection. 
 
In this case, aldol reaction leads to the formation of two new chiral centers. The intermediate 
boronic enolate constrained exclusively to the E-conformation, through the chair Zimmerman-
Traxler transition arrangement,[130] provides the anti adduct (Scheme 76). Developed by 
Andrus and co-workers, this type of anti selective aldol reaction of enantiopure 5,6-diphenyl-
4-oxa-2-pyrone with a broad range of aldehydes proved to be very useful for the synthesis of 
complex molecules.[127] 
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Scheme 76. Anti selective aldol reaction from E-enolate 8-55 through transition state 8-56. 
 
The aldol products (8-53 and 8-55) are somewhat prone to retro aldol reaction. Therefore, their 
newly formed secondary alcohol function was immediately protected as methoxymethyl 
(MOM) ether by treatment of crude aldol reaction mixture with iPr2EtN and freshly distilled 
MOMCl in anhydrous CH2Cl2 for several days at room temperature (Scheme 75). Other 
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attempts at protecting the alcohol (TBSOTf or TIPSOTf and base, BnBr and Ag2O, 
BnOC(=NH)CCl3 with acidic catalysis) were not successful. 
 
The substrates for the key transformation were readily prepared in high yields by Tebbe 
olefination using the Petasis reagent (Cp2TiMe2) in refluxing THF (Scheme 77).[146] We have 
turned away from using the traditional Tebbe reagent (Cp2ZrMe2) since it is much more 
expensive and more difficult to prepare when compared to Cp2TiMe2. The reactions were 
performed under nitrogen atmosphere to avoid decomposition of the Petasis reagent and the 
products formed. The acyclic enol ether 8-57 and all exocyclic enol ethers (8-58, 8-59, 8-60, 
8-61) were purified by chromatography on aluminium oxide and used immediately after 
isolation.  
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Scheme 77. Preparation of acyclic substrate 8-57 and exocyclic enol ethers 8-58, 8-59, 8-60 
and 8-61 using the Petasis reagent. 
 
8.3.2 Studies on the Tandem Hydroboration/Suzuki Coupling Sequence 
 
The present study was initiated with an acyclic system 8-57. Although it has been 
reported that these substrates are unreactive toward 9-BBN,[147] we found this not to be the 
case (Scheme 78). Given the tendency of β-alkoxy boranes to undergo syn-elimination (cf. 
intermediate 8-63), the formation of some side products for the acyclic substrates was 
expected.[147] The result of the hydroboration followed by Suzuki cross-coupling with 
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bromobenzene was a reasonable diastereoselectivity (90:10) but a moderate yield of 35% for 
the diol derivative 8-62. The stereochemical outcome (anti) was confirmed by the coupling of 
5.8 Hz for 1-H/2-H. The spectral data for 8-62 were in complete agreement with the literature 
data.[148]  
 
1. 9-BBN, THF, 23 °C, 6 h
2. PdCl2(dppf), Ph3As,
Cs2CO3, PhBr,
DMF/H2O, 23 °C, 14 h
OMe
Ph
OMe
OMe
Ph
OMePh
Ph
OMePh
+
8-62 (35%) 8-63 (15%)8-57  
 
Scheme 78. Hydroboration followed by Suzuki coupling of chiral enol ether 8-57. 
 
In contrast, the investigations with the mandelic acid derived cyclic enol ether 8-58 afforded 
better results (Scheme 79). Thus, the hydroboration of 8-58 followed by Suzuki coupling with 
the vinyl iodide 8-3 furnished compound 8-64 in good yield as a mixture of double-bond 
isomers (E/Z = 6:1). The diastereomer resulting from the hydroboration step was not detected. 
Most likely, the trans-hydroboration intermediate reacts much faster in the cross-coupling 
reaction than the corresponding cis-diastereomer.  
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1. 9-BBN, THF, 23 °C, 6 h
2. PdCl2(dppf), Ph3As,
Cs2CO3, 8-3,
DMF/H2O, 23 °C, 14 h
O
O
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O
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62% (E/Z 6:1)
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Scheme 79. Hydroboration followed by Suzuki coupling of chiral enol ether 8-58 with β-
iodostyrene 8-3. 
 
Surprisingly, the stereochemical outcome (syn-diol) for the hydroboration of enol ether 8-58 
was opposite to that reported by Sinaÿ when unsubstitued borane was used.[149] An indication 
for this was the relatively high coupling constant for the vicinal protons in the dioxolane ring 
(J = 8.3 Hz, Figure 46) for compound 8-64. This result might be explained by a possible 
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reversibility of the hydroboration step. On the other hand, much bigger size of 9-BBN in 
comparison to that of BH3 could be crucial for the selectivity in the presented case. Similar 
reactions using other five-membered exo-methylene compounds with aryl halides (PhBr or 8-
3) gave no results. 
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Figure 46. 1H NMR spectrum of the coupling product 8-64. 
 
After all, to increase the yields, to make this approach more general, and finally to extend the 
outcome of the described transformation, we turned our focus towards six-membered systems. 
Initial studies were carried out on substrates without a side chain (8-59 and ent-8-59) (Table 
5). The reactions afforded a single detectable diastereomer in high yield (compounds 8-66,    
8-67, 8-68).  
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Table 5. Suzuki cross-coupling of the exocyclic enol ethers 8-59 and 
ent-8-59. 
substrate R2X producta yield, % 
O O
PMP PMP
8-59  
PhBr 
O
O
PMP
PMP
Ph
8-66  
72 
O O
PMP PMP
ent-8-59  
I
8-3
OMe
O
 
O
O
PMP
PMP
8-67
OMe
O
 
87b 
O O
PMP PMP
8-59  
OTf
OMe
8-65c
OMe
O
 
O
O
PMP
PMP
OMe
8-68
OMe
O
 
53 
a Enol ether (1 equiv, 0.33 M) in THF, 9-BBN (1.2 equiv), 0 °C, stir for 6 h 
at 23 °C; add this solution to a solution of halide/triflate (1.2 equiv), Ph3As 
(0.05 equiv), Cs2CO3 (2 equiv), H2O (30 equiv), PdCl2(dppf) (0.05 equiv), 
23 °C, 14–16 h; DMF. b E/Z = 9:1. c from S. V. Kühnert[150] 
 
 
As presented in Table 6, substrates with a side chain on C3 were also studied. In this case, 
products 8-69 and 8-70 were obtained in high yield using the same condition as above. 
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Table 6. Suzuki cross-coupling of the exocyclic enol ethers 8-60 and 8-61. 
substrate R2X producta yield, % 
O
O
PMP
PMP
OMOM
Ph
8-60  
PhBr 
O
O
PMP
PMP
Ph
OMOM
Ph
8-69  
76 
O
O
PMP
PMP
OMOM
TBDPSO
8-61  
I
8-3
OMe
O
O
O
PMP
PMP
8-70
OMOM
Me
OTBDPS
OMe
O
 
74b 
a Enol ether (1 equiv, 0.33 M) in THF, 9-BBN (1.2 equiv), 0 °C, stir for 6 h at 23 °C; add this solution 
to a solution of halide/triflate (1.2 equiv), Ph3As (0.05 equiv), Cs2CO3 (2 equiv), H2O (30 equiv), 
PdCl2(dppf) (0.05 equiv), 23 °C, 14-16 h; DMF. b in the presence of KBr (1.2 equiv). 
 
 
With vinyl iodides as substrates (product 8-67; Table 5; compound 8-70; Table 6), it was 
found that in the coupling products the E/Z ratio is higher than in the starting iodide. This 
outcome can be explained by much lower reactivity of the corresponding Z-vinyl iodides. In 
fact, if an excess (2 equiv) of the vinyl iodide was used, the recovered vinyl iodide was 
enriched in the Z-isomer. 
 
The stereochemistry of the product in these cases is the result of a pseudoaxial attack of the 
borane to the double bond (structure 8-71, Figure 46). A clear indication of the stereochemical 
outcome is the coupling constant of 10.6 Hz for the axial-axial coupling for 5-H (structure 8-
66).  
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Figure 46. Pseudoaxial attack of borane H-BR2 to double bond of exocyclic enol ether 8-71 
and the product of coupling with PhBr (8-66). 
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Figure 47. 1H NMR spectrum of the coupling product 8-66. 
 
An absolute proof for this was obtained by oxidative ether cleavage from 8-66 (Scheme 80). 
Thus, stirring a solution of the dioxane 8-66 with CAN in a CH3CN/H2O system for 2 h 
afforded the diol 8-72 in 86% isolated yield. The optical rotation {[α]20D = +20.4 (c 1.0 in 
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CHCl3); [α]20D = +15.0 (c 1.0 in CHCl3);[151] [α]20D = –18.6 (c 1.3 in CHCl3)[152] for ent-8-72} 
and the spectral characteristics for 8-72 were in complete agreement with that reported in the 
literature. The sign and value of the optical rotation undoubtedly proved the absolute 
configuration and enantiomeric purity of 8-72 and thereby that of 8-66. It also allows a 
conclusion about the facial selectivity in the hydroboration step. Under similar conditions, the 
oxidative deprotection of compound 8-67 provided diol 8-73. 
 
O
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OH
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8-67 8-73  
 
Scheme 80. Liberation of the diols from the dioxanes 8-37 and 8-38. 
 
Given the ease of the liberation of the diol, this method affords synthetically useful 
enantiomerically pure diols which may be difficult to obtain by traditional methods.  
 
According to Chem3D (8.0) calculations, these substrates with substituents on C3 adopt a 
twistboat conformation with the p-methoxyphenyl groups occupying equatorial positions. 
Accordingly, the substituent in position 2 points in a pseudoequatorial direction. It is then 
obvious that the borane approaches from the convex face (cf. structure 8-74, Figure 48). In the 
resulting products such as 8-69 or 8-70, the 1,4-dioxane ring now shows a more or less 
distorted boat conformation. A clear indication of the stereochemical outcome is the coupling 
constant of 2.8 Hz for 2-H/3-H as in 8-75 (Figure 48). According to calculations, the dihedral 
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angle between the vicinal hydrogens H-2 and H-3 in 8-75 is approximately 48° and the 
measured coupling constants in compounds 8-69 and 8-70 is consistent with this angle.  
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Figure 48. Possible twist-boat conformations of 2-substituted-3-methylidene-1,4-dioxanes   
(8-74) and the derived hydroboration/cross-coupling products 8-75. 
 
In conclusion, we have developed a new and easy alternative for the synthesis of complex 
anti-1,2-diols by a tandem hydroboration/Suzuki coupling sequence of alkoxy enol ethers. An 
easily available glycolate-based chiral oxapyrone has been employed. The simplicity of the 
tandem reaction, the easy preparation of both enantiomers of the Andrus’ chiral oxapyrone, 
and a straightforward cleavage procedure complement other methods for the synthesis of 
highly functionalized diols. This methodology can be then successfully employed in the 
synthesis of complex natural products, and is used by us for the synthesis of the queenslandon 
core structure 6-2 as described below. 
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8.4 Synthesis of the Core Structure of the Macrolide Queenslandon 
 
Armed with the powerful methodology for the construction of polyol substructures, we 
have proceeded with the synthesis of the core structure of the macrolide queenslandon (6-2). 
 
As it is presented in the retrosynthetic analysis (Figure 40), the aliphatic moiety is constructed 
from protected δ-hydroxyaldehyde 8-6 and the dioxanone 8-7 via an aldol reaction employing 
the dicyclohexylboron enolate of 8-7 in the presence of Et3N forming the anti adduct 8-76 
with high selectivity (9:1 dr, determined by HPLC/MS of crude mixture) (Scheme 81).[153]  
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CH2Cl2, -80°C
2. aldehyde 8-6
 
 
Scheme 81. Stereoselective aldol reaction of aldehyde 8-6 with glycolate auxiliary 8-7. 
 
In this case, aldol reaction leads to the formation of two new chiral centers. As mentioned in 
section 8.3.1, the aldol product 8-76 is somewhat prone to retro aldol reaction. Therefore, after 
the aldol reaction is worked up, the newly formed secondary alcohol function was protected as 
methoxymethyl (MOM) ether (Scheme 82). Nevertheless, this route allowed for the 
convenient preparation of 8-77 in gram amounts.  
 
The main substrate for the key Suzuki cross-coupling reaction was prepared in high yield by 
Tebbe olefination of dioxanone 8-77 using Petasis conditions (Scheme 82). Following addition 
of 9-BBN to the enol ether 8-78, the intermediate borane 8-79 was subjected to a palladium-
catalyzed coupling reaction with iodostyrene 8-3. The latter was obtained by a Takai reaction 
with an E/Z-ratio of 5:1. Applying an excess (2.5 equiv) of 8-3 in the Suzuki coupling with    
8-79 delivered the alkene 8-80 enriched in the desired E-isomer (E/Z > 20:1). 
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Scheme 82. Protection of aldol product, Tebbe olefination, hydroboration, and Suzuki cross-
coupling. 
 
To reach the seco acid 8-82, the silyl ether of 8-80 was cleaved with an excess of the 
HF/pyridine complex at -20 °C in THF (Scheme 83). Using tetra-n-butylammonium fluoride 
(TBAF) in THF, even at reflux, left the starting material unchanged. Saponification of the 
methyl ester in 8-81 with LiOH after three hours at reflux proceeded essentially in quantitative 
yield. Macrolactone formation from seco acid 8-82 under standard Mitsunobu conditions 
(DEAD, Ph3P, toluene, 0 °C) gave rise to lactone 8-83 in unexpectingly high yield (78%). 
Most likely, conformational constraints on the backbone, imposed by the dioxane ring, 
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facilitate formation of the macrocycle. Cleavage of the dioxane in macrolactone 8-83 was 
accomplished with excess ceric ammonium nitrate in a CH3CN/H2O mixture at 0 °C resulting 
in diol 8-84. 
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Scheme 83. Synthesis of macrolactone 8-84 via Mitsunobu macrolactonization. 
 
Crystallization of lactone 8-84 from methanol provided crystals suitable for X-ray analysis. An 
ORTEP plot of 8-84 is shown in Figure 49 indicating the configurations at the chiral centers 
and the conformation of the macrocycle. The X-ray structure additionally proved the facial 
selectivity of the hydroboration step (8-78 to 8-79, and results obtained during model studies), 
originally inferred from NMR data. 
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Figure 49. X-ray structure of macrolactone 8-84. 
 
As a final challenge, differentiation of the two secondary hydroxy functions remained. A 
related transformation was described by Kirschning et al. in their total synthesis of 
tonantzitlolone where two outside hydroxyl groups of a triol were protected with triethylsilyl 
chloride (TESCl) and imidazole as base.[154] In the case at hand, the monosilylation of 8-84 
with TESCl was indeed possible but the reaction was rather slow, taking up to three weeks. 
Using the more reactive TESOTf (1.5 equiv), 2,6-lutidine as base, and low temperature (–50 
°C), we obtained the desired silyl ether 8-85 in 50% yield within 12 h (Scheme 84). Besides 
ether 8-85, some starting material plus a double protected derivative were present in the 
reaction mixture.  
 
Subsequent oxidation of alcohol 8-85 with Dess-Martin periodinane in dry CH2Cl2 followed 
smoothly and formed the ketone 8-86 in almost quantitative yield. Global deprotection of 8-87 
under acidic conditions provided the queenslandon analogue 6-2.  
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Scheme 84. Selective monoprotection, oxidation, and global deprotection. 
 
Additionally, deprotection of 8-4 led to triol 8-87: another analogue of queenslandon (6-1) 
(Scheme 85).  
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Scheme 85. Removal of MOM protecting group in 8-84. 
 
The regiochemistry in the selective TES-ether formation was inferred from the COSY NMR 
spectrum of the final compound, dihydroxyketone 6-2. Most supportive in the assignment was 
the absence of a cross-peak between 11-H and 13-H (Figure 50). Rather prominent 
correlations were seen for the methine H’s, 11-H and 13-H, with their neighboring methylene 
groups (marked as “c” and “f”, respectively). The keto group resonates at δ = 212.5 ppm in the 
13C NMR spectrum.  
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Figure 50. Fragment of COSY NMR spectrum of 6-2. 
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9 Conclusion II 
 
In summary, we developed an efficient asymmetric synthesis of macrolactone 6-2, 
featuring the complete aliphatic sector of queenslandon (6-1). The key steps in this synthesis 
were an anti selective aldol reaction, a tandem hydroboration/Suzuki cross-coupling, 
Mitsunobu macrolactonization, and selective mono-protection of diol 8-84.  
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Scheme 86. Key intermediates in the synthesis of the fully funcionalized core structure of 
queenslandon 6-2. 
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The synthesis of chiral aldehyde 8-6 started from racemic propylene oxide and proved to be 
more efficient as a known approach. The preparation of the Andrus auxiliary was optimized on 
the Wittig-Horner step and much higher yields were obtained as using the originally described 
procedures. All in all, the synthesis was started from cheap and commercially available 
starting materials. We also note that the chiral dioxane moiety served multiple purposes: (a) as 
a chiral auxiliary in the aldol reaction; (b) as the directing subunit in the diastereoselective 
hydroboration step; and (c) as a conformational constraint during the Mitsunobu 
macrolactonization. All chiral centers were essentially obtained via catalytic methods 
(Jacobsen resolution, ADH).  
 
The synthesis involved 15 steps and proceeded with good overall yield from racemic 
propylene oxide (8-9). Preliminary cytotoxicity assays (L929 mouse fibroblast cells) on 
macrolactone 6-2 showed an IC50 of 40 μg mL–1. At the same concentration, 8-87 was less 
active, reaching an inhibition of 40%.[155]  
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Figure 51. The structures of synthesized queenslandon analogues. 
 
The same strategy should allow for the preparation of further queenslandon analogues and the 
natural product itself. 
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10 Experimental Section 
 
10.1 General Remarcs 
 
10.1.1 Chemicals and working techniques 
 
The chemicals were purchased from the firms Acros, Aldrich, Fluka, Lancaster, Avocado and 
Merck. All reagents were obtained from commercial suppliers, and were used without further 
purification unless otherwise stated. All solvents were distilled and/or dried prior to use by 
standard methodology except for those, which were reagent grades. The applied petroleum 
ether fraction had a boiling point of 40–60 °C. Anhydrous solvents were obtained as follows: 
THF, diethyl ether and toluene by distillation from sodium and benzophenone; 
dichloromethane and chloroform by distillation from calcium hydride; acetone by distillation 
from phosphorous pentoxide. Absolute triethylamine and pyridine and diisopropylethylamine 
were distilled over calcium hydride prior to use. Unless and otherwise mentioned, all the 
reactions were carried out under a nitrogen atmosphere and the reaction flasks were pre-dried 
by heat gun under high vacuum. All the chemicals, which were air or water sensitive, were 
stored under inert atmosphere. Compounds that are not described in the experimental part 
were synthesized according to the literature. 
 
10.1.2 NMR-spectroscopy 
 
All the spectra were measured on a Bruker Advance 400 spectrometer, which operated at 400 
MHz for 1H and 100 MHz for 13C nuclei, respectively. 1H (400 MHz) and 13C NMR (100 
MHz): spectra were recorded at 295 K either in CDCl3 or [D6]DMSO; chemical shifts are 
calibrated to the residual proton and carbon resonance of the solvent: CDCl3 (δH = 7.25 ppm, 
δC = 77.0 ppm), [D6]DMSO (δH = 2.49 ppm, δC = 39.5 ppm). Data are reported as follows: 
chemical shift (multiplicity: s = singlet, d = doublet, t = triplet, ddd = doublet of doublet of 
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doublet, dt = doublet of triplet, td = triplet of doublet, m = multiplet, br = broadened, J = 
coupling constant (Hz), integration, peak assignment in italic form). 
10.1.3 Mass Spectrometry 
 
Mass spectra were recorded on a Finnigan Triple-Stage-Quadrupol Spectrometer (TSQ-70) 
from Finnigan-Mat. High-resolution mass spectra were measured on a modified AMD Intectra 
MAT 711 A from the same company. The used mass spectrometric ionization methods were 
electron-impact (EI), fast-atom bombardment (FAB) or field desorption (FD). FT-ICR-mass 
spectrometry and HR-FT-ICR mass spectra were measured on an APEX 2 spectrometer from 
Bruker Daltonic with electrospray ionization method (ESI). Some of the mass spectra were 
also measured on an Agilent 1100 series LC-MSD. Analytical HPLC-MS: HP 1100 Series 
connected with an ESI MS detector Agilent G1946C, positive mode with fragmentor voltage 
of 40 eV, column: Nucleosil 100–5, C-18 HD, 5 mm, 70 × 3 mm Machery Nagel, eluent: NaCl 
solution (5 mM)/acetonitrile, gradient: 0/10/15/17/20 min with 20/80/80/99/99% acetonitrile, 
flow: 0.6 mL min–1. High resolution mass (HRMS) are reported as follows: (ESI): calcd mass 
for the related compound followed by found mass. 
 
10.1.4 Infrared Spectroscopy 
 
The FT-IR spectra were recorded on a Fourier Transform Infrared Spectrometer model Jasco 
FT/IR-430. Solid samples were pulverized with potassium bromide and percent reflection 
(R%) was measured. The percent transmittance (T%) of liquid substances were measured in 
film between potassium bromide plates. Absorption band frequencies are reported in cm–1. 
 
10.1.5 Polarimetry 
 
Optical rotations were measured on a JASCO Polarimeter P-1020. They are reported as 
follows: [α]temperatureD (concentration, solvent). The unit of c is g/100 mL. Anhydrous CH2Cl2, 
CHCl3 or EtOH was used as a solvent. For the measurement the sodium D line = 589 nm was 
used. 
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10.1.6 Melting Points 
 
Melting points were determined with a Büchi Melting point B-540 apparatus and were not 
corrected. 
 
10.1.7 Chromatographic Methods 
 
Flash column chromatography was performed using flash silica gel (40-63 μm, 230-400 mesh 
ASTM) from Macherey-Nagel. 
Gas chromatography was performed on a CHROMPACK CP 9000 using a flame ionization 
detector, and carrier gas H2. Chiral gas chromatographic analyses were carried out on 13.5 m × 
0.25 mm column filled with deactivated fused silica with 30% 6-TBDMS-2,3-diacetyl-β-
cyclodextrin in PS 086 (df = 0.13 μm) and carrier gas H2 at 50 kPa and 30 °C. 
For GC-MS coupled chromatography, a GC-system series 6890 with an injector series 7683 
and MS-detector series 5973 from Hewlett Packard was used, with EI method, and carrier gas 
He. Analytical HPLC was performed on a Hewlett Packard HP 1100 system.  
Analytical thin layer chromatography (TLC) was performed on precoated with silica gel 60 
F254 plates (Merck) or Polygram Sil G/UV254 (Macherey Nagel). The compounds were 
visualized by UV254 light and the chromatography plates were developed with an aqueous 
solution of molybdophosphorous acid or an aqueous solution of potassium permanganate 
(heating with the hot gun). For preparation of the molybdate solution 20 g ammonium 
molybdate [(NH4)6Mo7O24·4H2O] and 0.4 g Ce(SO4)2·4H2O were dissolved in 400 mL of 10% 
H2SO4. The potassium permanganate solution was prepared from 2.5 g KMnO4 and 12.5 g 
Na2CO3 in 250 mL H2O. 
 
10.2 Experimental procedures 
 
All the experimental procedures are arranged in the ascending order of number of the 
compound. 
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Ethyl 1-benzyl-4-oxopiperidine-3-carboxylate (4-2) 
 
N
O
OEt
O
Bn  
 
Diethyl carbonate (19.4 mL, 18.9 g, 0.16 mol) was added dropwise under nitrogen atmosphere 
to a suspension of NaH (9.0 g, ~60% in mineral oil) in anhydrous toluene (125 mL). After the 
addition of several drops (3–5) of methanol, the mixture was heated at reflux and a solution of 
N-benzyl-4-piperidone (15.0 g, 0.08 mol) in anhydrous toluene (50 mL) was added dropwise 
during 35 min. Heating was maintained until the evolution of hydrogen ceased (approx. 2.5 h). 
The reaction mixture was then cooled to room temperature, stirred for additional 2 h, and 
acidified by careful addition of glacial AcOH. The resulting mixture was diluted with ice-cold 
water (~150 mL) and adjusted to pH ~ 8 with aqueous ammonia. The organic layer was 
separated and the aqueous phase was extracted with toluene (5 × 75 mL). The combined 
organic fractions were dried over Na2SO4 and evaporated to afford the crude mixture. 
Purification via column chromatography on silica gel gave the desired carboxylate 4-2, yield 
13.0 g (62%), yellow oil. 
 
Rf = 0.55–0.6 (petroleum ether/diethyl ether, 2:1); 
1H NMR (400 MHz, CDCl3): δ = 1.24 (t, J = 7.1 Hz, CO2CH2CH3), 1.85–1.94 (m, 2H, 5-H), 
2.15–2.25 (m, 2H, 6-H), 2.61–2.70 (m, 2H, 2-H), 3.44 (s, 2H, PhCH2NR2), 4.11 (dd, J = 14.1, 
7.1 Hz, CO2CH2CH3), 4.55–4.64 (m, 1H, 3-H), 7.16–7.28 (m, 5H, aromatic); 
NMR spectrum after standing in CDCl3 for some time contains the mixture of two compounds 
– the carboxylate 4-2 and its enol form. 
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1-Bromo-2-(bromomethyl)benzene (4-3a) 
 
Br
Br  
 
A CCl4 (130 mL) solution of o-bromotoluene (20.0 g, 117 mmol) and NBS (25.0 g, 140 
mmol) was refluxed for 9 h. The solid formed during the reaction was filtered off. After 
removal of the solvent in vacuo, distillation under reduced pressure gave 1-bromo-2-
(bromomethyl)benzene (4-3a) as a colorless liquid; yield 22.0 g (75%). 
 
b.p. 72–74 °C (0.8 mbar) 
 
Ethyl N-Benzyl-3-(2-bromobenzyl)-4-oxopiperidine-3-carboxylate (4-4a) 
 
N
O
Br
Bn
CO2Et
 
 
To a suspension of anhydrous K2CO3 (8.01 g, 58 mmol) and ethyl 1-benzyl-4-oxopiperidine-
3-carboxylate (4-2) (3.93 g, 15 mmol) in anhydrous THF (25 mL) was added under nitrogen a 
solution of 2-bromobenzyl bromide (4-3a) (4.5 g, 18.0 mmol) in anhydrous THF (25 mL). The 
mixture was refluxed for 6 h. Then the inorganic materials were filtered and washed with 
THF. The combined filtrates were concentrated to give an oily residue. The product was 
isolated by flash chromatography (petroleum ether/ethyl acetate, 20:1), yield 4.73 g (73 %), 
slightly yellow oil. 
 
Rf = 0.05 (petroleum ether/ethyl acetate, 20:1); 
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1H NMR (400 MHz, CDCl3): δ = 1.09 (t, J = 7.0 Hz, CO2CH2CH3), 2.23–2.30 (m, 1H, 6-H), 
2.32 (d, J = 11.5 Hz, 1H, 2-H), 2.80 (ddd, J = 14.4, 3.3, 2.0 Hz, 1H, 6-H), 2.81–2.91 (m, 1H, 
5-H), 2.95–3.01 (m, 1H, 5-H), 3.15 (d, J = 14.4 Hz, 1H, o-BrC6H4CH2), 3.45 (d, J = 14.4 Hz, 
1H, o-BrC6H4CH2), 3.47 (d, J = 13.1 Hz, 1H, PhCH2NR2), 3.56 (dd, J = 11.6, 2.8 Hz, 1H, 2-
H), 3.62 (d, J = 13.1 Hz, 1H, PhCH2NR2), 4.00–4.15 (m, 2H, CO2CH2CH3), 7.00–7.05 (m, 1H, 
ar.), 7.02–7.28 (m, 7H, ar.), 7.48 (d, J = 8.0 Hz, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 13.8 (CO2CH2CH3), 35.8, 40.5, 52.6, 61.0, 61.4, 61.8 (6C, 
sec.), 62.2 (C-3), 125.9, 127.0, 127.2, 128.1, 128.2, 128.9, 132.1, 132.8, 136.3, 137.7 (ar.), 
170.7 (CO2Et), 205.3 (C=O); 
HRMS (ESI): calcd. for C22H24BrNO3 [M+H]+: 430.1012, found 430.1013.  
 
 
Ethyl N-Benzyl-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)-carboxylate 
(4-5a) 
 
N
O
Bn
CO2Et
 
 
An oven-dried Schlenk tube fitted with a rubber septum was purged with nitrogen and charged 
with ethyl 1-benzyl-3-(2-bromobenzyl)-4-oxopiperidine-3-carboxylate (4-4a) (4.30 g, 10 
mmol), anhydrous toluene (50 mL), K3PO4 (4.25 g, 20 mmol), and Pd(dba)2 (115 mg, 2 
mol%). Then the tube was purged with nitrogen, and tBu3P (10 mL of 0.04 N in toluene, 4 
mol%) was added. The mixture was vigorously stirred in an oil bath at 110 °C for 12 h. The 
reaction mixture was then cooled to room temperature, diluted with diethyl ether (100 mL), 
filtered through Celite and concentrated in vacuo. The crude material was dissolved in diethyl 
ether and then the solvent was evaporated. This procedure was repeated three times which 
results in the precipitation of the crude product. The solids were washed with a mixture of 
pentane/diethyl ether (5:1), filtered and dried in vacuo. Alternatively, the crude material may 
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be purified by flash chromatography on silica gel (petroleum ether/diethyl ether, 9:1). The 
precipitation method provided the tricyclic compound 4-5a (2.3 g, 65%) as a yellow solid. 
 
Rf = 0.2 (petroleum ether/diethyl ether, 9:1); 
m.p. 117–119 °C; 
IR (KBr): υmax  = 2985, 2816, 1724, 1450, 1256, 744 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 1.30 (t, J = 7.1 Hz, CO2CH2CH3), 2.75 (dd, J = 10.6, 2.5 Hz, 
1H, 2-H), 3.00 (ddd, J = 10.6, 2.8 Hz, 1H, 2-H), 3.11 (d, J = 11.2 Hz, 1H, 4-H), 3.19 (dd, J = 
11.2, 2.8 Hz, 1H, 4-H), 3.41 (d, J = 17.2 Hz, 1H, 6-H), 3.42 (dd, J = 2.5 Hz, 1H, 1-H), 3.57 
(dd, J = 14.5 Hz, 2H, PhCH2NR2), 4.01 (d, J = 17.1 Hz, 1H, 6-H), 4.25 (dd, J = 14.1, 7.1 Hz, 
CO2CH2CH3), 6.87–6.95 (m, 3H, ar.), 7.12–7.22 (m, 5H, ar.), 7.25–7.31 (m, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 41.0 (C-6), 52.7 (C-1), 59.1 (C-5), 
60.2, 61.5, 61.8, 63.5 (4C, sec.), 126.2, 126.2, 127.0, 127.1, 127.5, 128.1 (CH, ar.), 128.2, 
136.3, 137.3, 138.2 (3C, quat. ar.), 170.2 (CO2Et), 207.4 (C=O); 
HRMS (ESI): calcd for C22H23NO3 [M+H]+ 350.1751, found 350.1752; methanol adduct 
(hemiacetal): calcd for C23H28NO4 [M+CH3OH+H]+: 382.2013, found 382.2008. 
 
 
2-Bromo-1-(bromomethyl)-3-methylbenzene (4-3b) 
 
Br
Br
Me
 
 
2-Bromo-1,3-dimethylbenzene (15.0 g, 0.081 mol) with stirring and irradiation with light 
(200W lamp) at 80 °C was added Br2 (13.0 g, 0.081 mol) in a dropwise fashion so, that before 
adding every next drop, the color of bromine in the reaction mixture vanished. After complete 
addition, the mixture was stirred for additional 30 min and fractionally distilled at reduced 
pressure to provide benzyl bromide 4-3b, yield 7.0 g (33%), colorless liquid. 
 
b. p. 85–90 °C (1 mbar) 
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1-Bromo-2-(bromomethyl)-4-methoxybenzene (4-3c)[59b] 
 
Br
MeO
Br
 
 
A mixture of carbon tetrachloride (45 mL), p-bromo-m-methylanisole (7.5 g, 37.3 mmol), N-
bromosuccinimide (7.0 g, 39.3 mmol), and 0.6 g (2.5 mmol) of benzoyl peroxide was heated 
from room temperature to reflux over a period of 25 min. Soon after the start of the reflux the 
solution turned orange. After 10 min the spontaneous heating had stopped and almost 
immediately thereafter the solution became colorless. The mixture was filtered and 
evaporation of the filtrate yielded crude product. Recrystallization of this material from 
petroleum ether (b. p. 30–60 °C) yielded 6.3 g (60%) of benzyl bromide 4-3c. 
 
m. p. 88–91 °C. 
 
1-Bromo-2-(bromomethyl)-4-fluorobenzene (4-3d) 
 
Br
F
Br
 
 
The reaction was performed with 2-bromo-5-fluorotoluene (10.3 g, 54.5 mmol) and with 
AIBN as radical initiator as described for 4-3a. Purification of the crude by distillation at 
reduced pressure gave the benzyl bromide 4-3d (8.9 g, 63%) as colorless viscous liquid. 
 
b. p. 118–124 °C. 
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3-Bromo-4-(bromomethyl)benzonitrile (4-3c) 
 
Br
N
Br  
 
The reaction was performed with 3-bromo-4-methylbenzonitrile (2.5 g, 12.8 mmol) and with 
AIBN as radical initiator as described for 4-3a. Purification of the crude by column 
chromatography (petroleum ether/ethyl acetate, 20:1) gave the benzyl bromide 4-3e (1.5 g, 
45%) as colorless solid. 
 
Rf = 0.23 (petroleum ether/ethyl acetate, 20:1). 
 
 
Ethyl N-Benzyl-3-(2-bromo-3-methylbenzyl)-4-oxopiperidine-3-carboxylate (4-4b) 
 
N
O
Br
Bn
CO2Et
Me
 
 
The reaction was performed with piperidone 4-2 (1.31 g, 5.0 mmol) and the benzyl bromide  
4-3b (1.32 g, 5.0 mmol) as described for 4-4a. Purification of the crude product by flash 
chromatography (petroleum ether/ethyl acetate, 20:1) gave the alkylated product 4-4b (1.2 g, 
54%) as colorless crystals. 
 
Rf = 0.05 (petroleum ether/ethyl acetate, 20:1); 
m. p. 60–61 °C; 
1H NMR (400 MHz, CDCl3): δ = 1.05 (t, J = 7.0 Hz, 3H, CO2CH2CH3), 2.20–2.27 (m, 1H, 6-
H), 2.30 (d, J = 11.4 Hz, 1H, 2-H), 2.32–2.38 (m, 4H, CH3Ar and 6-H), 2.78–2.87 (m, 1H, 5-
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H), 2.91–2.98 (m, 1H, 5-H), 3.16 (d, J = 14.4 Hz, 1H, ArCH2), 3.43 (d, J = 13.1 Hz, 1H, 
PhCH2NR2), 3.49 (d, J = 14.4 Hz, 1H, ArCH2), 3.52 (dd, J = 11.4, 3.0 Hz, 1H, 2-H), 3.60 (d, J 
= 13.1 Hz, 1H, PhCH2NR2), 3.97–4.12 (m, 2H, CO2CH2CH3), 6.93–7.05 (m, 3H, ar.), 7.25–
7.26 (m, 5H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 13.8 (CO2CH2CH3), 24.5 (CH3Ar), 36.5, 40.5, 52.5, 61.1, 
61.4, 61.8 (6C, sec.), 62.2 (C-3), 126.3, 127.2, 128.2 (4C, tert. ar.), 128.7 (quat. ar.), 128.9, 
129.2, 129.4 (4C, tert. ar.), 136.7, 137.8, 138.4 (3C, quat. ar.), 170.8 (CO2Et), 205.3 (C=O); 
HRMS (ESI): calcd. for C23H27BrNO3 [M+H]+: 444.1169, found 444.1174. 
 
 
Ethyl N-Benzyl-3-(2-bromo-5-methoxybenzyl)-4-oxopiperidine-3-carboxylate (4-4c) 
 
N
O
Br
Bn
CO2Et
OMe
 
 
The reaction was performed with piperidone 4-2 (2.61 g, 10.0 mmol) and benzyl bromide 4-3c 
(2.95 g, 11.0 mmol) as described for 4-4a. Purification of the crude product by flash 
chromatography (petroleum ether/diethyl ether, 9:1) gave the alkylated product 4-4c (2.4 g, 52 
%), yellow oil. 
 
Rf = 0.1 (petroleum ether/diethyl ether, 9:1); 
1H NMR (400 MHz, CDCl3): δ = 1.12 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.24–2.33 (m, 2H, 2-
H and 6-H), 2.40 (ddd, J = 14.4, 3.3, 2.0 Hz, 1H, 6-H), 2.97–3.03 (m, 1H, 5-H), 2.83–2.93 (m, 
1H, 5-H), 3.13 (d, J = 14.4 Hz, 1H, ArCH2), 3.41 (d, J = 14.4 Hz, 1H, ArCH2), 3.50 (d, J = 
13.3 Hz, 1H, PhCH2NR2), 3.58–3.66 (m, 2H, PhCH2NR2 and 2-H), 3.72 (s, 3H, CH3OAr), 
4.03–4.16 (m, 2H, CO2CH2CH3), 6.62 (dd, J = 8.8, 3.0 Hz, 1H, 4’-H, ar.), 6.78 (d, J = 3.0 Hz, 
1H, 6’-H, ar.), 7.21–7.31 (m, 5H, ar.), 7.37 (d, J = 8.8 Hz, 1H, 3’-H, ar.); 
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13C NMR (100 MHz, CDCl3): δ = 13.8 (CO2CH2CH3), 36.0 (ArCH2), 40.5 (C-5), 52.6 
(PhCH2NR2), 55.4 (CH3OAr), 60.9, 61.4, 61.8 (3C, sec.), 62.3 (C-3), 114.3 (tert. ar.), 116.4, 
117.5 (quat. ar.), 127.2, 128.2, 128.9, 133.1 (7C, tert. ar.), 137.2, 137.7 (2C, quat. ar.), 158.4 
(MeOC, quat. ar.), 170.8 (CO2Et), 205.3 (C=O); 
HRMS (ESI): calcd. for C23H27BrNO4 [M+H]+: 460.1118, found 460.1125. 
 
 
Ethyl 3-(2-brom-5-fluorobenzyl)-N-benzyl-4-oxopiperidine-3-carboxylate (4-4d) 
 
N
O
Br
Bn
CO2Et
F
 
 
a) To a suspension of anhydrous K2CO3 (13.25 g, 0.096 mol) and ethyl 1-benzyl-4-
oxopiperidine-3-carboxylate (4-2) (6.33 g, 0.024 mol) in anhydrous THF (50 mL) was added 
under nitrogen atmosphere a solution of 2-bromo-5-fluorobenzyl bromide (4-3d, 7.90 g, 0.029 
mol) in anhydrous THF (50 mL). The mixture was refluxed for 17 hours. Then inorganic 
materials were filtered and washed with THF (3 × 25 mL). The combined filtrates were 
evaporated to give an oily residue. The product was purified by flash chromatography 
(petroleum ether/ethyl acetate, 10:1), providing 4-4d as a slightly yellow oil, yield 3.00 g 
(29%).  
 
b) A mixture of potassium tert-butoxide (0.130 g, 14 mmol) and anhydrous THF (10 mL) was 
stirred at room temperature for 0.5 h. The resulting milky solution was cooled to 0 °C, and 
then 1-benzyl-4-oxopiperidine-3-carboxylate (4-2) (0.250 g, 9.5 mmol) in anhydrous THF (10 
mL) was added whereby the temperature was kept below 5 °C. The mixture was then warmed 
to room temperature and further stirred for 1h, resulting in a yellow solution. After cooling to 
0 °C a solution of 2-bromo-5-fluorobenzyl bromide (4-3d, 0.284 g, 11 mmol) in anhydrous 
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THF (10 mL) was added dropwise within 0.5 h. The reaction mixture was warmed to room 
temperature and stirred overnight. The mixture was cooled to 0 °C before saturated NH4Cl was 
added. After separation of the layers the aqueous phase was extracted with ethyl acetate (2 × 
50 mL). The combined organic layers were washed twice with brine, dried over Na2SO4 and 
filtered. The solvent was evaporated under reduced pressure and the residue purified by flash 
chromatography (petroleum ether/ethyl acetate, 10:1), providing 4-4d as a slightly yellow oil, 
yield 0.230 g (54%). 
 
Rf = 0.3 (petroleum ether/ethyl acetate, 10:1); 
1H NMR (400 MHz, CDCl3): δ = 1.06 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.20–2.28 (m, 2H, 6-
H), 2.35 (ddd, J = 14.5, 3.0, 2.0 Hz, 1H, 2-H), 2.79–2.88 (m, 1H, 5-H), 2.92-2.99 (m, 1H, 5-
H), 3.07 (d, J = 14.5 Hz, 1H, ArCH2), 3.36 (d, J = 14.5 Hz, 1H, ArCH2), 3.45 (d, J = 13.2 Hz, 
1H, PhCH2NR2), 3.52 (dd, J = 11.6, 2.8 Hz, 1H, 2-H), 3.57 (d, J = 13.2 Hz, 1H, PhCH2NR2), 
3.97–4.12 (m, 2H, CO2CH2CH3), 6.69–6.76 (m, 1H, ar.), 6.93 (dd, J = 9.6, 3.1 Hz, 1H, ar.), 
7.15–7.26 (m, 5H, ar.), 7.39 (dd, J = 8.6, 5.4 Hz, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 13.8 (CO2CH2CH3), 36.0, 40.5, 52.7, 61.0, 61.5, 61.7, 62.1, 
115.4, 115.6, 118.9, 119.1, 120.0, 127.3, 128.2, 128.9, 133.6, 133.7, 137.6, 138.4, 138.5, 
160.2, 162.6, 170.6 (CO2Et), 205.1 (C=O); 
HRMS (ESI): calcd for C22H24BrFNO3 [M+H]+: 448.09181, found 448.09176. 
 
 
Ethyl 3-(2-brom-4-cyanobenzyl)-N-benzyl-4-oxopiperidine-3-carboxylate (4-4e) 
 
N
O
Br
Bn
CO2Et
N
 
 
The reaction was performed with piperidone 4-2 (436 mg, 1.65 mmol) and benzyl bromide    
4-3e (500 mg, 1.8 mmol) as described for 4-4a. Purification of the crude product by flash 
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chromatography (petroleum ether/diethyl ether, 5:1) gave the alkylated product 4-4e (563 mg, 
72 %), slightly yellow oil. 
 
Rf = 0.2 (petroleum ether/ethyl acetate, 5:1);  
1H NMR (400 MHz, CDCl3): δ = 1.04 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.20–2.30 (m, 2H, 2-
H and 6-H), 2.22–2.26 (m, 1H, 6-H), 2.81–3.01 (m, 2H, 5-H), 3.10 (d, J = 14.5 Hz, 1H, 
ArCH2), 3.42 (d, J = 14.5 Hz, 1H, ArCH2), 3.45–3.50 (m, 2H, PhCH2NR2), 3.57 (d, J = 13.2 
Hz, 1H, 2-H), 3.92–4.10 (m, 2H, CO2CH2CH3), 7.06–7.12 (m, 2H, ar.), 7.15–7.25 (m, 3H, ar.), 
7.28 (d, J = 7.9 Hz, 1H, ar.), 7.39 (dd, J = 8.1, 1.5 Hz, 1H, ar.), 7.73 (d, J = 1.3 Hz, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 13.8 (CO2CH2CH3), 36.0, 40.4, 52.8, 61.1, 61.7, 61.7, 62.1, 
112.0, 117.2, 125.2, 127.4, 128.3, 129.0, 130.4, 132.5, 135.8, 137.8, 142.5, 170.4 (CO2Et), 
205.0 (C=O); 
HRMS (ESI): calcd for C23H24BrN2O3 [M+H]+: 455.09648, found 455.09658. 
 
 
Ethyl N-Benzyl-10-methyl-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)-
carboxylate (4-5b) 
 
N
O
Bn
CO2Et
Me
 
 
This compound was prepared as described for 4-5a using 455 mg (1.02 mmol) of the alkylated 
compound 4-4b. The crude product was purified by flash chromatography (petroleum 
ether/ethyl acetate, 20:1), yield 95 mg (30%), colorless oil.  
 
Rf = 0.1 (petroleum ether/ethyl acetate, 20:1); 
IR (film): υmax = 2951, 2812, 1728, 1458, 1261, 1107, 744 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.16 (s, 3H, CH3Ar), 
2.71 (dd, J = 10.6, 2.5 Hz, 1H, 2-H), 3.02 (ddd, J = 10.6, 2.8 Hz, 1H, 2-H), 3.10 (d, J = 11.2 
Experimental Section 149
Hz, 1H, 4-H), 3.16 (dd, J = 11.2, 2.8 Hz, 1H, 4-H), 3.41 (d, J = 17.3 Hz, 1H, 6-H), 3.57 (s, 2H, 
PhCH2NR2), 3.65 (dd, J = 2.5 Hz, 1H, 1-H), 3.99 (d, J = 17.3 Hz, 1H, 6-H), 4.24 (dd, J = 14.4, 
7.1 Hz, 2H, CO2CH2CH3), 6.88–6.96 (m, 2H, ar.), 7.01–7.07 (m, 2H, ar.), 7.14–7.20 (m, 4H, 
ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 18.4 (CH3Ar), 41.1 (C-6), 49.0 (C-1), 
58.9 (C-5), 59.4, 60.2, 61.5, 63.2 (4C sec.), 124.3, 126.7, 127.0, 127.8 (4C tert. ar.), 128.0, 
128.2, 134.6, 136.2, 138.2 (4C quat. ar.), 170.3 (CO2Et), 208.0 (C=O); 
HRMS (ESI): calcd for C23H26NO3 [M+H]+: 364.1907, found 364.1917. 
 
 
Ethyl N-Benzyl-8-methoxy-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)-
carboxylate (4-5c) 
 
N
O
Bn
CO2Et
OMe
 
 
This compound was prepared as described for 4-5a using 577 mg (1.25 mmol) of the alkylated 
compound 4-4c. The crude product was purified by flash chromatography (petroleum 
ether/ethyl acetate, 20:1), yield 144 mg (40%), yellow oil which crystallizes within several 
days. 
 
Rf = 0.1 (petroleum ether/ethyl acetate, 20:1); 
m. p. 84–85 °C; 
IR (KBr): υmax = 2943, 2816, 1724, 1608, 1454, 1265, 1088, 741 cm–1;  
1H NMR (400 MHz, CDCl3): δ = 1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.71 (dd, J = 10.5, 
2.5 Hz, 1H, 2-H), 2.97 (ddd, J = 10.6, 2.8, 1H, 2-H), 3.08 (d, J = 11.2, 1H, 4-H), 3.15 (dd, J = 
11.2, 2.8 Hz, 1H, 4-H), 3.38 (d, J = 17.4 Hz, 1H, 6-H), 3.39 (dd, J = 2.5 Hz, 1H, 1-H), 3.57 (s, 
2H, PhCH2NR2), 3.84 (s, 3H, CH3OAr), 3.97 (d, J = 17.4 Hz, 1H, 6-H), 4.20–4.27 (m, 2H, 
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CO2CH2CH3), 6.72–6.75 (m, 2H, ar.), 6.82–6.86 (m, 1H, ar.), 6.93–6.97 (m, 2H, ar.), 7.15–
7.19 (m, 3H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 41.1 (C-6), 52.0 (C-1 tert.), 55.3 
(CH3OAr), 58.8 (C-5 quat.), 60.3, 61.5, 62.0, 63.4 (4C sec.), 111.4, 112.3, 127.1, 128.1, 128.2, 
128.5 (8C tert. ar.), 129.6, 137.4, 138.2 (3C quat. ar.), 158.8 (MeOC quat. ar.), 170.3 (CO2Et), 
207.5 (C=O); 
HRMS (ESI): calcd for C23H26NO4 [M+H]+: 380.18563, found 380.18573; methanol adduct 
(hemiacetal) calcd for C24H30NO5 [M+CH3OH+H]+: 412.2119, found 412.2111. 
 
 
Ethyl N-benzyl-10-fluoro-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)-
carboxylate (4-5d) 
 
N
O
Bn
CO2Et
F
 
 
This compound was prepared as described for 4-5a using 300 mg (0.64 mmol) of the alkylated 
compound 4-4d. The crude product was purified by flash chromatography (petroleum 
ether/ethyl acetate, 20:1). The fractions containing the product were combined together and 
concentrated in vacuo. Recrystallization from heptane (2 mL) provides compound 4-5d as a 
white crystalline solid, yield 91 mg (37%). Additional amount (21 mg) of product could be 
separated from the mother filtrate by flash chromatography (overall yield 46%). 
 
Rf = 0.1 (petroleum ether/ethyl acetate, 20:1); 
m. p. 104–106 °C; 
1H NMR (400 MHz, CDCl3): δ = 1.33 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.76 (dd, J = 10.7 
2.1, Hz, 1H, 2-H), 2.93–2.99 (m, 1H, 2-H), 3.14 (d, J = 11.2 Hz, 1H, 4-H), 3.19 (dd, J = 11.2, 
2.8 Hz, 1H, 4-H), 3.38 (d, J = 17.4 Hz, 1H, ArCH2), 3.41–3.44 (m, 1H, 1-H), 3.56 (dd, J = 
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17.0, 13.5 Hz, 2H, PhCH2NR2), 4.02 (d, J = 17.4 Hz, 1H, ArCH2), 4.20–4.29 (m, 2H, 
CO2CH2CH3), 6.85–6.95 (m, 5H, ar.), 7.15–7.21 (m, 3H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 40.8 (sec.), 52.0 (tert.), 58.6 (quat.), 
60.3, 61.7, 61.8 (3C sec.), 63.4, 112.8, 113.1, 113.2, 113.5, 127.2, 128.1, 128.3, 128.9, 128.9, 
133.0, 138.0, 138.2, 138.3, 160.8, 163.2, 170.0 (CO2Et), 206.9 (C=O); 
HRMS (ESI): calcd for C23H27BrFNO3 [M+MeOH+H]+: 400.19179, found 400.19097. 
 
 
Ethyl N-benzyl-9-cyano-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)-
carboxylate (4-5e) 
 
N
O
Bn
CO2Et
N
 
 
This compound was prepared as described for 4-5a using 306 mg (0.64 mmol) of the alkylated 
compound 4-4e. The crude product was purified by flash chromatography (petroleum 
ether/ethyl acetate, 5:1). The fractions containing the product were combined together and 
concentrated in vacuo. Crystallization from petroleum ether/ ethyl acetate mixture (8:1, 5 mL) 
provides compound 4-5 as a white crystalline solid, yield 80 mg (33%). Additional amount (13 
mg) of product could be separated from mother filtrate by flash chromatography (overall yield 
35%). 
 
Rf = 0.2 (petroleum ether/ethyl acetate, 5:1); 
m. p. 158–160 °C; 
1H NMR (400 MHz, CDCl3): δ = 1.25 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.73 (d, J = 10.8 Hz, 
1H, 2-H), 2.87–2.95 (m, 1H, 2-H), 3.06–3.15 (m, 2H, 4-H), 3.38 (d, J = 18.3 Hz, 1H, ArCH2), 
3.43 (s, 1H, 1-H), 3.50 (dd, J = 21.6, 13.7 Hz, 2H, PhCH2NR2), 3.98 (d, J = 18.3 Hz, 1H, 
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ArCH2), 4.15–4.25 (m, 2H, CO2CH2CH3), 6.80 (d, J = 5.9 Hz, 2H, ar.), 7.09–7.21 (m, 4H, ar.), 
7.26 (d, J = 7.9 Hz, ar.), 7.52 (d, J = 7.9 Hz, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 41.0, 52.1, 58.9, 60.1, 61.5, 61.8, 63.2 
(4C sec.), 110.1, 118.6 (2C quat.), 127.1, 127.4, 128.0, 128.4, 130.7, 131.0, 137.6, 138.9, 
142.0, 169.5 (CO2Et), 205.5 (C=O); 
HRMS (ESI): calcd for C24H29BrN2O3 [M+MeOH+H]+: 407.19640, found 407.19584. 
 
 
Ethyl 1-Benzyl-4-(2-bromobenzyl)-3-oxopiperidine-4-carboxylate (4-11) 
 
N
O
Br CO2Et
Bn  
 
A mixture of potassium tert-butoxide (7.5 g, 65.0 mmol) and absolute tetrahydrofuran (150 
mL) was stirred at room temperature for 0.5 h. The resulting milky solution was cooled to 0 
°C, and then N-benzyl-3-oxo-4-piperidine carboxylate hydrochloride[60] (4-11) (10.0 g, 33.6 
mmol) was added via a powder dropping funnel whereby the temperature was kept below 5 
°C. The mixture was then warmed to room temperature and further stirred for 1 h, resulting in 
a yellow solution. After cooling to 0 °C, a solution of 2-bromobenzyl bromide (8.8 g, 35.2 
mmol) in absolute THF (40.0 mL) was added dropwise within 0.5 h. A maximum temperature 
of 2 °C was observed. The reaction mixture was warmed to room temperature and stirred for 4 
h. The reaction solution was cooled to 0 °C, before saturated NH4Cl solution (100 mL) was 
added. After separation of the layers, the aqueous phase was extracted with ethyl acetate (2 × 
100 mL). The combined organic layers were washed twice with saturated NaCl solution, dried 
over Na2SO4, and filtered. The solvent was evaporated under reduced pressure and the residue 
purified by flash chromatography (petroleum ether/ethyl acetate, 10:1) to yield 7.4 g (50%) of 
the product 4-11 as a slightly yellow oil. This compound should be used immediately after 
isolation, or can be kept longer time in inert atmosphere at –20 °C.  
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Rf = 0.2 (petroleum ether/ethyl acetate, 10:1); 
1H NMR (400 MHz, CDCl3): δ = 1.22 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 1.77–1.87 (m, 1H, 
CH2CH2), 2.55–2.65 (m, 2H, CH2CH2), 2.70–2.80 (m, 1H, CH2CH2), 3.12 (d, J = 15.9 Hz, 1H, 
ArCH2), 3.24 (d, J = 15.9 Hz, 1H, ArCH2), 3.31 (d, J = 14.1 Hz, 1H, 2-H), 3.51 (d, J = 14.1 
Hz, 1H, 2-H), 3.57 (s, 2H, PhCH2NR2), 4.15–4.25 (m, 2H, CO2CH2CH3), 7.08–7.15 (m, 1H, 
ar.), 7.22–7.37 (m, 7H, ar.), 7.57 (d, J = 8.1 Hz, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 13.9 (CO2CH2CH3), 30.0, 37.4, 48.7, 58.7, 61.4, 61.5 (6C, 
sec.), 62.2 (C-4, quat.), 125.9 (quat. ar.), 127.0, 127.3, 128.2, 128.3, 128.8, 132.3, 132.9 (9C 
tert. ar.), 136.2 (quat. ar.), 137.1 (quat. ar.), 169.8 (CO2Et), 203.9 (C=O); 
 
 
Ethyl 2-Benzyl-11-oxo-1,3,4,6-tetrahydro-1,5-methano-2-benzazocine-5(2H)-carboxylate 
(4-12) 
 
N
O
CO2Et
Bn  
 
An oven-dried Schlenk tube fitted with a rubber septum was purged with nitrogen and charged 
with ethyl 1-benzyl-3-(2-bromobenzyl)-4-oxopiperidine-3-carboxylate (4-11) (430 mg, 1 
mmol) in 5 mL of anhydrous toluene, K3PO4 (425 mg, 2 mmol), and Pd(dba)2 (34.5 mg, 6 mol 
%). Then tube was purged with nitrogen, and tBu3P (3 mL of 0.04 N in toluene, 12 mol %) 
was added. The mixture was vigorously stirred in a 110 °C oil bath for 48 h [if starting 
material is still presented in the reaction mixture, additional amount of Pd(dba)2 (34.5 mg) and 
tBu3P (3 mL of 0.04 N in toluene) should be added and heated further, till completion]. The 
reaction mixture was then cooled to room temperature and filtered through Celite. Then, the 
solvent was evaporated and the residue purified by flash chromatography (petroleum 
ether/ethyl acetate, 5:1), providing the bicyclic compound 4-12 as a light yellow oil, yield 125 
mg (35%).  
 
Rf = 0.5 (petroleum ether/ethyl acetate, 5:1); 
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IR (film): υmax = 2974, 2831, 1732, 1450, 1227, 737 cm–1;  
1H NMR (400 MHz, CDCl3): δ = 1.33 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 1.98 (ddd, J = 13.4, 
3.0, 1.8 Hz, 1H, 3-H), 2.49 (ddd, J = 12.8, 3.1, 1H, 4-H), 2.61 (ddd, J = 12.5, 5.5, 1.8, 1H, 4-
H), 2.87 (dddd, J = 13.2, 5.5, 1.8 Hz, 1H, 3-H), 3.27 (d, J = 17.6 Hz, 1H, 6-H), 3.42 (d, J = 
13.4 Hz, 1H, PhCH2NR2), 3.69 (d, J = 13.4 Hz, 1H, PhCH2NR2), 4.07 (d, J = 17.6 Hz, 1H, 6-
H), 4.08 (s, 1H, 1-H), 4.29 (dd, J = 14.4, 7.1 Hz, 2H, CO2CH2CH3), 6.98 (d, J = 7.6 Hz, 1H, 
ar.), 7.21–7.28 (m, 3H, ar.), 7.30–7.38 (m, 5H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.2 (CO2CH2CH3), 37.3 (C-2, sec.), 40.2 (C-6, sec.), 42.8 
(C-4, sec.), 57.1 (C-5, quat.), 57.7 (PhCH2NR2), 61.7 (CO2CH2CH3), 67.9 (C-1, tert.), 126.2, 
127.1, 127.3, 128.5, 128.6, 128.7 (8C tert. ar.), 129.9 (quat. ar.), 130.4 (tert. ar.), 136.4 (quat. 
ar.), 137.8 (quat. ar.), 171.2 (CO2Et), 205.0 (C=O); 
HRMS (ESI): calcd for C22H24NO3 [M+H]+: 350.1751, found 350.1749. 
 
 
ortho-Bromobenzyldimethylanilinium bromide (4-19a) 
 
Br
N
Me
Ph
Me
Br-
 
 
This compound was prepared by a modified literature procedure.[62] N,N-Dimethylaniline 
(12.2 g, 0.1 mol) and ortho-bromobenzyl bromide 4-3a (25.0 g, 0.1 mol) were mixed and 
diluted with benzene (100 mL). The resulting solution was stirred at room temperature for 48 
h, and then evaporated to dryness. The solids were treated with a 1:1 mixture of petroleum 
ether/diethyl ether and the slurry was heated before it was filtered. The yield was quantitive. 
The salt 4-19a should be kept under nitrogen atmosphere.  
 
1H NMR (400 MHz, CDCl3): δ = 3.93 (s, 6H), 5.52 (s, 2H), 7.14–7.24 (m, 2H), 7.40–7.54 (m, 
5H), 7.86 (d, J = 7.7 Hz, 2H); 
13C NMR (100 MHz, CDCl3): δ = 53.7, 71.7, 121.5, 127.3, 127.7, 127.9, 130.4, 130.7, 132.4, 
133.6, 135.4, 144.6; 
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Ethyl 3-(2-Bromobenzyl)-N-methyl-4-oxopiperidine-3-carboxylate (4-20a) 
 
N
O
Br
Me
CO2Et
 
 
To a suspension of NaH (235 mg, 5.85 mmol, 60% in mineral oil) was added ethyl 1-methyl-
4-oxopiperidine-3-carboxylate[61] (4-18) (1.07 g, 5.8 mmol) in toluene (20 mL). The mixture 
was then kept at 80 °C for 1 h. Then, powdered ortho-bromobenzyldimethylanilinium bromide 
(25a) (2.06 g, 5.55 mmol) was added in one portion to the suspension of the sodium salt at 
room temperature. This mixture was refluxed for 6 h. After cooling, the mixture was poured 
carefully into water (30 mL). The organic layer was separated, washed with saturated aqueous 
NaCl solution (2 × 20 mL), dried with Na2SO4, filtered, and evaporated to give an oily residue. 
The crude product was purified by flash chromatography (petroleum ether/ethyl acetate, 1:1) 
to give 0.74 g (38%) of 4-20a as a light yellow oil. 
 
Rf = 0.25 (petroleum ether/ethyl acetate, 1:1); 
1H NMR (400 MHz, CDCl3): δ = 1.15 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.20 (d, J = 11.6 Hz, 
1H, 2-H), 2.25–2.32 (m, 4H, N-CH3 and 6-H), 2.42 (ddd, J = 14.4, 3.0, 2.0 Hz, 1H, 6-H), 
2.84–2.94 (m, 1H, 5-H), 2.97–3.04 (m, 1H, 5-H), 3.17 (d, J = 14.4 Hz, 1H, o-BrPhCH2), 3.43 
(dd, J = 11.6, 3.0 Hz, 1H, 2-H), 3.47 (d, J = 14.4 Hz, 1H, o-BrPhCH2), 4.08–4.17 (m, 2H, 
CO2CH2CH3), 7.03–7.09 (m, 1H, ar.), 7.17–7.20 (m, 2H, ar.), 7.51 (d, J = 7.9 Hz, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.0 (CO2CH2CH3), 36.0, 40.5 (2C sec.), 45.6 (N-CH3), 
55.8, 61.6 (2C sec.), 62.9 (C-3 quat.), 125.9 (quat. ar.), 127.1 (4C tert. ar.), 128.4, 132.2, 132.9 
(4C tert. ar.), 136.1 (quat. ar.), 170.3 (CO2Et), 204.9 (C=O); 
HRMS (ESI): calcd for C16H21BrNO3 [M+H]+: 354.0699, found 354.0701. 
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Ethyl 3-(2-Bromo-3-methylbenzyl)-N-methyl-4-oxopiperidine-3-carboxylate (4-20b) 
 
N
O
Br
Me
CO2Et
Me
 
 
The alkylation was performed as described for 4-20a. For this reaction 1.07 g (5.8 mmol) of 
26 and 2.22 g (5.7 mmol) of the anilinium salt 4-19b were used. The product was isolated by 
flash chromatography (petroleum ether/diethyl ether, 1:1); yield 0.73 g (35%) as a slightly 
yellow oil.  
 
Rf = 0.2 (petroleum ether/diethyl ether, 1:1); 
1H NMR (400 MHz, CDCl3): δ = 1.15 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.20 (d, J = 11.6 Hz, 
1H, 2-H), 2.25–2.32 (m, 4H, N-CH3 and 6-H), 2.37–2.45 (m, 4H, CH3Ar and 6-H), 2.84–2.94 
(m, 1H, 5-H), 2.96–3.04 (m, 1H, 5-H), 3.22 (d, J = 14.4 Hz, 1H, ArCH2), 3.43 (dd, J = 11.6, 
2.8 Hz, 1H, 2-H), 3.53 (d, J = 14.4 Hz, 1H, ArCH2), 4.06–4.19 (m, 2H, CO2CH2CH3), 6.96–
7.00 (m, 1H, ar.), 7.05–7.10 (m, 2H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 13.8 (CO2CH2CH3), 24.6 (CH3Ar), 36.7, 40.6 (2C sec.), 
45.6 (N-CH3), 55.8, 61.5 (2C sec.), 61.6 (C-3 quat.), 62.9 (sec.), 126.4 (tert. ar.), 128.6 (quat. 
ar.), 129.3, 129.5 (2C tert. ar.), 136.5, 138.6 (2C quat. ar.), 170.4 (CO2Et), 204.9 (C=O); 
HRMS (ESI): calcd for C17H23BrNO3 [M+H]+: 368.0856, found 368.0857. 
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Ethyl N-Methyl-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)-carboxylate 
Hydrochloride (4-21a) 
 
N
O
Me
CO2Et
HCl  
 
An oven-dried Schlenk tube fitted with a rubber septum was purged with argon and charged 
with ethyl 1-methyl-3-(2-bromobenzyl)-4-oxopiperidine-3-carboxylate (4-20a) (745 mg, 2.16 
mmol) in 10 mL of anhydrous toluene, K3PO4 (1.3 g, 6.1 mmol), and Pd(dba)2 (50 mg, 4 mol. 
%). Then tube was purged with nitrogen, and tBu3P (4 mL of a 0.04 N solution in toluene, 8 
mol%) was added. The mixture was vigorously stirred in a 120 °C oil bath for 72 h. The 
reaction mixture was then cooled to room temperature, diluted with ether (10 mL), and filtered 
through celite. The filtrate was concentrated under reduced pressure. The crude material was 
then treated with a concentrated ethanol solution of HCl (1 mL), and subsequently the solvent 
was evaporated. The residue was dissolved in water (5 mL), and the solution washed with 
diethyl ether (10 mL) and CH2Cl2 (10 mL). The aqueous solution was evaporated, and the 
residue dried in vacuo to give 206 mg (35%) of the salt 4-21a as a yellow oily solid.  
 
IR (film): υmax = 3378 (br), 2819, 2673, 1720, 14589, 1281, 1084, 768 cm–1;  
1H NMR (400 MHz, CDCl3), free base: δ = 1.31 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.25 (s, 3H, 
N-CH3), 2.67 (dd, J = 10.6, 2.8, 1H, 2-H), 2.99 (ddd, J = 10.6, 2.5 Hz, 1H, 2-H), 3.02 (d, J = 
11.2 Hz, 1H, 4-H), 3.15 (dd, J = 11.2, 2.8, 1H, 4-H), 3.39 (dd, J = 2.5 Hz, 1H, 1-H), 3.52 (d, J 
= 17.45 Hz, 1H, 6-H), 4.02 (d, J = 17.4 Hz, 1H, 6-H), 4.27 (dd, J = 14.4, 7.1 Hz, 
CO2CH2CH3), 6.97 (d, J = 7.6 Hz, 1H, ar.), 7.12–7.25 (m, 3H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 41.0 (sec.), 45.0 (N-CH3), 52.5 (sec.), 
58.6 (C-5 quat.), 61.6, 64.7, 66.6 (3C sec.), 126.3, 126.6, 127.2, 127.5 (4C tert. ar.), 135.8, 
137.3 (2C quat. ar.), 170.3 (CO2Et), 207.5 (C=O); 
HRMS (ESI): calcd for C16H20NO3 [M+H]+: 274.1438, found 274.1432; methanol adduct 
(hemiacetal) calcd for C17H24NO4 [M+CH3OH+H]+: 306.1700, found 306.1699. 
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Ethyl N,10-Dimethyl-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)-
carboxylate (4-21b) 
 
N
O
Me
CO2Et
Me
 
 
The cyclization was performed as described for 4-21a using 147 mg (0.4 mmol) of 4-20b. The 
cyclized product 4-21b was isolated by flash chromatography (petroleum ether/ethyl acetate, 
20:1), yield 41 mg (36%).  
 
Rf = 0.15 (petroleum ether/ethyl acetate, 20:1); 
1H NMR (400 MHz, CDCl3): δ = 1.31 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.23 (s, 3H, CH3), 
2.27 (s, 3H, CH3), 2.63 (dd, J = 10.6, 2.8 Hz, 1H, 2-H), 2.99 (ddd, J = 10.6, 2.5 Hz, 1H, 2-H), 
3.02 (d, J = 11.2 Hz, 1H, 4-H), 3.14 (dd, J = 11.2, 2.8 Hz, 1H, 4-H), 3.49 (d, J = 17.3 Hz, 1H. 
6-H), 3.60 (dd, J = 2.5 Hz, 1H, 1-H), 4.01 (d, J = 17.3 Hz, 1H, 6-H), 4.23–4.30 (m, 2H, 
CO2CH2CH3), 6.98–7.03 (m, 2H, ar.), 7.09–7.13 (m, 1H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 18.5 (CH3Ar), 41.0 (sec.), 45.1 (N-
CH3), 48.7 (C-1 tert.), 58.5 (C-5 quat.), 61.5, 62.4, 66.3 (3C sec.), 124.6, 126.8, 128.0, 134.7, 
135.3, 135.7 (6C ar.), 170.4 (CO2Et), 208.1 (C=O). 
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Diethyl 11-Oxo-1,6-dihydro-1,5-methano-3-benzazocine-3,5(2H)-dicarboxylate (4-23a) 
 
N
O
CO2Et
CO2Et
 
 
The N-benzyl-protected substrate 4-5a (225 mg, 0.64 mmol) was mixed with 
ethyloxycarbonyl chloride (5 mL) and the mixture was heated at 60 °C for 3 days. Then, the 
excess of ethylchloroformate was removed by distillation in vacuo. Flash chromatography 
(petroleum ether/ethyl acetate, 5:1) of the residue gave the product 4-23a (135 mg, 64%) as an 
oil. Conversion of starting material was around 75%. According to the NMR data 4-23a is a 
mixture of rotamers. 
 
Rf = 0.1-0.2 (petroleum ether/ethyl acetate, 5:1); 
1H NMR (400 MHz, CDCl3): δ = 0.77 (t, J = 7.1 Hz, 2H); 1.13 (t, J = 7.1 Hz, 1H), 1.31 (t, J = 
7.1 Hz, 3H), 3.30–3.47 (m, 1.3H), 3.51–3.77 (m, 4H), 3.87–4.05 (m, 1.6H), 4.22-4.32 (m, 
2.6H), 4.37–4.60 (m, 0.5H), 4.79 (dd, J = 13.6, 3.3 Hz, 0.6H), 7.00–7.13 (m, 2H), 7.14–7.23 
(m, 2H). 
13C NMR (100 MHz, CDCl3): δ = 14.1, 39.0, 52.5, 53.2, 53.9, 59.7, 61.6, 61.8, 126.8, 127.3, 
127.7, 128.2, 134.4, 134.8, 155.8, 169.3, 205.3; 
HRMS (ESI): calcd for C18H22NO5 [M+H]+: 332.1493, found 332.1491. 
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3-Benzyl 5-Ethyl 11-Oxo-1,6-dihydro-1,5-methano-3-benzazocine-3,5(2H)-dicarboxylate 
(4-23b) 
 
N
O
CO2Bn
CO2Et
 
 
The N-benzyl compound 4-5a (1.0 g, 2.8 mmol) was mixed with benzyloxycarbonyl chloride 
(5 mL). The resulting mixture was then heated at 80 °C until the reaction was finished (up to 7 
days). During this time, every day, additional Cbz chloride (1 mL) was added. The progress of 
this reaction was followed by LC-MS. After completion, the liquid part was removed by 
distillation in vacuo at 80 °C. The crude product was purified by flash chromatography 
(petroleum ether/ethyl acetate, 5:1), yield 0.78 g (70%) of 4-23b as a colorless oil. According 
to the NMR data 4-23b is a mixture of rotamers. 
 
Rf = 0.1–0.2 (petroleum ether/ethyl acetate, 5:1); 
IR (film): υmax = 3440, 2931, 1713, 1443, 1227, 748 cm–1;  
1H NMR (400 MHz, CDCl3): δ = 1.27–1.35 (m, 3H); 3.28–3.46 (m, 1.5H), 3.52–3.59 (m, 
1.5H), 3.63–3.77 (m, 1H), 3.90–4.03 (m, 1H), 4.22–4.32 (m, 2.5H), 4.39–4.62 (m, 1.5H), 
4.72–4.98 (m, 2H), 6.85–7.02 (m, 2H), 7.03–7.36 (m, 7H); 
13C NMR (100 MHz, CDCl3): δ = 14.1, 39.0, 39.2, 52.4, 52.4, 53.2, 53.9, 54.1, 59.1, 59.6, 
61.9, 67.5, 67.6, 126.8, 126.9, 127.2, 127.4, 127.6, 127.8, 127.9, 128.2, 128.3, 128.4, 128.4, 
128.5, 133.5, 134.3, 134.6, 134.8, 135.8, 136.0, 154.9, 155.6, 169.2, 169.3, 205.2; 
HRMS (ESI): calcd for C23H24NO5 [M+H]+: 394.1649, found 394.1651. 
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Ethyl 11-Oxo-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine-5(2H)- carboxylate 
Hydroiodide Hydrate (4-22) 
 
N
H
H
OH
OH
EtO2C
I-
 
 
A solution of the Cbz-protected compound 4-23b (350 mg, 0.9 mmol) in CH3CN (35 mL) was 
placed in a room temperature water bath and treated with Me3SiI (1 mL, 7.3 mmol) in a 
dropwise fashion. The mixture was allowed to stir for 1 h, before the CH3CN was evaporated 
in vacuo [longer reaction time (up to 24 h) causes complete decomposition of the product and 
therefore stirring of the reaction mixture longer than 1 h should be avoided]. The residue was 
treated with water (35 mL) and this solution was washed with CH2Cl2. The aqueous phase was 
then evaporated to dryness resulting in yellow crystals of pure product 4-22, yield 290 mg 
(80%).  
 
m. p. 170–172 °C; 
IR (KBr): υmax = 3903, 3325, 2924, 2816, 1724, 1458, 1238, 1053, 771 cm–1; 
1H NMR (400 MHz, DMSO-d6): δ = 1.25 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.04 (d, J = 17.7 
Hz, 1H, 6-H), 3.08–3.15 (m, 3H), 3.30–3.53 (m, 3H), 3.64 (d, J = 17.7 Hz, 1H, 6-H), 4.13–
4.25 (m, 2H, CO2CH2CH3), 7.17–7.30 (m, 4H, ar.), 7.30–7.50 (m, 1H), 9.19 (br.s, 1H); 
13C NMR (100 MHz, DMSO-d6): δ = 13.9 (CO2CH2CH3), 35.6, 44.2, 47.0, 48.3, 48.5 (5C 
aliph.), 61.4 (CO2CH2CH3), 91.5 (C(OH)2), 126.3, 127.0, 127.9, 129.1 (4C tert. ar.), 134.3, 
134.7 (2C quat. ar.), 171.0 (CO2Et); 
HRMS (ESI): calcd for C15H18NO3 [M]+: 260.1281, found 260.1286; methanol adduct 
(hemiacetal) calcd for C16H22NO4 [M+CH3OH]+: 292.1543, found 292.1543. 
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Ethyl N-(Anilinocarbonyl)-11-oxo-1,3,4,6-tetrahydro-1,5-methano-3- benzazocine-5(2H)-
carboxylate (4-24) 
 
N
O
CO2Et
NO
Ph
H  
 
To a solution of the salt 4-22 (45 mg, 0.11 mmol) in acetonitrile (15 mL) was added Et3N (25 
μL, 0.18 mmol) and the mixture stirred for 1 h. Then, phenylisocyanate (20 μL, 0.18 mmol) 
was added and stirring was continued for 24 h at room temperature. The solvent was 
evaporated and the residue treated with hot CCl4. Non-soluble material, which mainly consists 
of triethylammonium salt, was removed by filtration and the filtrate concentrated in vacuo. 
The urea derivative 4-24 was obtained as a light yellow powder, yield 35 mg (84%). 
 
m. p. 199–203 °C;  
IR (KBr): υmax = 3348, 2920, 1743, 1635, 1535, 1446, 1234, 1026, 752 cm–1;  
1H NMR (400 MHz, CDCl3): δ = 1.30 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.52 (d, J = 17.8 Hz, 
1H, 6-H), 3.62–3.69 (m, 3H), 3.93–4.03 (m, 2H, 6-H and 4-H), 4.23–4.33 (m, 2H, 
CO2CH2CH3), 4.88 (dd, J = 13.6, 3.0 Hz, 1H, 4-H), 5.47 (br. s, 1H, NHPh), 6.75 (d, J = 7.8 
Hz, 2H, ar.), 6.91–6.97 (m, 1H, ar.), 7.08–7.17 (m, 4H, ar.), 7.22–7.30 (m, 2H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.0 (CO2CH2CH3), 39.0 (C-6 sec.), 52.4, 53.5, 54.6, 59.8, 
62.0 (5C aliph.), 120.5, 123.4, 127.3, 127.4, 128.1, 128.5, 128.7 (9C tert. ar.), 134.9, 135.1, 
138.1 (3C quat. ar.), 155.1 (R2NC(=O)NHPh), 169.2 (CO2Et), 204.6 (C=O); 
HRMS (ESI): calcd for C22H23N2O4 [M+H]+: 379.1652, found 379.1656; [M+Na]+: 401.1472, 
found 401.1475. 
 
 
Experimental Section 163
Ethyl 11-Oxo-N-tosyl-1,3,4,6-tetrahydro-1,5-methano-3-benzazocine- 5(2H)-carboxylate 
(4-25) 
 
N
O
S
CO2Et
Me
O
O
 
 
To a solution of the salt 4-22 (48 mg, 0.12 mmol) in acetonitrile (15 mL) was added Et3N (25 
μL, 0.18) and the mixture stirred for 1 h. Then, tosyl chloride (35 mg, 0.18 mmol) was added 
and stirring was continued for additional 24 h at room temperature. Then, the solvent was 
evaporated and the residue purified by flash chromatography (petroleum ether/ethyl acetate, 
3:1), providing the tosylate 4-25 as a light yellow oil, yield 42 mg (80%). This compound 
contains some hydrate.  
 
Rf = 0.1 and 0.3 (petroleum ether/ethyl acetate, 3:1, both spots are the product, compound is in 
equilibrium with adduct of water addition to the ketone); 
1H NMR (400 MHz, CDCl3): δ = 1.29 (m, 3H, CO2CH2CH3), 2.40 (s, 3H, p-CH3PhSO2N), 
3.12 (dd, J = 11.6, 2.5 Hz, 1H, 4-H), 3.40 (d, J = 12.1 Hz, 1H, 4-H), 3.46 (d, J = 17.6 Hz, 1H, 
6-H), 3.51 (dd, J = 2.5 Hz, 1H, 1-H), 3.93 (ddd, J = 11.6, 2.8 Hz, 1H, 4-H), 4.03 (d, J = 17.6 
Hz, 1H, 6-H), 4.13 (dd, J = 12.1, 3.3 Hz, 1H, 4-H), 4.26 (dd, J = 14.2, 7.1 Hz, 2H, 
CO2CH2CH3), 6.95 (d, J = 7.6 Hz, 1H, ar.), 7.11 (d, J = 7.6 Hz, 1H, ar.), 7.10–7.26 (m, 4H, 
ar.), 7.46 (d, J = 8.3 Hz, 2H, ar.); 
13C NMR (100 MHz, CDCl3): δ = 14.1 (CO2CH2CH3), 21.5 (p-CH3PhSO2N), 34.0 (C-6 sec.), 
51.3, 54.9, 55.9 (3C aliph.), 58.1 (quat.), 62.1 (sec.), 127.1, 127.2, 127.2, 127.9, 128.0, 129.8 
(8C tert. ar.), 134.2, 134.7, 134.8, 143.9 (4C quat. ar.), 169.0 (CO2Et), 205.2 (C=O); 
HRMS (ESI): calcd for C22H24NO5S [M+H]+: 414.1370, found 414.1366; C22H23NNaO5S 
[M+Na]+: 436.1174, found 436.1174. 
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Methyl 2-[(E)-2-iodovinyl]benzoate (8-3) 
 
OMe
O
I  
 
a) Methyl 2-formylbenzoate (8-17):[156] To a stirred solution of 2-formylbenzoic acid (10.0 g, 
66.7 mmol) in CH3CN (100 mL) was added K2CO3 (55.5 g, 402.2 mmol), followed by MeI 
(12.5 mL, 28.5 g, 202.1 mmol) and the resulted mixture was refluxed for 24 h. Then solids 
were filtered and washed twice with CH3CN (50 mL). Concentration of the filtrate at reduced 
pressure and vacuum distillation of the residue provided the formyl benzoate (7.6 g, 70%) as a 
colorless liquid.  
 
b. p. 73–74 °C (0.4 mbar). 
 
b) Methyl 2-[(E)-2-iodovinyl]benzoate (8-3): A mixture of anhydrous CrCl3 (23.3 g, 147.0 
mmol), freshly activated Zn (8.0 g, 125.0 mmol), and anhydrous NaI (18.4 g, 123.0 mmol) 
was placed under vacuum and heated to 100 °C for 2-3 min.[157] The solid mixture was stirred 
for 10 min under vacuum and then the flask was flushed with nitrogen. To the resulted mixture 
was added abs. THF (300 mL) whereby the color turned immediately to green, which was an 
indication of the formation of CrCl2. In a separate flask a solution of iodoform (14.4 g, 36.5 
mmol) in abs. THF (50 mL) was combined with 2-(carbmethoxy)-benzaldehyde (4.01 g, 24.5 
mmol) via a syringe. This solution was transferred via a cannula into the first Schlenk tube. 
The reaction mixture became brown and was stirred at RT for 4 h. It was then worked up by 
adding a solution of 1 N HCl (100 mL) and a spatula of EDTA·Na2. The mixture was extracted 
with Et2O after being stirred for 30 min at RT. The organic layer was separated, washed with a 
satd. aqueous solution of NaCl, dried over MgSO4, filtered, and concentrated under reduced 
pressure. The yellow-brown residue was purified by flash chromatography (petroleum 
ether/ethyl acetate, 10:1) affording 4.3 g (61%) of methyl 2-[(E)-2-iodovinyl]benzoate as a 5:1 
mixture of cis and trans isomers.  
 
Rf = 0.5 (petroleum ether/ethyl acetate, 10:1); 
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1H NMR (400 MHz, CDCl3): δ = 3.91 (s, 3H), 6.72 (d, J = 14.6 Hz, 1H), 7.33–7.38 (m, 1H), 
7.41–7.43 (m, 1H), 7.46–7.51 (m, 1H), 7.90 (dd, J = 7.8, 1.3 Hz, 1H), 8.22 (d, J = 14.6 Hz, 
1H);  
13C NMR (100 MHz, CDCl3): δ = 52.2, 79.0, 127.5, 128.0, 128.1, 130.6, 132.4, 139.3, 144.1, 
167.2. 
 
 
Methyl 2-[(E)-2-iodovinyl]-6-methoxybenzoate (8-22) 
 
I
OMe
OOMe
 
 
a) N,N-Diethyl-2-methoxybenzamide (8-19): To a stirred suspension of the 2-
methoxybenzoic acid (3.7 g, 24.2 mmol) in 25 mL of dry benzene was added (COCl)2 (5.3 
mL, 60.4 mmol) dropwise over 5 min. The resulting mixture was allowed to stir for 30 min 
and then the excess of the oxalyl chloride and the solvent were removed at reduced pressure. 
The solid residue was redissolved in benzene and Et2NH (3.8 mL, 36.5 mmol) was added 
dropwise at 0 °C and stirred for additional 3 h. The resulting mixture was diluted with ethyl 
acetate and washed with 1 N aq. HCl (3 × 20 mL). The organic phase was additionally washed 
with water, saturated NaCl solution, and dried over anhydrous MgSO4. After that, solvent was 
remover in vacuo and product was purified via flash chromatography on silica gel affording 
N,N-diethyl-2-methoxybenzamide in nearly quantitative yield (5.0 g). 
 
Rf = 0.22 (petroleum ether/ethyl acetate, 1:1). 
 
b) N,N-diethyl-2-formyl-6-methoxybenzamide (8-20): To a mixture of the amide from 
above (8-19) (5.0 g, 24.2 mmol) and TMEDA (4.7 mL, 31.2 mmol) in abs. THF and under 
inert atmosphere at –78 oC, very slowly was added s-BuLi (23.0 mL, 30 mmol, 1.3 M in 
hexane) in a dropwise fashion. The resulting yellow-orange solution was stirred at the same 
temperature for about 30 min and then at –90 °C DMF (9.3 mL, 120 mmol) was added from a 
syringe in one portion to this reaction mixture. The resulting reaction mixture was allowed to 
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stir at –78 oC for about 45 minutes after which it was gradually allowed to come to room 
temperature and stirred for another one hour. This was followed by the addition of saturated 
NH4Cl (50 mL). This mixture was poured into a separating funnel and organic layer was 
separated. After washing with water (50 mL) and saturated NaCl it was dried over anhydrous 
MgSO4. Removal of the solvent under reduced pressure and flash chromatography of the 
resulting crude product (petroleum ether/ethyl acetate) provided the aldehyde 8-20 as a 
colorless oil, yield 5.5 g (97%).  
 
Rf = 0.23 (petroleum ether/ethyl acetate, 1:1). 
 
c) Methyl 2-formyl-6-methoxybenzoate (8-21): To a stirred solution of the formilated amide 
8-20 (5.6 g, 23.8 mmol) in glacial AcOH (50 mL) was added conc. HCl (50 mL). The 
resulting solution was warmed to 90 oC and stirred overnight. The solution was concentrated 
to dryness under reduced pressure and the solid residue was dissolved in CH3CN (50 mL). To 
the resulting solution was added anhydrous K2CO3 (30 g) portionwise, followed by treatment 
with MeI (7.5 mL, 120 mmol). The reaction mixture was then refluxed for 24 h, after which 
time solids were filtered and washed twice with CH3CN (50 mL). Concentration of the filtrate 
at reduced pressure and flash chromatography of the crude mixture gave the formyl benzoate    
8-21 (4.49 g, 93%) as a colorless solid.  
 
Rf = 0.55 (petroleum ether/ethyl acetate). 
 
d) Methyl 2-[(E)-2-iodovinyl]-6-methoxybenzoate (8-22): The reaction was performed with 
the formyl benzoate 8-21 (2.0 g, 10.3 mmol) as described for 8-3. Purification of the crude 
product by flash chromatography (petroleum ether/ethyl acetate, 5:1) gave the iodoalkene 8-22 
(2.6 g, 79%, E/Z = 7:1), yellow solid. 
 
Rf = 0.4 (petroleum ether/ethyl acetate, 5:1); 
m.p. 89–92 °C. 
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Methyl 2-[(E)-2-iodovinyl]-3,4,6-trimethoxybenzoate (8-27) 
 
I
OMe
OOMe
MeO
OMe  
 
a) N,N-diethyl-2,4,5-trimethoxybenzamide (8-24): To a stirred suspension of the 2,4,5-
trimethoxybenzoic acid (2.2 g, 10.5 mmol) in 25 mL of dry benzene was added (COCl)2 (2.3 
mL, 26.2 mmol) dropwise over 5 min. The resulting mixture was allowed to stir for 30 min 
and then the excess of the oxalyl chloride and the solvent were removed at reduced pressure. 
The solid residue was redissolved in benzene and Et2NH (1.65 mL, 15.8 mmol) was added 
dropwise at 0 °C and stirred for additional 3 h. The resulting mixture was diluted with ethyl 
acetate and washed with 1 N aq. HCl (3 × 10 mL). The organic phase was additionally washed 
with water, saturated NaCl solution, and dried over anhydrous MgSO4. After that, solvent was 
removed in vacuo and product was purified via flash chromatography on silica gel affording 
2.8 g of N,N-diethyl-2,4,5-trimethoxybenzamide (8-24). 
 
Rf = 0.12 (petroleum ether/ethyl acetate, 1:1); 
m. p. 72–75 °C; 
1H NMR (400 MHz, CDCl3): δ = 1.02 (t, J = 6.6 Hz, 3H, CH2CH3), 1.20 (t, J = 6.6 Hz, 3H, 
CH2CH3), 3.10–3.23 (m, 2H, CH2CH3), 3.39–3.65 (m, 2H, CH2CH3), 3.77 (s, 3H, OCH3), 3.80 
(s, 3H, OCH3), 3.87 (s, 3H, OCH3), 6.48 (s, 1H, 3-H), 6.72 (s, 1H, 6-H); 
13C NMR (100 MHz, CDCl3): δ = 12.8 (CH2CH3), 14.0 (CH2CH3), 38.9 (CH2CH3), 42.8 
(CH2CH3), 56.0 (OCH3), 56.6 (OCH3), 97.6 (C-3), 111.2 (C-6), 118.0 (C-1), 143.2 (C-5), 
149.6 (C-4), 150.0 (C-2), 168.5 (C=O); 
HRMS (ESI): calcd. for C14H22NO4 [M+H]+: 268.15433, found 268.15414. 
 
b) N,N-diethyl-2-formyl-3,4,6-trimethoxybenzamide (8-25): The reaction was performed 
with the benzamide 8-24 (2.8 g, 10.5 mmol) as described for 8-20. Purification of the crude 
product by flash chromatography (petroleum ether/ethyl acetate, 1:9) gave the formylated 
benzamide 8-25 (1.98 g, 64%), colorless solid. 
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Rf = 0.33 (petroleum ether/ethyl acetate, 1:9); 
m. p. 90–94 °C; 
1H NMR (400 MHz, CDCl3): δ = 0.93 (t, J = 7.3 Hz, 3H, CH2CH3), 1.23 (t, J = 7.3 Hz, 3H, 
CH2CH3), 3.0 (q, J = 7.3 Hz, 2H, CH2CH3), 3.32–3.45 (m, 1H, CH2CH3), 3.60–3.72 (m, 1H, 
CH2CH3), 3.75 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 6.68 (s, 1H, 5-H), 
10.30 (s, 1H, CHO); 
13C NMR (100 MHz, CDCl3): δ = 12.1 (CH2CH3), 13.4 (CH2CH3), 38.6 (CH2CH3), 42.5 
(CH2CH3), 56.2 (OCH3), 56.5 (OCH3), 62.5 (OCH3), 102.7 (C-5), 118.1 (C-1), 126.9 (C-2), 
146.5 (C-3), 152.0 (C-4), 153.7 (C-6), 166.5 (C=O), 189.6 (CHO); 
HRMS (ESI): calcd. for C15H21NO5 [M+Na]+: 318.13119, found 318.13125. 
 
c) Methyl 2-formyl-3,4,6-trimethoxybenzoate (8-26): The reaction was performed with the 
formylated benzamide 8-25 (5.18 g, 17.6 mmol) as described for 8-21. Purification of the 
crude product by flash chromatography (petroleum ether/ethyl acetate, 1:2) gave methyl 2-
formyl-3,4,6-trimethoxybenzoate (8-26) (3.23 g, 72.5%), colorless solid. 
 
Rf = 0.55 (petroleum ether/ethyl acetate, 1:2); 
1H NMR (400 MHz, CDCl3): δ = 3.82 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.89 (s, 3H, 
OCH3), 3.91 (s, 3H, OCH3), 6.73 (s, 1H, 5-H), 10.33 (s, 1H, CHO); 
13C NMR (100 MHz, CDCl3): δ = 52.7 (OCH3), 56.2 (OCH3), 56.7 (OCH3), 62.6 (OCH3), 
102.6 (C-5), 113.9 (C-1), 127.4 (C-2), 146.2 (C-3), 153.0 (C-4), 154.6 (C-6), 167.5 (CO2Me), 
189.1 (CHO); 
HRMS (ESI): calcd. for C12H14NaO6 [M+Na]+: 277.06826, found 277.06829 
 
d) Methyl 2-[(E)-2-iodovinyl]-3,4,6-trimethoxybenzoate (8-27): The reaction was 
performed with the formyl benzoate 8-26 (1.7 g, 6.68 mmol) as described for 8-3. Purification 
of the crude product by flash chromatography (petroleum ether/ethyl acetate, 1:1) gave the 
iodoalkene 8-27 (1.66 g, 65.5%, E/Z = 8:1), yellow solid. 
 
Rf = 0.57 (petroleum ether/ethyl acetate, 1:1); 
m. p. 73–76 °C; 
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1H NMR (400 MHz, CDCl3): δ = 3.70 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.86 (s, 3H, 
OCH3), 3.88 (s, 3H, OCH3), 6.46 (s, 1H, 5-H), 6.94 (d, J = 14.9 Hz, 1’-H), 7.42 (d, J = 14.9 
Hz, 2’-H); 
13C NMR (100 MHz, CDCl3): δ = 52.6 (OCH3), 56.1 (OCH3), 56.5 (OCH3), 60.5 (OCH3), 
83.2 (C-2’), 96.9 (C-5), 114.6 (C-1), 130.0 (C-2), 138.1 (C-1’), 140.2 (C-6), 153.2 (C-3), 
154.3 (C-4), 167.8 (C=O). 
 
 
(2R)-2-Methyloxirane [(+)-8-28]:[126] 
 
Me
O
 
 
a) [(R,R)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminato(2-)]cobalt(II) 
 
N N
HH
t-Bu
t-Bu
t-Bu
t-BuOO
Co
 
 
A solution of cobalt(II) acetate tetrahydrate (5.98 g, 24.0 mmol) in MeOH (80 mL) was added 
dropwise to a solution of ligand [(R,R)-N,N’-bis(3,5-di-tert-butylsalicylidene)-1,2-
cyclohexanediamine] (10.9 g, 20.0 mmol) in CH2Cl2 (80 mL) via cannula. A brick-red solid 
began to precipitate before addition was complete. The sides of the reaction flask were rinsed 
with MeOH (20 mL), and the mixture was allowed to stir for 15 min at RT and then 30 min at 
0 °C. Precipitated solids were then filtrated and rinsed with cold (0 °C) MeOH (2 × 75 mL). 
The red solid was collected and dried in vacuo to yield [(R,R)-N,N’-bis(3,5-di-tert-
butylsalicylidene)-1,2-cyclohexanediaminato(2-)]cobalt(II) (11.6 g, 19.2 mmol, 96%). 
 
 
b) (2R)-2-Methyloxirane [(+)-8-28]:  
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A flask (100 mL) equipped with a stirring bar was charged with [(R,R)-N,N′-bis(3,5-di-tert-
butylsalicylidene)-1,2-cyclohexanediaminato(2-)]cobalt(II) (242 mg, 400 μmol, 0.002 equiv). 
The catalyst was dissolved in of toluene (5 mL) and treated with AcOH (240 μL, 4.2 mmol). 
The solution was allowed to stir at room temperature open to air for 30 min during which time 
the color changed from orange-red to dark brown. The solution was concentrated in vacuo to 
leave a crude brown solid. The resulting catalyst residue was dissolved in racemic propylene 
oxide (14.0 mL, 11.6 g, 200 mmol) at RT, the reaction flask was cooled to 0 °C, and H2O 
(1.98 mL, 110 mmol, 0.55 equiv) was added dropwise over 5 min. The reaction was allowed 
to warm to RT and stirred 14 h. The desired (R)-propylene oxide (5.35 g, 46%) was isolated 
by distillation from the reaction mixture at atmospheric pressure and 36 °C. The ee of the 
propylene oxide was determined to be >99% by chiral GC analysis.  
 
[α]20D = +11.8 (neat);  
1H NMR (400 MHz, CDCl3): δ = 1.25 (d, J = 5.3 Hz, 3H, CH3), 2.36 (dd, J = 2.8, 5.0 Hz, 1H, 
CH2), 2.68 (dd, J = 4.5, 4.5 Hz, 1H, CH2), 2.89-2.96 (m, 1H, CH). 
 
 
(5R)-5-Hydroxyhexanal ethandiol acetal (8-30a) 
 
Me
OH
O
O
 
 
The solution of 2-(2-bromoethyl)-1,3-dioxolane (9.1 g, 6.0 mL, 50 mmol, d20 1.515 g mL-1) in 
anhydrous THF (25 mL) was added dropwise (25-30 min) to a stirred mixture of magnesium 
turnings (1.5 g, 60 mmol) and anhydrous THF (5 mL) at RT (water bath, inner temperature 
should not exceed 30 °C). The resulting solution was stirred for further 30 min, and then 
cooled in an ice bath, followed by the addition of catalytic amounts of CuI (ca. 20 mg, 0.1 
mmol). At this temperature, a solution of freshly distilled (R)-propylene oxide (5 mL, 4.1 g, 70 
mmol) in anhydrous THF (25 mL) was slowly added dropwise within 30-40 min. After 
complete addition, the reaction mixture was slowly allowed to warm to RT (6 h). Then, the 
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mixture was treated with saturated NH4Cl solution (100 mL) and extracted with Et2O (5 × 50 
mL). The combined organic extracts were washed with satd. NaCl solution (100 mL), dried 
with MgSO4, and filtered. Removal of solvent in vacuum afforded a slightly yellow liquid, 
which was distilled at low pressure to give the desired (5R)-5-hydroxyhexanal ethanediol 
acetal 8-30a, yield 4.6 g as a colorless liquid (58%). This acetal was immediately used in the 
next step. 
 
b. p. 72–76 °C at 1 mbar  
 
 
(5R)-5-(tert-Butyldiphenylsilyloxy)hexanal ethandiol acetal (8-31a) 
 
Me
OTBDPS
O
O
 
 
Freshly distilled (R)-5-hydroxyhexanal acetal 8-30a (4.6 g, 29 mmol) was dissolved in 
anhydrous DMF (20 mL). To the solution were added at 0 °C imidazole (2.1 g, 30 mmol), 
DMAP (50 mg), and TBDPS-chloride (8.35 g, 7.9 mL, 34.0 mmol, d20 1.057 g mL-1). The 
resulting mixture was stirred for 12 h and then diluted with ice (ca. 100 g). The product was 
extracted with Et2O (3 × 40 mL), the combined organic extracts were washed with satd. NaCl 
solution (2 × 50 mL), than dried over MgSO4, filtered, and concentrated in vacuo to provide 
11.3 g (99%) of acetal 8-31a as a colorless oil.  
 
Rf = 0.45 (petroleum ether/EtOAc, 10:1);  
[α]20D = +12.0 (c 2.0, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 1.04 (s, 9H, (CH3)3CSi), 1.06 (d, J = 5.1 Hz, 3H, 
CH3CHOSi), 1.38–1.58 (m, 6H, (CH2)3), 3.80-3.85 (m, 3H, OCH2CH2O, CH3CHOSi), 3.90–
3.94 (m, 2H, OCH2CH2O), 4.77 (dd, J = 4.8, 4.8 Hz, 1H, CH2CHO2), 7.32–7.43 (m, 6H, Ph), 
7.65–7.70 (m, 4H, Ph);  
13C NMR (100 MHz, CHCl3): δ = 19.2 ((CH3)3CSi), 19.7 (C-3), 23.1 (C-6), 27.0 ((CH3)3CSi), 
33.9 (CH2), 39.2 (C-4), 64.8 (CH2), 69.4 (C-5), 104.5 (CHO2), 127.4, 127.4, 129.3, 129.4, 
134.5, 134.9, 135.8;  
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HRMS (ESI): calcd for C24H35O3Si [M+H]+: 399.23500, found 399.23498. 
 
 
(5R)-5-(tert-Butyldiphenylsilyloxy)hexanal (8-6) 
 
Me H
OTBDPS O
 
 
The acetal 8-31a (5.0 g, 12.5 mmol) was dissolved in a THF/AcOH mixture (120 mL, 1:2) 
followed by the addition of water (5 mL). The mixture was refluxed until the starting material 
was consumed (approximately 30 h). The solvents were evaporated in vacuo and the residue 
was dissolved in Et2O (200 mL). The solution was washed with sat. NaHCO3 solution so, that 
the organic layer is no more acidic. The ether solution was dried over Na2SO4, filtered, and the 
solvent evaporated in vacuo. The crude aldehyde was passed through a short pad of silica gel 
(petroleum ether/EtOAc, 10:1) to give the aldehyde 8-6 (3.6 g, 81%) as a colorless oil.  
 
With PPTS (10% mol) in an acetone/H2O mixture under reflux the yield after 8 days was ca. 
50%; the deprotection was not complete.  
 
Rf = 0.4 (petroleum ether/EtOAc, 10:1);  
[α]20D = +9.5 (c 2.3, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 1.05 (s, 9H, (CH3)3CSi), 1.07 (d, J = 6.1 Hz, 3H, 
CH3CHOSi), 1.36–1.53 (m, 2H, 4-CH2), 1.58-1.67 (m, 2H, CH2CH2CHO), 2.27 (ddd, J = 1.8, 
7.3, 7.3 Hz, 2H, CH2CH2CHO), 3.80–3.90 (m, 1H, CH3CHOSi), 7.35–7.45 (m, 6H, aromatic 
TBDPS), 7.65–7.70 (m, 4H, aromatic TBDPS), 9.67 (dd, J = 1.8, 1.8 Hz, 1H, CHO);  
13C NMR (100 MHz, CDCl3): δ = 17.7 (C-3), 19.2 ((CH3)3CSi), 23.1 (C-6), 27.0 ((CH3)3CSi), 
38.6 (C-4), 43.7 (C-2), 69.0 (C-5), 127.4, 127.5, 129.4, 129.5, 134.3, 134.6, 135.8, 135.9, 
202.6 (CHO);  
HRMS (ESI): calcd for C23H34NaO3Si [M+CH3OH+Na]+: 409.21694, found 409.21704.  
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Diethyl 4-methoxybenzyl-phosphonate (8-34): 
 
MeO
P(OEt)2
O
 
 
a) p-Methoxybenzyl bromide (8-33): Neat p-methoxybenzylalcohol (110 mL, 122.4 g, 0.886 
mol) was added dropwise to a solution of PBr3 (45 mL, 129.6 g, 0.48 mol) in diethyl ether 
(500 mL) at RT. After complete addition, stirring was continued for 2 h before the mixture 
was poured on ice (1 L). The ether layer was separated, washed with satd. NaHCO3 solution, 
dried with MgSO4, filtered, and concentrated in vacuo. The residue was distilled under 
reduced pressure to yield 105 g (89%) of p-methoxybenzyl bromide.  
 
b.p. 113 °C, 9 mbar [lit.[158] b.p. 77-80 °C (0.8 mm)];  
1H NMR (400 MHz, CDCl3): δ = 3.81 (s, 3H, OCH3), 4.53 (s, 2H, CH2Br), 6.90 (d, J = 8.8 
Hz, 2H, aromatic H), 7.35 (d, J = 8.8 Hz, 2H, aromatic H);  
13C NMR (100 MHz, CDCl3): δ = 33.9, 55.0, 113.9, 129.7, 130.2, 159.4. 
 
b) Diethyl 4-methoxybenzyl-phosphonate (8-34): A solution of p-methoxybenzylbromide 
(105.0 g, 0.522 mol) in P(OEt)3 (250 mL) was refluxed for 5 h followed by removal of 
bromethane and triethylphosphite by distillation at normal pressure.[159] Vacuum distillation of 
the residue provided 128 g (95%) of product.  
 
b.p. 161–165 °C (1 mbar);  
1H NMR (400 MHz, CDCl3): δ = 1.17 (t, J = 7.2 Hz, 6H), 3.02 (d, J = 21.0 Hz, 2H), 3.71 (s, 
3H), 3.90–4.00 (m, 4H), 6.78 (d, J = 8.1 Hz, 2H), 7.15 (dd, J = 8.1, 2.5 Hz, 2H);  
13C NMR (100 MHz, CDCl3): δ = 16.2, 32.5 (d, 139.1 Hz), 55.0, 61.9, 113.8, 123.1, 130.6, 
158.3. 
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(E)-4,4'-Dimethoxystilbene (8-35) 
 
OMe
MeO  
 
To a mechanically stirred solution of diethyl 4-methoxybenzyl-phosphonate (2.59 g, 10 mmol) 
in DMF (15 mL) was added KOtBu (2.24 g, 20 mmol) portionwise at 0 °C and the solution 
was stirred for 20 min. Thereafter, freshly distilled p-anisaldehyde (2.04 g, 15 mmol), 
dissolved in DMF (5 mL) was added dropwise to the cooled mixture within 10 min. The 
solution was allowed to stir for an additional 30 min, then warmed to RT and stirred for 1 h. 
The reaction was quenched with cold H2O (50 mL). Crystals were collected by vacuum 
filtration and washed with cold acetone to give 2.05 g (85%) of the (E)-4,4'-dimethoxy-
stilbene as a colorless crystalline solid.  
 
Rf = 0.40 (petroleum ether/EtOAc, 2:1);  
m. p. 213–215 °C (lit.[127c] m. p. 211–214 °C);  
1H NMR (400 Hz, CDCl3) δ = 3.83 (s, 6 H), 6.87–6.93 (m, 6 H), 7.41–7.44 (m, 4 H);  
13C NMR (100 MHz, CDCl3) δ =: 55.3, 114.1, 126.1, 127.4, 130.4, 159.0. 
 
 
(1S,2S)-1,2-Bis-(4-methoxyphenyl)ethane-1,2-diol (8-36) 
 
PMP
OH
PMP
HO
 
 
(DHQ)2PHAL (0.284 g, 0.365 mmol), K3Fe(CN)6 (36.1 g, 109.4 mmol), K2CO3 (15.1 g, 109.4 
mmol), and K2OsO2(OH)4 (0.054 g, 0.146 mmol) were dissolved in a 1:1 mixture of water 
(182 mL) and t-butyl alcohol (182 mL). MeSO2NH2 (3.47 g, 36.5 mmol) was then added and 
the vigorously stirred mixture was cooled to 0 °C. At this point stilbene 8-35 (8.75 g, 36.5 
mmol) was added in one portion. The resulting mixture was allowed to warm to RT during 3 
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h, followed by stirring for 30 h. The reaction was quenched with solid Na2SO3 (55 g) and the 
solution extracted with EtOAc (3 × 300 mL). The combined organic layers were washed with 
2N KOH solution (40 mL), dried over MgSO4, filtered, and concentrated in vacuo. 
Purification of the residue by recrystallization from petroleum ether/EtOAc (3:2, 75 mL) 
provided diol 8-36 (8.4 g, 84%) as a colorless solid.  
 
Rf = 0.1 (petroleum ether/EtOAc, 2:1);  
[α]20D = –120 (c 1.50, CH2Cl2); [(R,R)-isomer using (DHQD)2PHAL: [α]25D = +132.4 (c 1.50, 
CH2Cl2)]; 
m. p. 102–105 °C;  
1H NMR (400 Hz, CDCl3): δ = 2.90 (br s, 2H, OH), 3.74 (s, 6 H, OCH3), 4.58 (s, 2H, 
ArCHO), 6.71–6.76 (m, 4H), 6.97–7.04 (m, 4 H);  
13C NMR (100 MHz, CDCl3): δ = 55.1, 78.7, 113.4, 128.1, 132.0, 159.1.  
 
 
(S,S)-5,6-Bis-(4-methoxyphenyl)-[1,4]-dioxan-2-one (8-7) 
 
OO
PMP PMP
O
 
 
A stirred solution of diol 8-36 (7.09 g, 25.9 mmol), dibutyltin oxide (7.09 g, 28.5 mmol), and 
benzene (400 mL) was heated to reflux in a flask equipped with a Dean-Stark trap for 24 h. 
After cooling to RT, tetra n-butylammonium iodide (15.3 g, 41.4 mmol) and tert-butyl 
bromoacetate (7.6 mL, 51.8 mmol) were then added and refluxing was continued for 48 h. The 
mixture was then cooled to RT, diluted with Et2O (500 mL) and the precipitate was filtered (n-
Bu4NI mainly). The filtrate was washed with 10% Na2S2O3 solution (500 mL). The layers 
were separated and the aqueous phase was extracted with Et2O (4 × 300 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. Recrystallization 
of the residue from absolute EtOH (100 mL) provided 4.51 g (55%) of dioxanone 14 as a 
colorless crystalline solid.  
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Rf = 0.14 (petroleum ether/EtOAc, 2:1);  
[α]20D = –125 (c 1.68, CH2Cl2);  
m.p. 116–118 °C.  
1H NMR (400 MHz, CDCl3): δ = 3.75 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 4.52 (d, J = 9.4 Hz, 
1 H, 5-H), 4.54 (d, J = 17.7 Hz, 1H, CH2),4.73 (d, J = 17.7 Hz, 1H, CH2), 5.39 (d, J = 9.4 Hz, 
1 H, 6-H), 6.72–6.78 (m, 4H), 6.92–6.98 (m, 4H);  
13C NMR (100 MHz, CDCl3): δ = 55.2 (OCH3), 66.2 (CH2), 80.3 (C-5), 86.1 (C-6), 113.7 (2 
CH PMP), 113.7 (2 CH PMP), 126.8 (quat C PMP), 127.1 (quat C PMP), 128.5 (2 CH PMP), 
128.6 (2 CH PMP), 159.8 (COMe PMP), 159.9 (COMe PMP), 167.2 (CO2R). 
 
 
(5S)-2,2-Dimethyl-5-phenyl-1,3-dioxolan-4-one (8-51) 
 
O
O
O
Ph  
 
A mixture of (S)-mandelic acid (1.0 g, 6.6 mmol) and 2,2-dimethoxypropane (0.97 mL, 0.82 g, 
7.9 mmol) was refluxed in benzene (10 mL) with the azeotropic removal of benzene-methanol 
mixture in a Dean-Stark apparatus for 3 h. The reaction mixture was then cooled down to 
room temperature and the solvent was evaporated in vacuo. The crude product was purified by 
column chromatography (petroleum ether/ethyl acetate, 5:1) on silica gel affording 1.13 g 
(89%) of the product as a colorless solid. 
 
Rf = 0.7 (hexanes/ethyl acetate, 5:1) 
m. p. = 71–74 °C 
1H NMR (CDCl3, 400 MHz): δ = 1.67 (s, 3H, CH3), 1.73 (s, 3H, CH3) 5.39 (s, 1H, H-5), 
7.35–7.50 (m, 5H, aromatic); 
13C NMR (CDCl3, 100 MHz): δ = 26.2 (CH3), 27.2 (CH3), 75.9 (5-C), 110.9 (Me2C), 126.4 
(tert. ar.), 128.7 (tert. ar.), 129.0 (tert. ar.), 134.4 (quat. ar.), 171.4 (C=O). 
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(3S,5S,6S)-3-[(1S)-3-Phenyl-1-hydroxypropyl]-5,6-bis-(4-methoxyphenyl)-[1,4]-dioxan-2-
one (8-53) 
 
O
O
O OH
PMP
PMP  
 
To a cooled solution (–78 °C) of dioxanone[127] 8-7 (0.233 g, 0.740 mmol) in dry CH2Cl2 (20 
mL) were added in a dropwise fashion Et3N (0.26 mL, 1.86 mmol) followed by 
cHex2BOTf[160] (1.85 mL, 1.0 M in abs. hexane) under a nitrogen atmosphere. The resulting 
solution was stirred at –78 °C for 3 h before freshly distilled 3-phenylpropanal (0.119 g, 0.888 
mmol) was added in dry CH2Cl2 (1 mL) dropwise over 10 min at this temperature. The 
resulting solution was stirred at –78 °C for 12 h at which time it was quenched by the addition 
of pH 7 buffer (2.5 mL), MeOH (2 mL) and 30% aqueous H2O2 (0.5 mL). The solution was 
vigorously stirred for 1 h and then warmed to room temperature before it was diluted with 
Et2O (50 mL). The aqueous layer was extracted with Et2O (4 × 50 mL) and the combined 
organic layers were washed with dilute NaHCO3 solution (30 mL). Drying of the combined 
organic layers with anhydrous MgSO4 was followed by filtration, and concentration of the 
filtrate to afford 0.9 g of crude product as a yellow oil, which was used in the next step without 
further purification. During flash chromatography retro aldol reaction might take place. The 
selectivity was found to be 10:1 (anti/anti) via 1H NMR and LC-MS of the crude reaction 
material.  
 
Rf = 0.27 (petroleum ether/EtOAc, 3:1);  
[α]20D = –119.5 (c 1.0, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 1.96–2.06 (m, 1H, CH2), 2.13–2.22 (m, 1H, CH2), 2.74-2.84 
(m, 1H, CH2), 2.90–3.00 (m, 1H, CH2), 3.22 (br s, 1H, OH), 3.79 (s, 3H, CH3OAr), 3.80 (s, 
3H, CH3OAr), 4.15–4.21 (m, 1H, CHOH), 4.5 (d, J = 6.0 Hz, 1H, H-3), 4.85 (d, J = 9.0 Hz, 
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1H, H-5), 5.42 (d, J = 9.0 Hz, 1H, H-6), 6.77–6.82 (m, 4H, CH, PMP), 6.95–7.02 (m, 4H, CH, 
PMP), 7.19–7.26 (m, 3H, CH, Ph), 7.29–7.34 (m, 2H, CH, Ph); 
13C NMR (CDCl3, 100 MHz): δ = 31.4 (CH2), 34.7, 55.2 (2 CH3OAr), 71.7 (CHOH), 75.7 (C-
3), 78.1 (C-5), 84.8 (C-6), 113.7, 125.9, 126.4, 127.7, 128.3, 128.4, 128.5, 128.7 (tert. Ph and 
PMP), 141.6 (quat. Ph), 159.7, 160.0 (2COMe of PMP), 170.5 (C=O); 
HRMS (ESI): calcd for C27H28NaO6 [M+Na]+: 503.20402, found 503.20393. 
 
 
(3S,5S,6S)-3-[(1S)-3-Phenyl-1-(methoxymethoxy)propyl]-5,6-bis-(4-methoxyphenyl)-
[1,4]-dioxan-2-one (8-54) 
 
O
O
O OMOM
PMP
PMP  
 
To a stirred, cooled (0 °C) solution of crude aldol product (0.9 g) in CH2Cl2 (90 mL) were 
added N,N-diisopropylethylamine (15.4 mL, 11.6 g, 90.0 mmol), chloromethylmethyl ether 
(3.42 mL, 3.62 g, 45.0 mmol), and tetrabutylammonium iodide (665 mg, 1.80 mmol). The 
reaction mixture was protected from light and allowed to reach room temperature within 12 h. 
After stirring for 3 days, saturated aqueous NaHCO3 solution (100 mL) was added followed by 
Et2O (150 mL). The organic layer was washed with 1 N HCl (50 mL) and brine (30 ml), and 
the basic aqueous layer was extracted with Et2O (2 × 50 ml). The combined organic extracts 
were dried (Na2SO4), filtered, and concentrated in vacuo. Flash chromatography of the residue 
provided the MOM ether as slightly yellow oil, yield 0.18 g (50%).  
 
Rf = 0.3 (petroleum ether/EtOAc, 3:1);  
[α]20D = –68.9 (c 0.45, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 2.05–2.21 (m, 2H, CH2), 2.67–2.77 (m, 1H, CH2), 2.78–2.88 
(m, 1H, CH2), 3.43 (s, 3H, OCH2OCH3), 3.74 (s, 3H, CH3OAr), 3.75 (s, 3H, CH3OAr), 4.16–
4.23 (m, 1H, 1’-H), 4.79 (dd, J = 7.0, 17.0 Hz, 2H, OCH2OCH3), 4.89 (d, J = 3.0 Hz, 1H, 3-
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H), 4.95 (d, J = 8.5 Hz, 1H, 5-H), 5.40 (d, J = 8.5 Hz, 1H, 6-H), 6.72–6.77 (m, 4H, PMP), 
6.95–7.02 (m, 4H, PMP), 7.17–7.22 (m, 3H, Ph), 7.25–7.30 (m, 2H, Ph); 
13C NMR (CDCl3, 100 MHz): δ = 32.1 (CH2), 32.6, 55.1 (2 CH3OAr), 56.0 (OCH2OCH3), 
74.7 (CHOMOM), 78.1 (C-3), 80.55 (C-5), 84.6 (C-6), 97.0 (OCH2OCH3),113.6, 113.7, 
125.9, 127.0, 127.9, 128.3, 128.4, 128.5, 128.6 (tert. Ph and PMP), 141.5 (quat. Ph), 159.7, 
159.8 (2 COMe of PMP), 167.9 (C=O); 
HRMS (ESI): calcd for C30H36NaO8 [M+MeOH+Na]+: 547.23060, found 547.23024. 
 
 
(3R,5R,6R)-3-[(1R,5R)-5-(tert-Butyldiphenylsilyloxy)-1-hydroxyhexyl]-5,6-bis-(4-
methoxyphenyl)-[1,4]-dioxan-2-one (8-55) 
 
O
O
O OH
PMP
PMP
OTBDPS
 
 
To a cooled (–78 °C) solution of dioxanone ent-8-7 (0.233 g, 0.740 mmol) in dry CH2Cl2 (20 
mL) was added in a dropwise fashion Et3N (0.26 mL, 1.86 mmol) followed by cHex2BOTf[160] 
(1.85 mL, 1.0 M in abs. hexane) under a nitrogen atmosphere. The resulting solution was 
stirred at -78 °C for 3 h at which time (5R)-5-(tert-butyldiphenylsilyloxy)hexanal (8-6) (0.314 
g, 0.888 mmol), dissolved in dry CH2Cl2 (1 mL) was added dropwise over 10 min. The 
resulting solution was stirred at –78 °C for 12 h before it was quenched at that same 
temperature by the addition of pH 7 buffer (2.5 mL), MeOH (2 mL) and 30% aqueous H2O2 
(0.5 mL). The mixture was stirred vigorously for 1 h and then warmed to room temperature 
when it was diluted with Et2O (50 mL). The aqueous layer was extracted with Et2O (4 × 50 
mL) and the combined organic layers were washed with dilute NaHCO3 solution (30 mL). The 
combined organic layers were dried with anhydrous MgSO4, filtered, and concentrated in 
vacuo to afford 1.0 g of crude product as a yellow oil, which was used for the next step 
without further purification (approximately half of the product decomposes during flash 
chromatography on silica gel (petroleum ether/EtOAc, 2:1)). The selectivity was found to be 
9:1 (anti-1/anti-2) according to 1H NMR and LC-MS of the crude reaction material.  
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Data for the purified product:  
Rf = 0.48 (petroleum ether/EtOAc, 2:1);  
1H NMR (CDCl3, 400 MHz): δ = 1.00–1.06 (m, 12H, (CH3)3CSi, CH3CHOSi), 1.35–1.92 (m, 
6H, (CH2)3), 2.86 (d, J = 5.0 Hz, 1H, OH), 3.75 (s, 3H, CH3OAr), 3.76 (s, 3H, CH3OAr), 3.83 
(dd, J = 6.0, 11.5 Hz, 1H, 5’-H), 4.02–4.08 (m, 1H, CHOH), 4.43 (d, J = 5.5 Hz, 1H, 3-H), 
4.87 (d, J = 9.0 Hz, 1H, 5-H), 5.37 (d, J = 9.0 Hz, 1H, 6-H), 6.74 (d, J = 8.5 Hz, 2H, CH 
PMP), 6.76 (d, J = 8.5 Hz, 2H, CH PMP), 6.94 (d, J = 8.5 Hz, 2H, CH PMP), 6.98 (d, J = 8.5 
Hz, 2H, CH PMP), 7.30–7.41 (m, 6H, aromatic TBDPS), 7.63–7.68 (m, 4H, aromatic 
TBDPS); 
13C NMR (CDCl3, 100 MHz): δ = 19.3 ((CH3)3CSi), 20.9 (C-3’), 23.1 (C-6’), 27.0 
((CH3)3CSi), 33.3 (C-2’, C-4’), 39.1, 55.2 (CH3OAr), 69.4 (C-5’), 73.0 (CHOH), 76.0 (C-3), 
77.9 (C-5), 85.0 (C-6), 113.8, 126.6 (aromatic PMP), 127.4, 127.5 (aromatic TBDPS), 127.9, 
128.5, 128.7 (aromatic PMP), 129.4, 129.5 (aromatic TBDPS), 134.6, 134.8 (aromatic 
TBDPS), 135.8, 135.9 (aromatic TBDPS), 159.7 (COMe), 160.0 (COMe), 170.2 (C=O); 
HRMS (ESI): calcd for C40H48NaO7Si [M+Na]+: 723.33236, found 723.33153. 
 
 
(3R,5R,6R)-3-[(1R,5R)-5-(tert-Butyldiphenylsilyloxy)-1-(methoxymethoxy)hexyl]-5,6-bis-
(4-methoxyphenyl)-[1,4]-dioxan-2-one (8-56) 
 
O
O
O OMOM
PMP
PMP
OTBDPS
 
 
To a stirred, cooled (0 °C) solution of crude aldol product 8-55 (1.0 g) in CH2Cl2 (30 mL) 
were added N,N-diisopropylethylamine (5.1 mL, 3.86 g, 30.0 mmol), chloromethylmethyl 
ether (1.14 mL, 1.20 g, 15.0 mmol), and tetrabutylammonium iodide (222 mg, 0.60 mmol). 
The reaction mixture was protected from light and allowed to reach room temperature within 
12 h. After stirring for 3 days, saturated aqueous NaHCO3 solution (40 mL) was added 
followed by Et2O (50 mL). The organic layer was washed with 1 N HCl (150 mL) and brine 
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(10 mL), and the basic aqueous layer was extracted with Et2O (2 × 25 mL). The combined 
organic extracts were dried (Na2SO4), filtered, and concentrated in vacuo. Flash 
chromatography of the residue provided the MOM ether as a slightly yellow oil, yield 0.24 g 
(45% for two steps from aldehyde).  
 
Rf = 0.18 (petroleum ether/EtOAc, 5:1);  
1H NMR (400 MHz, CDCl3): δ = 1.01–1.06 (m, 12H, (CH3)3CSi, 6’-H), 1.30–1.40 (m, 1H, 
CH2), 1.42–1.55 (m, 3H, CH2), 1.65–1.76 (m, 2H, 2’-H), 3.37 (s, 3H, CH3OCH2O), 3.75 (s, 
3H, CH3OAr), 3.76 (s, 3H, CH3OAr), 3.80–3.88 (m, 1H, 5’-H), 4.04–4.10 (m, 1H, 1-H), 4.73 
(dd, J = 7.0, 10.0 Hz, 2H, OCH2OCH3), 4.77 (d, J = 2.5 Hz, 1H, 3-H), 4.98 (d, J = 8.5 Hz, 1H, 
5-H), 5.39 (d, J = 8.5 Hz, 1H, 6-H), 6.74 (d, J = 2.0 Hz, 2H, CH PMP), 6.77 (d, J = 2.0 Hz, 
2H, CH PMP), 6.97 (d, J = 3.0 Hz, 2H, CH PMP), 7.00 (d, J = 3.0 Hz, 2H, CH PMP), 7.33–
7.42 (m, 6H, aromatic TBDPS), 7.65–7.70 (m, 4H, aromatic TBDPS); 
13C NMR (100 MHz, CDCl3): δ = 19.2 ((CH3)3CSi), 21.7 (C-3’), 23.2 (C-6’), 27.0 
((CH3)3CSi), 31.0, 39.3 (C-2’, C-4’), 55.2 (CH3OPh), 56.0 (CH2OCH3), 69.4 (C-5’), 74.8 
(CHOMOM), 78.0 (C-3), 81.1 (C-5), 84.8 (C-6), 96.7 (OCH2OCH3), 113.6, 113.7, 127.1 
(aromatic of PMP), 127.4, 127.5 (aromatic of TBDPS), 128.0, 128.6, 128.7 (aromatic of 
PMP), 129.4, 129.5, 134.4 134.8, 135.8 (aromatic of TBDPS), 156.7, 159.8 (2COMe of PMP), 
167.8 (C=O); 
HRMS (ESI): calcd for C42H52NaO8Si [M+Na]+: 735.33237, found 735.33270. 
 
 
General Procedure 1 for Petasis Olefination  
 
To a stirred solution of the substrate (1 equiv, 0.25 M) in dry THF was added the Petasis 
reagent (3 equiv, solution in toluene (10 % wt)). The resulting orange reaction mixture was 
warmed to 65 °C and stirred in the dark under an argon atmosphere till more than 90% of the 
starting material was consumed (as indicated by TLC). The solution was cooled to room 
temperature and the titanium compounds were precipitated by addition of a large excess of 
petroleum ether (ca. 50 mL/mmol of substrate). The resulting heterogeneous mixture was 
poured onto a basic alumina column and eluted quickly. In order to ensure that the entire 
product was out of the column, the alumina bed was flushed with a petroleum ether/ethyl 
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acetate (4:1) mixture. The column fractions were pooled together and concentrated. In cases 
where the stability of the product was good, it was column chromatographed on alumina to 
obtain the pure compound.  
 
 
[(1S)-1,2-Dimethoxyprop-2-enyl]benzene (8-57) 
 
OMe
Ph
MeO
 
 
This enol ether was prepared according to general procedure 1, yield 67 mg (56%), colorless 
oil. This compound was utilized immediately after workup.  
 
Rf = 0.5 (petroleum ether/ethyl acetate, 9:1); 
1H NMR (C6D6, 400 MHz): δ = 3.07 (s, 3H, OCH3), 3.18 (s, 3H, OCH3), 3.97 (d, J = 2.0 Hz, 
1H, C=CH2), 4.50 (d, J = 1.8 Hz, 1H, C=CH2), 4.55 (br s, 1H, PhCH), 7.05–7.22 (m, 3H, Ph), 
7.53 (d, J = 7.3 Hz, 2H, Ph); 
HRMS (ESI): calcd for C11H14NaO2 [M+Na]+: 201.08860, found 201.08867. 
 
 
(5S)-2,2-Dimethyl-4-methylene-5-phenyl-1,3-dioxolane (8-58) 
 
O
O
Ph
 
 
This enol ether was prepared according to general procedure 1. Purification was done by 
chromatography on Al2O3 (petroleum ether/ethyl acetate, 18:1), yield 188 mg (92%), slightly 
yellow oil.  
 
Rf = 0.5 (petroleum ether/ethyl acetate, 18:1);  
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1H NMR (C6D6, 400 MHz): δ = 1.32 (s, 3H, CH3), 1.49 (s, 3H, CH3), 3.66 (t, J = 1.8 Hz, 1 H, 
C=CH2), 4.49 (dd like t, J = 1.8, 2.3 Hz, 1H, C=CH2), 5.42 (br s, 1H, PhCH), 7.06–7.15 (m, 
3H, Ph.), 7.35 (dd, J = 8.3, 1.3 Hz, 2H, Ph); 
13C NMR (C6D6, 100 MHz): δ = 25.0 (CH3 acetonide), 26.7 (CH3 acetonide), 80.0 (CHPh), 
80.5 (CH2=C), 110.9 (C(CH3)), 128.3, 128.57, 128.64 (tert. ar.), 139.5 (quat. ar.), 160.8 
(CH2=C). 
 
 
(2R,3R)-2,3-Bis(4-methoxyphenyl)-5-methylene-1,4-dioxane (8-59) 
 
O
O
PMP
PMP  
 
This enol ether was prepared according to general procedure 1, yield 69 mg (68 %), slightly 
yellow oil. This compound was utilized immediately after workup.  
 
Rf = 0.3 (petroleum ether/ethyl acetate, 4:1); 
1H NMR (C6D6, 400 MHz): δ = 3.17 (s, 3H, CH3OAr), 3.18 (s, 3H, CH3OAr), 4.19 (s, 1H, 
C=CH2), 4.24 (d, J = 13.1 Hz, 1H, 6-H), 4.28 (d, J = 13.1 Hz, 1H, 6-H), 4.48 (d, J = 9.3 Hz, 
1H, 2-H), 4.69 (s, 1 H, C=CH2), 4.81 (d, J = 9.3 Hz, 1H, 3-H), 6.60 (d, J = 8.6 Hz, 2H, ar.), 
6.62 (d, J = 8.6 Hz, 2H, ar.), 6.97 (d, J = 8.6 Hz, 2H, ar.), 6.99 (d, J = 8.6 Hz, 2H, ar.). 
 
 
  Experimental Section 184 
(3S,5S,6S)-2-Methylidene-3-[(1S)-3-phenyl-1-(methoxymethoxy)propyl]-5,6-bis[4-
(methyloxy)phenyl]-3-propyl-1,4-dioxane (8-60) 
 
O
O
OMOM
PMP
PMP  
 
This enol ether was prepared according to general procedure 1. Purification was done by 
chromatography on Al2O3 (petroleum ether/ethyl acetate, 4:1), yield 25 mg (67%), colorless 
oil.  
 
Rf = 0.45 (petroleum ether/ethyl acetate, 4:1);  
[α]20D = –166.3 (c 1.12, CH2Cl2);  
1H NMR (C6D6, 400 MHz): δ = 2.00–2.11 (m, 1H, 2’-H), 2.35–2.37 (m, 1H, 2’-H), 2.85–2.99 
(m, 2H, 3’-H), 3.18 (s, 6H, CH3OAr), 3.33 (s, 3H, OCH2OCH3), 4.33 (d, J = 9.6 Hz, 1H, 5-H), 
4.54 (d, J = 9.4 Hz, 1H, 3-H), 4.57 (s, 1H, C=CH2), 4.55–4.62 (m, 1H, 1’-H), 4.64 (d, J = 7.1 
Hz, 1 H, OCH2OCH3), 4.79 (d, J = 9.6 Hz, 1H, 6-H), 4.88 (s, 1H, C=CH2), 4.91 (d, J = 7.1 Hz, 
1H, OCH2OCH3), 6.60 (d, J = 8.6 Hz, 2H, PMP), 6.62 (d, J = 8.6 Hz, 2H, PMP), 6.92 (d, J = 
8.6 Hz, 2H, PMP), 6.95 (d, J = 8.6 Hz, 2H, PMP), 7.02–7.07 (m, 1H, Ph), 7.12–7.16 (m, 2H, 
Ph), 7.23 (d, J = 7.3 Hz, 2H, Ph); 
13C NMR (C6D6, 100 MHz): δ = 30.9 (C-3’), 33.8 (C-2’), 54.6 (2 ArOCH3), 55.6 
(OCH2OCH3), 74.6 (C-6), 75.5 (C-5), 77.2 (C-1’), 86.0 (C-3), 96.3 (C=CH2), 97.6 
(OCH2OCH3), 113.6 (tert. ar.), 126.0–129.2 (tert. ar.),129.9, 130.0 (quat. PMP), 142.8 (quat. 
Ph), 156.7 (C=CH2), 159.8, 159.9 (2COMe of PMP); 
HRMS (ESI): calcd for C30H34NaO6 [M+Na]+: 513.22476, found 513.22506. 
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(3R,5R,6R)-3-[(1R,5R)-5-(tert-Butyldiphenylsilyloxy)-1-(methoxymethoxy)hexyl]-2-
methylidene-5,6-bis-(4-methoxyphenyl)-[1,4]-dioxan-2-one (8-61) 
 
O
O
OMOM
PMP
PMP
OTBDPS
 
 
This enol ether was prepared according to general procedure 1. Purification was done by 
chromatography on Al2O3 (petroleum ether/ethyl acetate, 9:1), yield 149 mg (91%), slightly 
yellow oil. 
 
Rf = 0.35 (petroleum ether/ethyl acetate, 9:1);  
[α]20D = +63.8 (c 0.8, CH2Cl2);  
1H NMR (C6D6, 400 MHz): δ = 1.06 (d, J = 6.1 Hz, 3H, 6’-H), 1.18 (s, 9H, (CH3)3CSi), 1.43–
1.60 (m, 2H, 3’-H, 4’-H), 1.60–1.79 (m, 3H, CH2), 1.84–1.93 (m, 1H, 2’-H), 3.18 (s, 3H, 
OCH3), 3.19 (s, 3H, OCH3), 3.32 (s, 3H, CH2OCH3), 3.85–3.95 (m, 1H, 5’-H), 4.36 (d, J = 9.3 
Hz, 1H, 3-H), 4.59 (m, 1H, 1’-H), 4.60 (s, 1H, C=CH2), 4.68 (d, J = 7.0 Hz, 1H, 5-H), 4.84 
(dd, J = 11.0, 9.5 Hz, 2H, CH2OCH3), 4.87 (d, J = 7.0 Hz, 1H, 6-H), 4.91 (s, 1H, C=CH2), 
6.61 (d, J = 8.7 Hz, 4H, CH PMP), 6.99 (d, J = 8.7 Hz, 2H, CH PMP), 7.02 (d, J = 8.7 Hz, 2H, 
CH PMP), 7.17–7.24 (m, 6H, aromatic), 7.75–7.84 (m, 4H, aromatic);  
13C NMR (C6D6, 100 MHz): δ = 19.5 ((CH3)3CSi), 20.3 (C-3’), 23.2 (C-6’), 27.3 ((CH3)3CSi), 
31.9 (C-2’), 40.1 (C-4’), 54.6 (2 OCH3), 55.7 (CH2OCH3), 70.0 (C-5’), 74.3 (C-6), 75.4 (C-5), 
77.7 (C-1’), 86.0 (C-3), 96.3 (C=CH2), 96.9 (CH2OCH3), 113.7, 127.8, 129.8, 130.0, 130.1, 
135.0, 135.2, 136.3, 156.8 (C-2), 159.8, 159.9;  
HRMS (ESI): calcd for C43H54NaO7Si [M+Na]+: 733.35310, found 733.35347. 
 
 
General procedure 2 for the tandem hydroboration-Suzuki coupling reaction 
 
A THF solution of the substrate (1 equiv, 0.33 M) in a Schlenk flask was thoroughly degassed 
by freeze-pump-thaw method. Then 9-BBN (1.2 equiv, 0.5 M solution in THF) was added at 0 
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°C under an argon atmosphere. The resulting reaction mixture was allowed to stir at room 
temperature for about 6 hours. Meanwhile, in a separate Schlenk flask, a solution of the halide 
(or triflate) (1.2 equiv), triphenyl arsine (0.05 equiv), cesium carbonate (2 equiv), water (30 
equiv), in DMF (2 mL/ mmol of halide (or triflate)) was degassed by the same method. For the 
coupling of triflate 21, KBr (1.2 equiv) was added at this point. This flask was purged with 
argon and under a continuous flow of argon, PdCl2(dppf) (0.05 equiv) was added. To the 
resulting red suspension was added the above mixture from the hydroboration reaction. This 
was then stirred under argon at room temperature for a further 14-16 hours. The reaction was 
worked up by addition of saturated NH4Cl solution (15 mL/mmol of substrate). The resulting 
mixture was poured into a separating funnel and the layers were separated. The aqueous layer 
was extracted twice with ethyl acetate and the combined organic extracts were washed 
successively with saturated Na2S2O3, water and brine. The organic phase was dried over 
anhydrous MgSO4, filtered, concentrated under reduced pressure, and flash column 
chromatographed on silica, eluting with a petroleum ether/ethyl acetate mixture to afford the 
pure product.  
 
 
[(1S,2R)-1,2-Dimethoxy-3-phenylpropyl]benzene (8-62) 
 
OMe
Ph
MeO
Ph  
 
The tandem hydroboration/cross coupling reaction to give compound 2 was performed 
according to general procedure 2, yield 7 mg (35%), colorless oil. 
 
Rf = 0.5 (petroleum ether/ethyl acetate, 9:1);  
1H NMR (CDCl3, 400 MHz): δ = 2.77 (dd, J = 14.1, 8.3 Hz, 1H, CH2), 2.94 (dd, J = 14.1, 3.3 
Hz, 1H, CH2), 2.99 (s, 3H, OCH3), 3.25 (s, 3H, OCH3), 3.45 (ddd, J = 8.3, 5.8, 3.3 Hz, 1H, 
CH2CH(OMe)), 4.08 (d, J = 5.8 Hz, 1H, PhCH(OMe)), 7.15–7.40 (m, 10H, ar.); 
13C NMR (CDCl3, 100 MHz): δ = 36.9 (CH2), 56.9 (OCH3), 58.9 (OCH3), 84.8 
(CH2CH(OMe)), 86.2 (PhCH(OMe)), 125.9, 127.7, 128.1, 129.6 (tert. ar.), 139.3 (quat. ar.); 
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HRMS (ESI): calcd for C17H20NaO2 [M+Na]+: 279.13555, found 279.13550. 
 
 
Methyl 2-{(1E)-3-[(4S,5S)-2,2-dimethyl-5-phenyl-1,3-dioxolan-4-yl]prop-1-enyl}benzoate 
(8-64) 
 
OMe
O
O
O
Ph  
 
This dioxolane derivative was prepared according to general procedure 2. Compound 6 was 
obtained as a 6:1 mixture of E/Z isomers. It is advisable to store it at –20 °C to prevent 
isomerization of the olefin, yield 22 mg (62%), colorless oil.  
 
Rf = 0.35 (petroleum ether/ethyl acetate, 9:1); 
[α]20D = –28.6 (c 0.8, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 1.52 (s, 3H, CH3), 1.58 (s, 3H, CH3), 2.51–2.68 (m, 2H, 
CH2), 3.88 (s, 3H, CO2CH3), 3.90–3.98 (m, 1H, CH2CHOR), 4.68 (d, J = 8.3 Hz, 1H, CHPh), 
6.09 (td, J = 14.2, 7.1 Hz, 1H, CH=CHCH2), 7.18–7.43 (m, 9H, ar. and CH=CHCH2), 7.84 (d, 
J = 8.6 Hz, 1H, ar.); 
13C NMR (CDCl3, 100 MHz): δ = 27.1 (CH3), 27.3 (CH3), 34.7 (CH2), 52.0 (CO2CH3), 82.6 
(CH2CHOR), 82.59 (PhCHOR), 108.8 (CMe2), 126.8 (CH=CHCH2), 127.0, 127.4 (tert. ar.), 
128.2 (CH=CHCH2), 128.6, 130.3, 131.2, 132.0 (tert. ar.), 137.6 (quat. ar.), 139.1 (quat. ar.), 
167.9 (C=O); 
HRMS (ESI): calcd for C22H24NaO4 [M+Na]+: 375.15668, found 375.15683. 
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(2S,3S,5R)-5-Benzyl-2,3-bis(4-methoxyphenyl)-1,4-dioxane (8-66) 
 
O
O
PMP
PMP
Ph
 
 
This dioxane derivative was prepared according to general procedure 2, yield 46 mg (72%), 
colorless oil.  
 
Rf = 0.4 (petroleum ether/ethyl acetate, 3:1);  
[α]20D = –43.4 (c 1.0, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 2.77 (dd, J = 14.0, 7.3 Hz, 1H, CH2Ph), 3.0 (dd, J = 14.0, 
5.6 Hz, 1H, CH2Ph), 3.59 (dd like t, J = 11.4, 10.6 Hz, 1H, 6-H), 3.71 (s, 3H, CH3OAr), 3.73 
(s, 3H, CH3OAr), 3.93 (dd, J = 11.4, 2.5 Hz, 1H, 6-H), 4.10 (dddd, J = 10.6, 7.3, 5.6, 2.5 Hz, 
1H, 5-H), 4.22 (d, J = 8.8 Hz, 1H, 3-H), 4.41 (d, J = 8.8 Hz, 1H, 2-H), 6.68 (d, J = 8.6 Hz, 2H, 
PMP), 6.70 (d, J = 8.6 Hz, 2H, PMP), 6.91 (d, J = 8.6 Hz, 2H, PMP), 6.94 (d, J = 8.6 Hz, 2H, 
PMP), 7.17–7.32 (m, 5H, aromatic); 
13C NMR (CDCl3, 100 MHz): δ = 38.6 (CH2Ph), 55.1 (2CH3OAr), 70.8 (C-6), 76.1 (C-3), 
83.3 (C-2), 83.7 (C-5), 113.2 (tert. PMP), 113.3 (tert. PMP), 126.4, 128.4, 128.6, 129.3 (tert. 
ar.), 130.1 (quat. PMP), 130.4 (quat. PMP), 137.4 (quat Ph), 159.0 (COMe PMP); 
HRMS (ESI): calcd for C25H26NaO4 [M+Na]+: 413.17233, found 413.17241. 
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Methyl 2-{(1E)-3-[(2S,5R,6R)-5,6-bis(4-methoxyphenyl)-1,4-dioxan-2-yl]prop-1-
enyl}benzoate (8-67) 
 
O
O
PMP
PMP
O
OMe
 
 
This dioxane derivative was prepared according to general procedure 2, yield 89 mg (87%), 
colorless foam. This compound was obtained as a 9:1 mixture of E/Z isomers. It is advisable to 
store this compound at -20 °C in order to avoid isomerization of the olefin.  
 
Rf = 0.4 (petroleum ether/ethyl acetate, 9:1);  
[α]20D = +55.7 (c 1.4, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 2.36–2.46 (m, 1H, 3’-H), 2.46–2.56 (m, 1H, 3’-H), 3.59 (dd 
like t, J = 11.3, 10.6 Hz, 1H, 3’’-H), 3.64 (s, 6H, 2CH3OAr), 3.79 (s, 3H, CO2CH3), 3.90–3.98 
(m, 1H, 2’’-H), 4.00 (dd, J = 11.3, 2.3 Hz, 3’’-H), 4.19 (d, J = 9.0 Hz, 1H, 6’’-H), 4.36 (d, J = 
9.0 Hz, 1H, 5’’-H), 6.11 (ddd, J = 14.2 Hz, 7.3, 7.0 Hz, 1H, 2’-H), 6.62 (d, J = 8.6 Hz, 2H, 
PMP), 6.63 (d, J = 8.6 Hz, 2H, PMP), 6.87 (d, J = 8.6 Hz, 2H, PMP), 6.89 (d, J = 8.6 Hz, 2H, 
PMP), 7.17 (d, J = 14.2 Hz, 1H, 1’-H), 7.19 (t, J = 7.8 Hz, 1H, 4-H), 7.35 (t, J = 7.8 Hz, 1H, 5-
H), 7.45 (d, J = 7.8 Hz, 1H, 3-H), 7.78 (d, J = 7.8 Hz, 1H, 6-H); 
13C NMR (CDCl3, 100 MHz): δ = 35.7 (C-3’), 52.0 (CO2CH3), 55.0 (CH3OAr), 71.0 (C-3’’), 
75.1 (C-2’’), 83.3 (C-5’’), 83.6 (C-6’’), 113.2 (tert. ar.), 113.2 (tert. PMP), 126.8 (C-1’), 128.0 
(C-2’), 127.3, 128.6, 128.1, 128.7, 130.1, 130.3, 130.4 (tert. ar.), 131.2 (C-6), 132.0 (C-4), 
139.1 (C-2), 159.0 (2 COMe of PMP), 167.8 (C=O); 
HRMS (ESI): calcd for C29H30NaO6 [M+Na]+: 497.19346, found 497.19317. 
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Methyl 2-{[(2R,5S,6S)-5,6-bis(4-methoxyphenyl)-1,4-dioxan-2-yl]methyl}-6-
methoxybenzoate (8-68) 
 
OMe
CO2Me
O
O
PMP
PMP  
 
This dioxane derivative was prepared according to general procedure 2 with added KBr (1.2 
equiv), yield 108 mg (53%), colorless foam.  
 
Rf = 0.2 (petroleum ether/ethyl acetate, 2:1);  
[α]20D = –25.1 (c 1.1, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 2.72 (dd, J = 14.0, 7.0 Hz, 1’-H), 2.94 (dd, J = 14.0, 6.1 Hz, 
1H, 1’-H), 3.57 (dd like t, J = 11.1, 10.9 Hz, 1H, 3’’-H), 3.72 (s, 3H, CH3OAr), 3.74 (s, 3H, 
CH3OAr), 3.82 (s, 3H, CO2CH3), 3.90 (s, 3H, CH3OAr), 3.91 (dd, J = 11.1, 2.5 Hz, 1H, 3’’-
H), 4.11 (dddd, J = 10.9, 7.0, 6.1, 2.5 Hz, 1H, 2’’-H), 4.22 (d, J = 8.9 Hz, 1H, 6’’-H), 4.39 (d, 
J = 8.9 Hz, 1H, 5’’-H), 6.68 (d, J = 8.6 Hz, 2H, PMP), 6.70 (d, J = 8.6 Hz, 2H, PMP), 6.80 (d, 
J = 8.3 Hz, 1H, 5-H), 6.90 (d, J = 8.6 Hz, 2H, PMP), 6.92 (d, J = 8.3 Hz, 1H, 3-H), 6.93 (d, J 
= 8.6 Hz, 2H, PMP), 7.27 (t, J = 8.3 Hz, 1H, 4-H); 
13C NMR (CDCl3, 100 MHz): δ = 35.7 (C-1’), 52.3 (CO2CH3), 55.1 (2 CH3OAr), 55.9 
(CH3OAr), 70.8 (C-3’’), 75.8 (C-6’’), 83.3 (C-5’’), 83.7 (C-2’’), 109.2 (C-5), 113.2 (2 tert. 
PMP), 113.3 (2 tert. PMP), 122.6 (C-3), 124.0 (C-1), 128.6 (tert. PMP), 128.7 (tert. PMP), 
130.1 (quat. PMP), 130.3 (C-4), 130.4 (quat. PMP), 135.9 (C-2), 156.4 (C-6), 159.0, 159.1 (2 
COMe of PMP), 168.6 (C=O); 
HRMS (ESI): calcd for C28H30NaO7 [M+Na]+: 501.18837, found 501.18819. 
 
 
Experimental Section 191
(2S,3S,5R,6S)-2,3-Bis[4-(methyloxy)phenyl]-6-[(1S)-3-phenyl-1-(methoxymethoxy) 
propyl]-5-(phenylmethyl)-1,4-dioxane (8-69) 
 
O
O
PMP
PMP
OMOM
Ph
Ph
1' 3'
 
 
This dioxane derivative was prepared according to general procedure 2, yield 18 mg (76%), 
colorless oil. 
 
Rf = 0.35 (petroleum ether/ethyl acetate, 3:1);  
[α]20D = +4.1 (c 0.81, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 1.97–2.09 (m, 1H, 2’-H); 2.21-2.33 (m, 1H, 2’-H), 2.84 (dd 
like t, J = 8.3, 7.8 Hz, 2H, 3’-H), 2.87 (dd, J = 14.2, 8.6 Hz, 1H, CH2Ph), 3.03 (dd, J = 14.2, 
4.6 Hz, 1H, CH2Ph), 3.53 (s, 3H, OCH2OCH3), 3.75 (s, 6H, 2 CH3OAr), 3.89 (dd, J = 9.1, 2.8 
Hz, 1H, 6-H), 4.29 (d, J = 9.6 Hz, 1H, 2-H), 4.39-4.33 (m, 1H, 1’-H), 4.40 (d, J = 9.6 Hz, 1H, 
3-H), 4.61 (ddd, J = 8.6, 4.6, 2.8 Hz, 1H, 5-H), 4.86 (d, J = 6.8 Hz, 1H, OCH2OCH3), 4.89 (d, 
J = 6.8 Hz, 1H, OCH2OCH3), 6.70 (d, J = 8.8 Hz, 2H, PMP), 6.71 (d, J = 8.8 Hz, 2H, PMP), 
6.86 (d, J = 8.8 Hz, 2H, PMP), 6.90 (d, J = 8.8 Hz, 2H, PMP), 7.13–7.30 (m, 10H, aromatic), 
13C NMR (CDCl3, 100 MHz): δ = 29.7 (C-3’), 33.1 (C-2’), 38.0 (CH2Ph), 55.1 (2 CH3Ar), 
56.4 (OCH2OCH3), 73.7 (C-2), 74.7 (C-3), 77.8 (C-5), 80.6 (C-1’), 84.5 (C-6), 97.1 
(OCH2OCH3), 113.3 (tert. PMP), 113.2 (tert. PMP), 125.7, 126.1, 128.2, 128.3, 128.6, 128.8, 
129.2 (tert. ar.), 130.2 (quat. PMP), 130.4 (quat. PMP), 139.6 (quat. Ph), 142.7 (quat. Ph’), 
159.0, 159.1 (2COMe of PMP); 
HRMS (ESI): calcd for C36H40NaO6 [M+Na]+: 591.27171, found 591.27203. 
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Methyl 2-((1E)-3-{(2S,3S,5R,6R)-3-((1R,5R)-5-{(tert-Butyldiphenylsilyloxy)}-1-
{[(methyloxy)methyl]oxy}-hexyl)-5,6-bis[4-(methyloxy)phenyl]-1,4-dioxan-2-yl}-1-
propenyl)benzoate (8-70) 
 
Me
OTBDPS
O O
OMOM
PMPPMP
O
MeO
2'
5'' 6''
5'''
 
 
This dioxane derivative was prepared according to general procedure 2. This compound was 
obtained as a 10:1 mixture of E/Z isomers. It is advisable to store this compound at -20 °C in 
order to avoid isomerization of the olefin, yield 180 mg (74%), slightly yellow oil.  
 
Rf = 0.4 (petroleum ether/ethyl acetate, 4:1);  
[α]20D = +8.9 (c 0.9, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 0.96 (d, J = 6.1 Hz, 3H, 6’’’-H), 1.0 (s, 9H, (CH3)3CSi), 
1.30–1.84 (m, 6H, CH2), 2.48–2.69 (m, 2H, 3’-H), 3.40 (s, 3H, OCH2OCH3), 3.73 (s, 3H, 
CH3OAr), 3.74 (s, 3H, CH3OAr), 3.76 (m, 1H, 1’’’-H), 3.78 (dd, J = 8.9, 2.5 Hz, 1H, 3’’-H), 
3.86 (s, 3H, CO2CH3), 4.18–4.25 (m, 1H, 5’’’-H), 4.31 (d, J = 9.4 Hz, 1H, 5’’-H), 4.43 (d, J = 
9.4 Hz, 1H, 6’’-H), 4.43–4.51 (m, 1H, 2’’-H), 4.74 (d, J = 6.8 Hz, 1H, OCH2OCH3), 4.77 (d, J 
= 6.8 Hz, 1H, OCH2OCH3), 6.26 (ddd, J = 14.4, 8.1, 7.1 Hz, 1H, 2’-H), 6.68 (d, J = 8.6 Hz, 
2H, PMP), 6.72 (d, J = 8.6 Hz, 2H, PMP), 6.88 (d, J = 8.6 Hz, 2H, PMP), 6.94 (d, J = 8.6 Hz, 
2H, PMP), 7.19–7.44 (m, 9H, aromatic, 1’-H), 7.52 (d, J = 7.8 Hz, 1H, 3-H), 7.57–7.66 (m, 
4H, aromatic), 7.82 (dd, J = 7.8, 1.0 Hz, 1H, 6-H); 
13C NMR (CDCl3, 100 MHz): δ = 18.9 ((CH3)3CSi); 19.1 (C-3’’C), 22.8 (C-6’’’), 27.0 
((CH3)3CSi), 30.7 (C-3’), 35.8 (C-2’’’), 39.8 (C-4’’’), 52.0 (CO2CH3), 55.1 (CH3OAr), 55.2 
(CH3OAr), 56.3 (OCH2OCH3), 69.6 (C-5’’’), 73.4 (C-5’’), 74.7 (C-6’’), 77.9 (C-1’’’), 79.6 
(C-3’’), 84.6 (C-2’’), 96.8 (OCH2OCH3), 113.2 (PMP), 113.3 (PMP), 126.7 (C-9), 127.3, 
127.4 (CH, aromatic), 128.2 (C-1), 128.7, 128.8, 129.3, 129.4, 130.2, 130.3 (tert. ar.), 130.5 
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(C-2’), 131.9 (tert. ar.), 134.6, 134.9 (quat. ar.), 135.80, 135.9 (tert. ar.), 139.3 (C-2), 159.1 (2 
COMe of PMP), 168.0 (C=O), 
HRMS (ESI): calcd for C53H68NO9Si [M+NH4]+: 890.46579, found 890.46626. 
 
 
(2R)-3-Phenylpropane-1,2-diol (8-72) 
 
HO
OH
Ph
 
 
To a stirred solution of the dioxane 8-66 (38 mg, 97 μmols) in CH3CN/H2O mixture (9:1) (2 
mL), was added CAN (117 mg, 0.21 mmol). The resulting yellow solution was stirred at room 
temperature for 2 h, during which the starting material was completely consumed. The mixture 
was diluted with water (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The combined 
organic extracts were dried over MgSO4 and filtered. The filtrate was concentrated under 
reduced pressure, the crude product loaded onto a silica column and chromatographed using 
petroleum ether/ethyl acetate (1:1) as eluent to afford pure diol 8-72 as a colorless oil, yield 
12.7 mg (86%).  
 
Rf = 0.3 (petroleum ether/ethyl acetate, 1:1);  
[α]20D = +20.4 (c 1.0, CHCl3); [α]20D = +15.0 (c 1.0, CHCl3);[151]  
1H NMR (CDCl3, 400 MHz): δ = 2.13 (br s, 2H, OH), 2.69–2.84 (m, 2H, H-3), 3.50 (dd, J = 
11.1, 7.1 Hz, 1H, 1-H), 3.68 (dd, J = 11.1, 2.8 Hz, 1H, 1-H), 3.87–3.99 (m, 1H, 2-H), 7.17-
7.35 (m, 5H, aromatic); 
13C NMR (CDCl3, 100 MHz): δ = 39.8 (C-3), 66.0 (C-1), 73.0 (C-2), 128.6 (2 tert. ar.), 129.3 
(2 tert. ar.), 137.7 (quat. ar.); 
HRMS (ESI): calcd for C9H12NaO2 [M+Na]+: 175.07295, found 175.07445. 
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(S,E)-Methyl 2-(4,5-dihydroxypent-1-enyl)benzoate (8-73) 
 
CO2Me
OH
OH
 
 
To a stirred solution of the dioxane 8-67 (40 mg, 84.3 μmol) in CH3CN/H2O (9:1) (2 mL), was 
added CAN (102 mg, 0.186 mmol). The resulting solution was stirred at room temperature for 
3 h, during which the starting material was almost completely consumed. The mixture was 
diluted with water (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The combined organic 
extracts were dried over anhydrous MgSO4 and filtered. The filtrate was concentrated under 
reduced pressure and the crude residue was purified by flash chromatography (petroleum 
ether/ethyl acetate, 1:4) to afford the pure diol 8-73 as a colorless gel, yield 16.2 mg (81%). 
NMR analysis indicated a ratio of 8:1 of E/Z isomers.  
 
Rf = 0.25 (petroleum ether/ethyl acetate, 1:4);  
[α]20D = +7.9 (c 1.1, CH2Cl2);  
1H NMR (CDCl3, 400 MHz): δ = 2.25–2.31 (m, 1H, 3’-H), 2.32–2.41 (m, 2H, 3’-H, OH), 2.81 
(br s, 1H, OH), 3.46–3.56 (m, 1H, 5’-H), 3.62–3.70 (m, 1H, 5’-H), 3.75–3.81 (m, 1H, 4’-H), 
3.82 (s, 3H, CO2CH3), 5.96 (ddd, J = 15.9, 7.9, 7.3 Hz, 1H, 2’-H), 7.09 (d, J = 15.9 Hz, 1H, 
1’-H), 7.20–7.28 (m, 1H, aromatic), 7.38–7.43 (m, 2H, aromatic), 7.82 (d, J = 7.8 Hz, 1H, 3-
H); 
13C NMR (CDCl3, 100 MHz): δ = 37.0 (C-3’), 52.2 (CO2CH3), 66.3 (C-5’), 71.3 (C-4’), 127.7 
(C-1’), 127.3 (C-2), 128.3 (C-2’), 127.0, 130.3, 132.3, 132.9 (tert. ar.), 139.7 (C-1), 167.8 
(C=O); 
HRMS (ESI): calcd for C13H16NaO4 [M+Na]+: 259.09408, found 259.09413.  
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(3S,5S,6S)-3-[(1S,5R)-5-(tert-Butyldiphenylsilyloxy)-1-hydroxyhexyl]-5,6-bis-(4-methoxy 
phenyl)-[1,4]-dioxan-2-one (8-76) 
 
Me
OTBDPS
O
O
OH O
PMP
PMP  
 
To a cooled (-78 °C) solution of (-)-dioxanone 8-7 (0.233 g, 0.740 mmol) in dry CH2Cl2 (20 
mL) was added in a dropwise fashion Et3N (0.26 mL, 1.86 mmol) followed by cHex2BOTf[160] 
(1.85 mL, 1.0 M in abs. hexane). The resulting solution was stirred at -78 °C for 3 h at which 
time (5R)-5-(tert-butyldiphenylsilyloxy)hexanal 8-6 (0.314 g, 0.888 mmol), dissolved in dry 
CH2Cl2 (1 mL) was added dropwise over 10 min. The resulting solution was stirred at -78 °C 
for 12 h before it was quenched at the same temperature by the addition of pH 7 buffer (2.5 
mL), MeOH (2 mL) and 30% aqueous H2O2 (0.5 mL). The mixture was stirred vigorously for 
1 h and then warmed to RT when it was diluted with Et2O (50 mL). The aqueous layer was 
extracted with Et2O (4 × 50 mL) and the combined organic layers were washed with satd. 
NaHCO3 solution (30 mL). The combined organic layers were dried with anhydrous MgSO4, 
filtered, and concentrated in vacuo to afford ~1.0 g of crude product as a yellow oil, which was 
used for the next step without further purification [approximately half of the product can 
decompose during flash chromatography on silica gel (petroleum ether/EtOAc, 2:1)]. The 
selectivity was found to be 9:1 (anti-1/anti-2) according to 1H NMR and LC-MS of the crude 
reaction material.  
 
Data for the purified product:  
Rf = 0.48 (petroleum ether/EtOAc, 2:1);  
[α]20D = –74.1 (c 1.6, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 1.03–1.15 (m, 12H, (CH3)3CSi, CH3CHOSi), 1.40–1.79 (m, 
6H, (CH2)3), 3.00 (br s, 1H, OH), 3.75 (s, 6H, CH3OAr), 3.86–3.95 (m, 1H, CH3CHOSi), 
4.05–4.11 (m, 1H, 1’-H), 4.50 (d, J = 5.4 Hz, 1H, 3-H), 4.96 (d, J = 9.2 Hz, 1H, 5-H), 5.41 (d, 
J = 9.2 Hz, 1H, 6-H), 6.78 (d, J = 8.8 Hz, 2H, CH PMP), 6.79 (d, J = 8.8 Hz, 2H, CH PMP), 
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6.99 (d, J = 8.8 Hz, 2H, CH PMP), 7.02 (d, J = 8.8 Hz, 2H, CH PMP), 7.34–7.44 (m, 6H, 
aromatic TBDPS), 7.70–7.75 (m, 4H, aromatic TBDPS);  
13C NMR (100 MHz, CDCl3): δ = 19.1 ((CH3)3CSi), 20.8 (C-4’), 23.1 (C-6’), 26.9 
((CH3)3CSi), 33.3 (C-2’), 39.0 (C-3’), 55.0 (CH3OAr), 69.3 (C-5’), 73.1 (C-1’),75.9 (C-3), 
77.7 (C-5), 84.8 (C-6), 113.6, 126.5, 127.3, 127.4, 127.8, 128.7, 128.4, 129.3, 134.4, 134.7, 
135.7, 159.6, 159.8, 170.0 (C=O);  
HRMS (ESI): calcd for C40H48NaO7Si [M+Na]+: 723.33236, found 723.33153. 
 
 
(3S,5S,6S)-3-[(1S,5R)-5-(tert-Butyldiphenylsilyloxy)-1-(methoxymethoxy)hexyl]-5,6-bis-
(4-methoxyphenyl)-[1,4]-dioxan-2-one (8-77) 
 
Me
OTBDPS
O O
OMOM
O
PMPPMP  
 
To a stirred, cooled (0 °C) solution of crude aldol product 8-76 (~ 1.0 g) in CH2Cl2  (30 mL) 
were added N,N-diisopropylethylamine (5.1 mL, 3.86 g, 30.0 mmol), chloromethylmethyl 
ether (MOMCl)[161] (1.14 mL, 1.20 g, 15.0 mmol), and tetrabutylammonium iodide (222 mg, 
0.6 mmol). The reaction mixture was protected from light and allowed to reach RT. After 
stirring for 14 days [daily addition of MOMCl (about 0.1 mL) and N,N-diisopropylethylamine 
(about 0.2 mL) can speed up progress of the reaction], satd. aqueous NaHCO3 solution (40 
mL) was added followed by Et2O (50 mL). The organic layer was washed with satd. NaCl 
solution (100 mL), and the basic aqueous layer was extracted with Et2O (2 × 25 mL). The 
combined organic extracts were dried (Na2SO4), filtered, and concentrated in vacuo. Flash 
chromatography of the residue (petroleum ether/EtOAc, 3:1) provided MOM ether 8-77 (0.24 
g, 45% for two steps from aldehyde 8-6) as slightly yellow oil.  
 
Rf = 0.36 (petroleum ether/EtOAc, 3:1); 
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[α]20D = –71.6 (c 1.1, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 0.98–1.06 (m, 12H, (CH3)3CSi, CH3CHOSi), 1.36–1.57 (m, 
4H, 2 CH2), 1.63–1.78 (m, 2H, CH2), 3.37 (s, 3H, OCH2OCH3), 3.75 (s, 3H, CH3OAr), 3.76 
(s, 3H, CH3OAr), 3.81–3.87 (m, 1H, 5’-H), 4.03–4.09 (m, 1H, 1’-H), 4.73 (dd, J = 8.3, 7.1 Hz, 
2H, OCH2OCH3), 4.77 (d, J = 2.6 Hz, 1H, 3-H), 4.98 (d, J = 8.6 Hz, 1H, 5-H), 5.37 (d, J = 8.6 
Hz, 1H, 6-H), 6.73–6.77 (m, 4H, CH PMP), 6.98 (d, J = 8.8 Hz, 4H, CH PMP), 7.33–7.42 (m, 
6H, aromatic TBDPS), 7.65–7.70 (m, 4H, aromatic TBDPS);  
13C NMR (100 MHz, CDCl3): δ = 19.2 (CH3)3CSi), 21.5 (C-3’), 23.1 (C-6’), 27.0 (CH3)3CSi), 
30.9, 39.2 (C-2’, C-4’), 55.2 (CH3OAr), 56.0 (OCH2OCH3), 69.4 (C-5’), 74.7 (CHOMOM), 
77.9 (C-3), 81.1 (C-5), 84.9 (C-6), 96.6 (OCH2OCH3), 113.6, 113.7, 127.2, 127.4, 127.5, 
128.1, 128.6, 128.7, 129.4, 129.5, 134.5, 134.8, 135.8, 135.9, 159.7 (COMe of PMP), 159.8 
(COMe of PMP), 167.8 (C=O);  
HRMS (ESI): calcd for C42H52NaO8Si [M+Na]+: 735.33237, found 735.33270. 
 
 
(3S,5S,6S)-3-[(1S,5R)-5-(tert-Butyldiphenylsilyloxy)-1-(methoxymethoxy)hexyl]-2-
methylidene-5,6-bis-(4-methoxyphenyl)-[1,4]-dioxan-2-one (8-78) 
 
Me
OTBDPS
O O
OMOM
PMPPMP  
 
To a stirred solution of the lactone 8-77 (924 mg, 1.3 mmol) in dry THF (15 mL) was added 
the freshly prepared Petasis reagent Cp2TiMe2 (1.6 g, 7.8 mmol, 6 equiv.) dissolved in toluene 
(25 mL). The resulting orange reaction mixture was warmed to 65 °C and stirred in the dark 
under an argon atmosphere until the starting material was consumed (as indicated by TLC, 
approximately 36 h). The solution was cooled to RT and the titanium compounds were 
precipitated by addition of petroleum ether (ca. 200 mL). The resulting heterogeneous mixture 
was poured on a basic alumina column and eluted quickly. In order to ensure that the entire 
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product was out of the column, the alumina bed was finally flushed with a petroleum 
ether/EtOAc (4:1) mixture. The fractions were pooled and concentrated in vacuo. Purification 
was done by chromatography on basic Al2O3 (petroleum ether/EtOAc, 9:1) yielding 840 mg 
(91%) of the product as a slightly yellow oil.  
 
Rf = 0.35 (petroleum ether/EtOAc, 9:1); 
1H NMR (400 MHz, C6D6): δ = 1.06 (d, J = 6.1 Hz, 3H, 6’-H), 1.18 (s, 9H, (CH3)3CSi), 1.43–
1.60 (m, 2H, 3’-H, 4’-H), 1.60–1.79 (m, 3H, CH2), 1.84–1.93 (m, 1H, 2’-H), 3.18 (s, 3H, 
CH3OAr), 3.19 (s, 3H, CH3OAr), 3.32 (s, 3H, OCH2OCH3), 3.85–3.95 (m, 1H, 5’-H), 4.36 (d, 
J = 9.3 Hz, 1H, 3-H), 4.59 (m, 1H, 1’-H), 4.60 (s, 1H, C=CH2), 4.68 (d, J = 7.0 Hz, 1H, 5-H), 
4.84 (dd, J = 11.0, 9.5 Hz, 2H, OCH2OCH3), 4.87 (d, J = 7.0 Hz, 1H, 6-H), 4.91 (s, 1H, 
C=CH2), 6.61 (d, J = 8.7 Hz, 4H, CH PMP), 6.99 (d, J = 8.7 Hz, 2H, CH PMP), 7.02 (d, J = 
8.7 Hz, 2H, CH PMP), 7.17–7.24 (m, 6H, aromatic), 7.75–7.84 (m, 4H, aromatic);  
13C NMR (100 MHz, C6D6): δ = 19.5 ((CH3)3CSi), 20.3 (C-3’), 23.2 (C-6’), 27.3 ((CH3)3CSi), 
31.9 (C-2’), 40.1 (C-4’), 54.6 (2 CH3OAr), 55.7 (CH2OCH3), 70.0 (C-5’), 74.3 (C-6), 75.4 (C-
5), 77.7 (C-1’), 86.0 (C-3), 96.3 (C=CH2), 96.9 (CH2OCH3), 113.7, 127.8-129.8, 130.0, 130.1, 
135.0, 135.2, 136.3, 156.8 (C-2), 159.9, 159.9;  
HRMS (ESI): calcd for C43H54NaO7Si [M+Na]+: 733.35310, found 733.35347. 
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Methyl 2-((1E)-3-{(2R,3R,5S,6S)-3-((1S,5R)-5-{(tert-Butyldiphenylsilyloxy)}-1-
{[(methyloxy)methyl]oxy}-hexyl)-5,6-bis[4-(methyloxy)phenyl]-1,4-dioxan-2-yl}-1-
propenyl) benzoate (8-80) 
 
Me
OTBDPS
O O
OMOM
PMPPMP
O
MeO
 
 
To a solution of the enol ether 8-78 (695 mg, 0.98 mmol) in absolute THF (10 mL) a solution 
of 9-BBN (2.35 mL, 1.17 mmol, 0.5 M in THF) was added at 0 °C. The resulting reaction 
mixture was allowed to stir at RT for about 6 h. Meanwhile, in a separate flask, a solution of 
the methyl 2-[(E)-2-iodovinyl]benzoate (8-3) (720 mg, 2.5 mmol), triphenyl arsine (15 mg, 
0.049 mmol, 5% mol), cesium carbonate (1.3 g, 4.0 mmol), deionized water (0.1 mL), in abs. 
DMF (24 mL) was prepared. This flask was purged with argon and PdCl2(dppf) (40 mg, 0.049 
mmol, 5% mol) was added. To the resulting suspension was added the above mixture from the 
hydroboration reaction. This was then stirred under argon at RT for a further 14-16 h. The 
reaction was worked up by addition of satd. NH4Cl solution (20 mL). The mixture was poured 
into a separating funnel and extracted twice with EtOAc. The combined organic extracts were 
washed successively with satd. Na2S2O3 solution, water and satd. NaCl solution. The organic 
phase was dried over anhydrous MgSO4, filtered, concentrated under reduced pressure, and 
purified by flash chromatography (petroleum ether/EtOAc, 4:1) to afford the pure coupling 
product (630 mg, 74%) as a slightly yellow oil. This compound was obtained as >20:1 mixture 
of E/Z isomers. It is advisable to store this compound at -20 °C in order to avoid isomerization 
of the double bond.  
 
Rf = 0.4 (petroleum ether/EtOAc, 4:1); 
[α]20D = +22.0 (c 2.0, CHCl3); 
1H NMR (400 MHz, CDCl3,): δ = 0.94 (m, 12H, 6’’’-H, (CH3)3CSi), 1.30–1.84 (m, 6H, CH2), 
2.45–2.63 (m, 2H, 3’-H), 3.33 (s, 3H, OCH2OCH3), 3.64 (s, 3H, CH3OAr), 3.65 (s, 3H, 
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CH3OAr), 3.71–3.79 (m, 2H, 3’’-H, 5’’’-H), 3.79 (s, 3H, CO2CH3), 4.13–4.19 (m, 1H, 2’’-H), 
4.28 (d, J = 9.4 Hz, 1H, 5’’-H), 4.37 (d, J = 9.4 Hz, 1H, 6’’-H), 4.40–4.44 (m, 1H, 1’’’-H), 
4.67 (dd, J = 12.9, 6.8 Hz, 2H, OCH2OCH3), 6.26 (ddd, J = 15.6, 6.8, 6.8 Hz, 1H, 2’-H), 6.62 
(d, J = 8.6 Hz, 2H, PMP), 6.65 (d, J = 8.6 Hz, 2H, PMP), 6.83 (d, J = 8.6 Hz, 2H, PMP), 6.87 
(d, J = 8.6 Hz, 2H, PMP), 7.15–7.33 (m, 9H, aromatic and 1’-H), 7.45 (d, J = 7.8 Hz, 1H, 3-
H), 7.53–7.58 (m, 4H, aromatic), 7.75 (d, J = 7.8 Hz, 1H, 6-H);  
13C NMR (100 MHz, CDCl3): δ = 18.9 ((CH3)3CSi), 19.1 (C-3’’’), 23.1 (C-6’’’), 26.9 
((CH3)3CSi), 30.7 (C-3’), 35.8 (C-2’’’), 39.9 (C-4’’’), 51.9 (CO2CH3), 55.0 (2 CH3OAr), 56.2 
(OCH2OCH3), 69.7 (C-5’’’), 73.3 (C-5’’), 74.5 (C-6’’), 77.8 (C-1’’’), 79.6 (C-3’’), 84.7 (C-
2’’), 96.7 (OCH2OCH3), 113.2 (PMP), 113.3 (PMP), 126.6 (C-9), 127.3, 127.4, 128.1 (C-1), 
128.6, 128.7, 129.2, 129.3, 130.2, 130.3, 130.5 (C-2’), 131.8, 134.5 (quat C SiPh), 134.9 (quat 
C SiPh), 135.8, 139.2 (C-2), 159.1 (2 COCH3 PMP), 167.9 (CO2CH3);  
HRMS (ESI): calcd for C53H68NO9Si [M+NH4]+: 890.46579, found 890.46626. 
 
 
Methyl 2-((1E)-3-{(2R,3R,5S,6S)-3-((1S,5R)-5-hydroxy)-1-(methyloxymethyl)oxy-hexyl-
5,6-bis[4-(methyloxy)phenyl]-1,4-dioxan-2-yl}-1-propenyl)benzoate (8-81) 
 
O O
PMPPMP
O
MeO
OMOM
OH
Me
 
 
To a cooled (–20 °C) solution of substrate 8-80 (0.20 g, 0.23 mmol) in dry THF (10 mL) in a 
plastic vial, pyridine·HF complex (2.0 mL, freshly opened flask) was added slowly in a 
dropwise fashion (approx. within 15 min.). The resulting solution was stirred at 0 °C for 24 h 
at which time K2CO3 was added portionwise until the mixture was basic. The mixture was 
diluted with THF (20 mL) and stirred for 2 h. Solids were filtered, then washed with Et2O (50 
mL). The filtrate was washed with satd. NaCl solution, dried over Na2SO4, filtered, and 
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concentrated in vacuo to afford crude product. Flash chromatography of the residue 
(petroleum ether/EtOAc, 1:1) furnished hydroxy ester 8-81 (125 mg, 86%) as a colorless oil.  
 
Rf = 0.32 (petroleum ether/EtOAc, 1:1); 
[α]20D = –2.7 (c 0.9, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 1.10 (d, J = 5.8 Hz, 3H, 6’’’-H), 1.25–1.40 (m, 2H, CH2), 
1.40–1.60 (m, 2H, CH2), 1.60–1.75 (m, 1H, CH2), 1.75–1.90 (m, 1H, CH2), 2.45–2.65 (m, 2H, 
3’-H), 3.37 (s, 3H, OCH2OCH3), 3.55–3.67 (m, 7H, CH3OAr, 5’’’-H), 3.75–3.84 (m, 4H, 
CO2CH3, 3’’-H), 4.15–4.20 (m, 1H, 2’’-H), 4.29 (d, J = 9.3 Hz, 1H, 5’’-H), 4.39 (d, J = 9.3 
Hz, 1H, 6’’-H), 4.45-4.50 (m, 1H, 1’’’-H), 4.73 (dd, J = 11.7, 6.8 Hz, 2H, OCH2OCH3), 6.20 
(ddd, J = 15.5, 6.5, 6.5 Hz, 1H, β-CH=CH), 6.59–6.67 (m, 4H, PMP), 6.81–6.90 (m, 4H, 
PMP), 7.13–7.23 (m, 2H, 4-H, α-CH=CH), 7.33 (dd, J = 7.8 Hz, 1H, 5-H), 7.45 (br d, J = 7.8 
Hz, 1H, 3-H), 7.75 (br d, J = 7.8 Hz, 1H, 6-H);  
13C NMR (100 MHz, CDCl3): δ = 19.1 (C-3’’’), 23.2 (C-6’’’), 30.0 (C-2’’’), 35.7 (C-3’), 39.2 
(C-4’’’), 51.9 (CO2CH3), 55.0 (2 CH3OAr), 56.3 (OCH2OCH3), 67.2 (C-5’’’), 73.4 (C-3’’), 
74.7 (C-1’’’), 78.0 (C-5’’), 79.4 (C-2’’), 84.5 (C-6’’), 96.8 (OCH2OCH3), 113.2 (2 CH, PMP), 
113.3 (2 CH, PMP), 126.6 (C-4), 127.2 (C-3), 128.1 (C-1), 128.5 (2 CH, PMP), 128.7 (2 CH, 
PMP), 130.0 (C-6, α-CH=CH), 130.2 (β-CH=CH), 130.3 (quat C PMP), 130.3 (quat C PMP), 
131.8 (C-5), 139.1 (C-2), 159.1 (COCH3 PMP), 159.1 (COCH3 PMP), 167.9 (CO2CH3);  
HRMS (ESI): calcd for C37H49NaO9 [M+Na]+: 657.30340, found 657.30326. 
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2-((1E)-3-{(2R,3R,5S,6S)-3-((1S,5R)-5-Hydroxy)-1-(methyloxymethyl)oxy-hexyl-5,6-bis[4- 
(methyloxy)phenyl]-1,4-dioxan-2-yl} -1-propenyl)benzoic acid (8-82) 
 
O O
PMPPMP
O
HO
OMOM
OH
Me
 
 
A solution of hydroxy ester 8-81 (130 mg, 0.2 mmol) in a mixture of THF (4 mL), MeOH (2 
mL), and H2O (1 mL) was treated with LiOH·H2O (96 mg, 2.3 mmol), followed by stirring the 
mixture at 60 °C for 20 h. After the mixture cooled to RT, it was diluted with Et2O (30 mL) 
and water (20 mL). The organic layer was separated. Through the aqueous layer was bubbled 
air for 60 min in order to remove the rest of organic solvent. This inorganic solution was then 
acidified (pH ~ 3) by slow addition of aqueous hydrochloric acid (1 M solution, approx. 2.2 
mL) and stirred additionally for 30 min. The white precipitate was filtered, washed with 
acidified water (20 mL, 0.01 N HCl) and dried in vacuo for several h to give 126 mg (97%) of 
hydroxy acid 8-82, which was used in the next step without additional purification.  
 
Rf = 0.2–0.3 (petroleum ether/EtOAc, 1:1);  
1H NMR (400 MHz, CDCl3): δ = 1.15 (br s, 3H, 6’’’-H), 1.40–1.60 (br m, 3H, CH2), 1.68–
2.05 (br m, 3H, CH2), 2.57–2.76 (br m, 2H, 3’-H), 3.47 (br s, 3H, OCH2OCH3), 3.65–3.83 (br 
m, 7H, CH3OAr, 5’’’-H), 3.88–3.97 (br m, 1H, 3’’-H), 4.25–4.35 (br m, 1H, 2’’-H), 4.40–4.54 
(br m, 3H, 1’’’-H, 5’’-H, 6’’-H), 4.77 (br d, J = 8.8 Hz, 2H, OCH2OCH3), 6.12–6.27 (br m, 
1H, β-CH=CH), 6.7 (br s, 4H, PMP), 6.93 (br s, 4H, PMP), 7.25–7.32 (br m, 1H, 4-H), 7.36–
7.58 (br m, 3H, α-CH=CH, 3-H, 5-H), 7.95–8.03 (br m, 1H, 6-H);  
13C NMR (100 MHz, CDCl3): δ = 19.7 (C-3’’’), 23.6 (C-6’’’), 30.3 (C-2’’’), 35.7 (C-3’), 38.6 
(C-4’’’), 55.1 (2 CH3OAr), 56.3 (OCH2OCH3), 68.0 (C-5’’’), 73.2 (C-3’’), 75.3 (C-1’’’), 78.2 
(C-5’’), 78.7 (C-2’’), 84.9 (C-6’’), 96.7 (OCH2OCH3), 113.3 (2 CH, PMP), 113.3 (2 CH, 
PMP), 126.9 (C-4), 127.2 (C-3), 127.6 (C-1), 128.6 (2 CH, PMP), 128.8 (2 CH, PMP), 129.3 
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(β-CH=CH), 130.1 (C-6), 130.3 (α-CH=CH), 131.2 (quat C PMP), 131.3 (quat C PMP), 132.7 
(C-5), 140.0 (C-2), 159.1 (COCH3 PMP), 159.1 (COCH3 PMP), 171.7 (CO2H);  
HRMS (ESI): calcd for C36H44NaO9 [M+Na]+: 643.28775, found 643.28745. 
 
 
(2S,3S,4aR,5S,9S,18aR)-5-(Methoxymethoxy)-2,3-bis(4-methoxyphenyl)-9-methyl-
2,3,4a,5,6,7,8,9,18,18adecahydro-11H-[1,4]dioxino[2,3-h][2]benzoxacyclotetradecin-11-
one (8-83) 
 
O
O Me
O
O
OMOM
PMP
PMP
9
4a
12
16
 
 
To a cooled (0 °C) solution of hydroxy acid 8-82 (120 mg, 0.19 mmol) in abs. toluene (20 mL) 
was added freshly recrystallized PPh3 (105 mg, 0.4 mmol). After 15 min at the same 
temperature, the mixture was very slowly treated (approx. 25 min) with DEAD (~40% 
solution in toluene, 130 μL, 0.4 mmol). Within 15 h of stirring, the reaction mixture was 
warmed to RT. After evaporation of the solvent, the residue was purified by flash 
chromatography (petroleum ether/EtOAc, 3:1) to give 91 mg (78%) of macrolactone 8-83 as a 
colorless oil, which was treated with 20 mL of hot heptane followed by evaporation of the 
solvent to give white solid material.  
 
Rf = 0.55 (petroleum ether/EtOAc, 2:1);  
[α]20D = +23.5 (c 1.8, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 1.32 (d, J = 5.8 Hz, 3H, CH3CHO2CAr), 1.55–1.71 (m, 4H, 
2 CH2), 1.85–1.96 (m, 2H, CH2), 2.48–2.55 (m, 1H, 18-H), 3.33–3.43 (m, 1H, 18-H), 3.55 (s, 
3H, OCH2OCH3), 3.73 (s, 3H, CH3OAr), 3.75 (s, 3H, CH3OAr), 4.01 (dd, J = 6.5, 2.8 Hz, 1H, 
4a-H), 4.27 (ddd, J = 11.6, 2.8, 2.8 Hz, 1H, 5-H), 4.46 (d, J = 9.3 Hz, 1H, 3-H), 4.58–4.54 (m, 
1H, 18a-H), 4.70 (d, J = 9.3 Hz, 1H, 2-H), 4.87 (d, J = 6.6 Hz, 1H, OCH2OCH3), 5.00 (d, J = 
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6.6 Hz, 1H, OCH2OCH3), 5.22–5.31 (m, 1H, 9-H), 6.17 (ddd, J = 15.5, 10.3, 4.8 Hz, 1H, β-
CH=CH), 6.68-6.75 (m, 4H, PMP), 6.88 (d, J = 15.5 Hz, 1H, α-CH=CH), 6.91–6.94 (m, 2H, 
PMP), 6.96–7.00 (m, 2H, PMP), 7.28 (dd, J = 7.3, 7.3 Hz, 1H, 13-H), 7.41 (dd, J = 7.3, 7.3 
Hz, 1H, 14-H), 7.46 (br d, J = 7.3, Hz, 1H, 12-H), 7.52 (br d, J = 7.3 Hz, 15-H);  
13C NMR (100 MHz, CDCl3): δ = 19.4 (C-6), 19.8 (CH3CHO2Ar), 30.7 (C-8), 35.3 (C-18), 
35.8 (C-7), 55.1 (2 CH3OAr), 56.3 (OCH2OCH3), 72.3 (C-9), 72.6 (C-4a), 76.5 (C-5), 76.6 (C-
3), 79.8 (C-18a), 86.4 (C-2), 95.7 (OCH2OCH3), 113.3 (CH, PMP), 113.4, (CH, PMP), 126.6 
(C-15), 126.9 (C-13), 127.7 (C-12), 128.8 (2 CH, PMP), 128.9 (2 CH, PMP), 129.6 (β-
CH=CH), 130.3 (C-14), 130.4 (2 quat C PMP), 131.1 (α-CH=CH), 132.6 (C-11a), 135.8 (C-
15a), 159.1 (2 COCH3 of PMP), 169.6 (C=O);  
HRMS (ESI): calcd for C36H42NaO8 [M+Na]+: 625.27719, found 625.27721. 
 
 
(3S,7S,8R,9R)-8,9-Dihydroxy-7-(methoxymethoxy)-3-methyl-3,4,5,6,7,8,9,10-octahydro-
1H-2-benzoxacyclotetradecin-1-one (8-84) 
 
O
O Me
OH
OH
OMOM
 
 
To a stirred solution of CAN (183 mg, 0.33 mmol, 10 equiv) in a CH3CN/H2O mixture (5 mL, 
10:1) at 0–5 °C (ice bath) a solution of macrolactone 8-83 (20 mg, 33 μmol) in CH3CN (1 mL) 
was added dropwise. The resulting solution was stirred at the same temperature for 8 h, during 
which time the starting material was completely consumed (if reaction is not finished, 
additional amount of CAN can be added at 0 °C and stirred further at the same temperature). 
The mixture was diluted with satd. aqueous NH4Cl solution (5 mL) and extracted with CH2Cl2 
(3 × 10 mL). The combined organic extracts were washed with satd. aqueous NaHCO3 
solution, dried over MgSO4 and filtered. The filtrate was concentrated under reduced pressure; 
the crude product loaded onto a flash silica gel column and eluted using a CHCl3/MeOH 
mixture (40:1) to afford pure diol 8-84 (9.6 mg, 80%) as a colorless oil.  
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Rf = 0.15 (CHCl3/MeOH, 40:1); 
[α]20D = +137 (c 1.1, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 1.33 (d, J = 6.3 Hz, 3H, CH3CHO2Ar), 1.45–1.60 (m, 3H, 
CH2), 1.65–1.75 (m, 2H, CH2), 2.03-2.16 (m, 1H, CH2), 2.58–2.77 (m, 2H, CH2CH=CH), 3.44 
(s, 3H, OCH2OCH3), 3.69 (dd, J = 3.5, 3.5 Hz, 1H, 8-H), 3.82 (ddd, J = 8.8, 3.5, 3.5 Hz, 1H, 
7-H), 3.94 (ddd, J = 7.3, 4.3, 4.3 Hz, 1H, 9-H), 4.70 (dd, J = 18.1, 6.6 Hz, OCH2OCH3), 5.24–
5.33 (m, 1H, CH3CHO2CAr), 6.02 (ddd, J = 15.5, 9.8, 5.3 Hz, 1H, β-CH=CH), 6.86 (d, J = 
15.5 Hz, 1H, α-CH=CH), 7.26–7.31 (m, 1H, 15-H), 7.38–7.43 (m, 2H, 13-H, 14-H), 7.64 (d, J 
= 7.8 Hz, 1H, 16-H);  
13C NMR (100 MHz, CDCl3): δ = 20.0 (CH3CHO2Ar), 20.5 (C-5), 30.8 (C-6), 35.5 (C-4), 
37.7 (C-10), 56.1 (OCH2OCH3), 71.3 (C-3), 72.0 (C-8), 75.1 (C-9), 83.9 (C-7), 97.0 
(OCH2OCH3), 127.0 (C-15), 127.5 (C-13), 128.8 (β-CH=CH), 129.1 (C-16), 131.2 (C-14), 
131.2 (C-16a), 132.5 (α-CH=CH), 137.7 (C-12a), 169.0 (CO2R);  
HRMS (ESI): calcd for C20H28O6Na [M+Na]+: 387.17781, found 387.17780. 
 
 
(3S,7S,8S,9R)-8-Hydroxy-7-(methoxymethoxy)-3-methyl-9-[(triethylsilyl)oxy]-
3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecin-1-one (8-85) 
 
O
O Me
TESO
OH
OMOM
 
 
To a mixture of MOM-protected triol 8-84 (14 mg, 38 μmol) and 2,6-lutidine (20 μL, 18.5 mg, 
0.17 mmol) in abs. CH2Cl2 (4 mL) at -80 °C was slowly added TESOTf (10 μL). After 3 h at -
50 °C additional triflate (5 μL) was added and the resulting mixture stirred further for 12 h at 
the same temperature. Then the mixture was treated with satd. NH4Cl solution (3 mL) and 
extracted with CH2Cl2 (3 × 10 mL). The combined organic extracts were washed with brine, 
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dried over MgSO4, filtered, and concentrated. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, 5:1) to afford 9.2 mg (50%) of the TES-protected 
alcohol 8-85 as a colorless oil.  
 
Rf = 0.45 (petroleum ether/EtOAc, 5:1); 
[α]20D = –16 (c 0.5, CHCl3);  
1H NMR (400 MHz, CDCl3): δ = 0.64 (q, J = 15.7, 7.9 Hz, 6H, OSi(CH2CH3)3), 0.97 (t, J = 
7.9 Hz, 9H, OSi(CH2CH3)3), 1.35 (d, J = 6.3 Hz, 3H, CH3CHO2Ar), 1.40–1.75 (m, 5H, CH2), 
1.95-2.05 (m, 1H, CH2), 2.25 (br s, 1H, OH), 2.46–2.57 (m, 1H, 10-H), 2.66–2.75 (m, 1H, 10-
H), 3.40 (s, 3H, CH3OCH2O), 3.72–3.78 (m, 2H, 8-H, 9-H), 4.00–4.05 (m, 1H, 7-H), 4.65 (dd, 
J = 10.1, 6.9 Hz, 2H, CH3OCH2O), 5.11–5.21 (m, 1H, 3-H), 6.15 (ddd, J = 15.7, 7.3, 7.3 Hz, 
1H, β-CH=CH), 6.97 (d, J = 15.7 Hz, 1H, α-CH=CH), 7.24–7.31 (m, 1H, 15-H), 7.39–7.44 
(m, 2H, 13-H, 14-H), 7.78 (br d, J = 7.7 Hz, 16-H);  
13C NMR (100 MHz, CDCl3): δ = 4.9 (OSiCH2CH3), 6.9 (OSiCH2CH3), 20.2 (CH3CHO2Ar), 
20.9 (C-5), 29.9 (C-6), 35.1 (C-4), 36.9 (C-10), 55.8 (OCH2OCH3), 72.5 (C-3), 73.3 (C-8), 
76.7 (C-9), 81.2 (C-7), 95.7 (OCH2OCH3), 126.8 (C-15), 127.7 (β-CH=CH), 130.0 (C-13), 
130.2 (C-16), 130.3 (C-16a), 131.4 (C-14), 131.4 (α-CH=CH), 138.1 (C-12a), 168.8 (CO2R);  
HRMS (ESI): calcd for C26H42NaO6Si [M+Na]+: 501.26429, found 501.26434. 
 
 
(3S,7S,9R)-7-(Methoxymethoxy)-3-methyl-9-[(triethylsilyl)oxy]-4,5,6,7,9,10-hexahydro-
1H-2-benzoxacyclotetradecine-1,8(3H)-dione (8-86) 
 
O
O Me
TESO
O
OMOM
 
 
To a solution of alcohol 8-85 (5 mg, 10.5 μmol) in abs. CH2Cl2 (4 mL) at 0 °C (ice bath) was 
added Dess-Martin periodinane solution in CH2Cl2 (0.1 mL, 15% wt., 20.5 mg, d20 1.36 g   
mL-1). The resulting mixture was stirred at the same temperature for 1 h. Then the mixture was 
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treated with satd. NaHCO3 solution and extracted with CH2Cl2 (3 × 5 mL). The combined 
extracts were dried over MgSO4, filtered, and concentrated in vacuo. The crude ketone 8-86 
(5.5 mg) was used in the next step without additional purification.  
 
Data for purified product:  
Rf = 0.45 (petroleum ether/EtOAc, 5:1);  
1H NMR (400 MHz, CDCl3): δ = 0.63 (q, J = 15.6, 7.8 Hz, 6H, OSi(CH2CH3)3), 0.97 (t, J = 
7.8 Hz, 9H, OSi(CH2CH3)3), 1.37 (d, J = 5.8 Hz, 3H, CH3CHO2Ar), 1.45–1.67 (m, 5H, CH2), 
1.98–2.10 (m, 1H, CH2), 2.65–2.75 (m, 1H, 10-H), 2.87–2.97 (m, 1H, 10-H), 4.20–4.27 (m, 
1H, 7-H), 4.59–4.65 (m, 1H, 9-H), 5.12-5.20 (m, 1H, 3-H), 6.04 (ddd, J = 15.6, 7.9, 5.5 Hz, 
1H, β-CH=CH), 6.96 (d, J = 15.6 Hz, α-CH=CH), 7.23–7.30 (m, 1H, 15-H), 7.35–7.42 (m, 
2H, 13-H, 14-H), 7.78 (d, J = 7.3 Hz, 16-H);  
13C NMR (100 MHz, CDCl3): δ = 4.7 (OSi(CH2CH3)3), 6.8 (OSi(CH2CH3)3), 20.3 
(CH3CHO2Ar), 20.8 (C-5), 29.3 (C-6), 35.3 (C-4), 38.2 (C-10), 56.1 (CH3OCH2O), 72.5 (C-3), 
76.3 (C-9), 78.1 (C-7), 96.8 (CH3OCH2O), 126.9 (C-15), 127.1 (β-CH=CH), 128.1 (C-13), 
129.9 (C-16a), 130.1 (C-16), 131.6 (C-14), 132.5 (α-CH=CH), 137.7 (C-12a), 168.2 (CO2R), 
207.3 (R2C=O). 
 
 
des-Oxy-di-des-methoxy-(-)-queenslandon (6-2) 
 
O
O Me
OH
O
OH
 
 
A solution of protected ketone 8-86 (5 mg, 10.5 μmol) in a THF/MeOH mixture (4 mL, 1/1) 
was treated with concentrated HCl (0.1 mL) and refluxed for 36 h. Then the mixture was 
neutralized with aqueous NaHCO3 solution (5 mL) and extracted with CHCl3 (5 × 10 mL). 
The combined organic extracts were dried over Na2SO4, filtered, and concentrated in vacuo. 
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The residue was purified by flash chromatography (CHCl3/MeOH, 40:1) to give 2.2 mg (65%) 
of queenslandon analog 6-2.  
 
Rf = 0.25 (CHCl3/MeOH, 40:1); 
[α]20D = –84.5 (c 0.15, MeOH);  
1H NMR (400 MHz, CDCl3): δ = 1.38 (d, J = 6.1 Hz, 3H, CH3CHO2Ar), 1.43–1.75 (m, 5H, 
CH2), 1.98–2.10 (m, 1H, CH2), 2.77–2.95 (m, 3H, 10-H, 13-OH), 3.58 (br s, 1H, 11-OH), 
4.30–4.37 (m, 1H, 13-H), 4.61–4.68 (m, 1H, 11-H), 5.14–5.23 (m, 1H, 17-H), 5.87 (ddd, J = 
15.5, 8.8, 5.1 Hz, 1H, β-CH=CH), 7.08 (d, J = 15.5 Hz, α-CH=CH), 7.28–7.35 (m, 2H, 4-H, 
6-H), 7.40–7.47 (m, 1H, 5-H), 7.89 (br d, J = 7.8 Hz, 5-H);  
13C NMR (100 MHz, CDCl3): δ = 20.4 (CH3CHO2Ar), 20.4 (C-15), 33.1 (C-14), 35.3 (C-16), 
36.8 (C-10), 72.1 (C-17), 74.8 (C-11), 75.1 (C-13), 126.0 (C-4), 127.3 (β-CH=CH), 128.6 (C-
6), 129.3 (C-2), 130.9 (C-3), 132.1 (C-5), 133.9 (α-CH=CH), 138.6 (C-7), 168.0 (CO2R), 
212.5 (R2C=O);  
HRMS (ESI): calcd for C18H22O5Na [M+Na]+: 341.13594, found 341.13588. 
 
 
(3S,7S,8S,9R)-7,8,9-Trihydroxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-2-
benzoxacyclotetra decin-1-one (8-87) 
 
O
O Me
OH
OH
OH
 
 
A solution of MOM-protected diol 8-84 (22 mg, 6 μmol) in a THF/MeOH mixture (4 mL, 1:1) 
was treated with concentrated HCl (0.1 mL) and refluxed for 36 h. Then the mixture was 
treated with satd. NaHCO3 solution (10 mL) and extracted with CHCl3 (3 × 15 mL). The 
combined organic extracts were dried over Na2SO4, filtered, and evaporated to dryness. 
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Purification by flash chromatography (CHCl3/MeOH, 40:1) afforded the triol 8-87 as a 
colorless solid (13 mg, 67%). 
 
Rf = 0.2 (CHCl3/MeOH, 40:1); 
m.p. 122–126 °C; 
[α]20D = –34.5 (c 0.7, CH2Cl2);  
1H NMR (400 MHz, CD3OD): δ = 1.24 (d, J = 6.3 Hz, 3H, CH3CHO2Ar), 1.30–1.85 (m, 6H, 
CH2), 2.32–2.41 (m, 1H, 10-H), 2.67–2.77 (m, 1H, 10-H), 3.55–3.60 (m, 1H, 8-H), 3.70–3.75 
(m, 1H, 7-H), 3.87–3.94 (m, 1H, 9-H), 5.09–5.18 (m, 1H, CH3CHO2CAr), 6.05 (ddd, J = 15.5, 
9.8, 5.3 Hz, 1H, β-CH=CH), 6.79 (d, J = 15.5 Hz, 1H, α-CH=CH), 7.20 (dd, J = 7.5, 7.5 Hz, 
1H), 7.35 (dd, J = 7.5, 7.5 Hz, 1H), 7.40 (br d, J = 7.5 Hz, 1H), 7.45 (br d, J = 7.5 Hz, 1H);  
13C NMR (100 MHz, CD3OD): δ = 19.8 (CH3CHO2Ar), 21.0 (C-5), 33.4 (C-6), 36.3 (C-4), 
38.8 (C-10), 73.5 (C-3), 74.7 (C-8), 75.2 (C-9), 78.6 (C-7), 127.9 (C-15), 128.2 (C-13), 129.6 
(β-CH=CH), 131.6 (C-16a), 132.2 (C-14), 132.3 (C-13), 132.8 (α-CH=CH), 138.6 (C-12a), 
170.7 (CO2R);  
HRMS (ESI): calcd for C18H24O5Na [M+Na]+: 343.15159, found 343.15203. 
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128.7
128.1
127.5
127.2
113.7
113.6
96.6
84.9
81.1
77.9
74.7
69.4
56.0
55.2
39.2
30.9
27.0
23.1
19.2
12
7.
2
12
7.
4
12
7.
5
12
8.
1
12
8.
6
12
8.
7
12
9.
4
12
9.
4
13
4.
5
13
4.
8
13
5.
8
13
5.
9
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7 6 5 4 3 2 1
Chemical Shift (ppm)
Benzene-d6 Me
OTBDPS
O O
OMOM
PMPPMP
8-78
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8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Chloroform-d
Me
OTBDPS
O O
OMOM
PMPPMP
O
MeO
8-80
 
 
Chloroform-d
167.9
159.1
139.2
135.8
131.8
130.3
130.2
129.2
128.7
128.1
127.3
127.3
126.6
113.2
96.7
84.7
79.6
77.8
74.5
73.3
69.7
56.2
55.0
51.9
39.9
35.8
30.7
26.9
23.1
19.1
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8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Chloroform-d
O O
PMPPMP
O
MeO
OMOM
OH
Me
8-81
 
 
Chloroform-d
19.1
23.2
30.0
35.7
39.2
51.9
55.0
56.3
67.2
73.4
74.7
78.0
79.4
84.5
96.8
113.3
126.6
127.2
128.1
128.5
128.7
130.0
130.2
130.3
131.8
139.1
159.1
159.1
167.9  
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8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Chloroform-d
O O
PMPPMP
O
HO
8-82
OMOM
OH
Me
 
 
Chloroform-d
171.7
159.1
140.0
132.7
131.3
131.2
130.3
130.1
128.8
128.6
127.6
126.9
113.3
96.7
84.9
78.7
78.2
75.3
73.2
68.0
56.3
55.1
38.6
35.7
30.3
23.6
19.7
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7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
Chloroform-d
O
O Me
O
O
OMOM
PMP
PMP
8-83
 
 
Chloroform-d
169.6
159.2
135.8
132.6
131.1
130.4
130.3
129.6
128.9
128.8
127.7
126.6
113.4
113.3
95.7
86.4
79.8
76.6
72.6
72.3
56.3
55.1
35.9
35.3
30.7
19.8
12
6.
6
12
6.
9
12
7.
7
12
8.
8
12
8.
9
12
9.
6
13
0.
31
30
.4
13
1.
1
13
2.
6
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7 6 5 4 3 2
Chemical Shift (ppm)
O
O Me
OH
OH
OMOM
8-84
 
 
Chloroform-d
169.0
137.7
132.6
131.2
131.2
129.1
128.8
127.5
127.0
97.0
83.9
75.1
72.0
71.2
56.1
37.7
35.6
30.9
20.5
20.0
12
7.
0
12
7.
5
12
8.
8
12
9.
1
13
1.
2
13
1.
2
13
2.
6
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7 6 5 4 3 2 1
Chemical Shift (ppm)
Chloroform-d
O
O Me
TESO
OH
OMOM
8-85
 
 
Chloroform-d
4.9
6.9
20.2
20.9
29.9
35.1
36.9
55.8
72.5
73.3
76.7
81.2
95.7
126.8
127.7
130.0
130.2
130.3
131.4
131.4
138.1
168.8  
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8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Chloroform-d
O
O Me
TESO
O
OMOM
8-86
 
 
Chloroform-d
4.7
6.8
20.3
20.8
29.3
35.3
38.2
56.1
72.5
76.3
78.1
96.8
126.9
127.1
128.1
129.9
130.1
131.6
132.5
137.7
168.2
207.3  
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8 7 6 5 4 3 2
Chemical Shift (ppm)
Chloroform-d
O
O Me
OH
O
OH
6-2
 
 
Chloroform-d
212.5
168.0
138.6
133.9
132.1
130.9
129.3
128.6
127.3
126.0
75.1
74.8
72.1
36.8
35.3
33.1
20.4
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